An investigation into the feasibility of incorporating ketoconazole into solid lipid microparticles by Jhundoo, Henusha Devi
  
AN INVESTIGATION INTO THE FEASIBILITY OF INCORPORATING 
KETOCONAZOLE INTO SOLID LIPID MICROPARTICLES 
 
 
 
A Thesis Submitted to Rhodes University in  
Fulfilment of the Requirements for the Degree of  
 
 
 
 
MASTER OF SCIENCE (PHARMACY) 
 
 
by 
 
 
 
Henusha Devi Jhundoo 
 
 
 
 
 
 
December 2014 
 
 
Faculty of Pharmacy 
Rhodes University  
Grahamstown 
South Africa 
i 
 
ABSTRACT 
 
One of the major challenges of the oral administration of ketoconazole (KTZ), an inhibitor of 
sterol 14α-demethylase, used in the management of systemic and topical mycoses in immuno-
compromised and paediatric patients is the lack of availability of liquid dosage forms. In order to 
overcome this challenge, extemporaneous preparations have been manufactured by care-givers 
and health care providers by crushing or breaking solid oral dosage forms of KTZ and mixing 
with a vehicle to produce a liquid dosage form that can be swallowed by patients. However, the 
use of extemporaneous preparations may lead to under or over-dosing if the care-givers are not 
guided accordingly. Furthermore, the dearth of information on the stability of these KTZ-
containing extemporaneous preparations may lead to ineffective antifungal therapy and 
complicate the problems of resistance as it is difficult to estimate the shelf-lives of these 
extemporaneous products under varying storage conditions due to the susceptibility of KTZ to 
chemical degradation. Therefore, there is a need for formulation scientists to develop novel drug 
delivery systems that avoid the need for extemporaneous preparations, possess well-established 
limits of stability and minimize the risks of systemic adverse effects to facilitate KTZ therapy. 
The use of solid lipid microparticles (SLM) as potential carriers for the oral administration of 
KTZ was investigated since solid lipid carriers are known to exhibit the advantages of traditional 
colloidal carriers. The research undertaken in these studies aimed to investigate the feasibility of 
developing and manufacturing solid lipid microparticles (SLM), using a simple micro-emulsion 
technique, as a carrier for KTZ.  
 
Prior to pre-formulation, formulation development and optimization studies of KTZ-loaded SLM, 
it was necessary to develop and validate an analytical method for the in vitro quantitation and 
characterization of KTZ in aqueous dispersions of SLM during development and assessment 
studies. An accurate, precise, specific and sensitive reversed-phase high performance liquid 
chromatographic (RP-HPLC) method coupled with UV detection at 206 nm was developed, 
optimized and validated for the analysis of KTZ in formulations.  
 
Formulation development studies were preceded by solubility studies of KTZ in different lipids. 
Labrafil
®
 M2130 CS was found to exhibit the best solubilising potential for KTZ. Pre-formulation 
studies were also designed to determine the polymorphic behavior and the crystallinity of KTZ 
and Labrafil
®
 M2130 CS that was used for subsequent manufacture of the solid lipid carriers. 
DSC and FTIR studies revealed that there were no changes in the crystallinity of KTZ or 
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Labrafil
®
 M2130 CS following exposure to a temperature of 60°C for 1 hour. In addition the 
potential for physicochemical interaction of KTZ with the lipid Labrafil
®
 M2130 CS was 
investigated using DSC and FTIR and the results revealed that KTZ was molecularly dispersed in 
Labrafil
®
 M2130 CS and that it is unlikely that KTZ would interact with the lipid. It was 
therefore established that KTZ and Labrafil
®
 M2130 CS were thermo-stable at a temperature of 
60°C and thus a micro-emulsion technique could be used to manufacture the KTZ-loaded SLM.  
 
Drug-free and KTZ-loaded SLM were prepared using a modified micro-emulsion technique that 
required the use of an Ultra-Turrax
®
 homogenizer set at 24 000 rpm for 5 minutes followed by 
the use of the Erweka GmbH homogenizer. SLM were characterized in terms of particle size 
(PS), zeta potential (ZP), shape and surface morphology using scanning electron microscopy 
(SEM) and transmission electron microscopy (TEM). In addition drug loading capacity (DLC) 
and encapsulation efficiency (EE) of SLM for KTZ were assessed using RP-HPLC. Formulation 
development and optimization studies of KTZ-loaded SLM were initially aimed at selecting an 
emulsifying system that was able to stabilize the SLM in an aqueous dispersion. Successful 
formulations were selected based on their ability to remain physically stable on the day of 
manufacture. Pluronic
®
 F68 used in combination with Lutrol
®
 E40, Soluphor
® 
P, Soluplus
®
 
produced unstable dispersions on the day of manufacture and these combinations were not 
investigated further. However, the formulation of a stable KTZ-loaded SLM dispersion was 
accomplished by use of a combination of Pluronic
®
 F68, Tween 80 and sodium cholate as the 
surfactant system. Increasing amounts of Labrafil
®
 M2130 CS resulted in the production of 
particles with low DLC and EE, a large PS and a relatively unchanged ZP. An optimum 
concentration of 10% w/v Labrafil
®
 M2130 CS was selected to manufacture the KTZ-loaded 
SLM. Studies to determine the influence of KTZ loading on the quality of SLM revealed that 
concentrations of KTZ > 5% w/v led to a reduction in DLC and EE and an increase in PS with 
minimal impact on the ZP. Stability studies conducted at 25°C/65% RH and 40°C/75% RH for up 
to 30 days following manufacture revealed that batch SLM 15 manufactured using 10% w/v 
Labrafil
®
 M2130 CS, 5% w/v KTZ and a combination of 4% w/v Pluronic
®
 F-68, 2% w/v Tween 
80 and 1% w/v sodium cholate produced the most stable dosage form when stored at 25°C/65% 
RH for up to 30 days. However, storage at 40°C/75% RH resulted in instability of the 
formulation.  
 
An aqueous dispersion of KTZ-loaded SLM has been developed and assessed and may offer an 
alternative to extemporaneous preparations used for KTZ therapy in paediatric and immuno-
compromised patients.   
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STUDY OBJECTIVES 
 
Antifungal therapy is commonly required by immuno-compromised and paediatric patients in 
South Africa. The use of ketoconazole (KTZ) as an extemporaneous preparation is widespread for 
the treatment of systemic and topical fungal infections due to the lack of availability of antifungal 
medicines in child appropriate forms. Solid oral dosage forms of KTZ are usually broken or 
crushed and mixed with a vehicle to administer the molecule in a liquid dosage form that can be 
easily swallowed by the patients. The use of extemporaneous preparations of KTZ may lead to 
under or over-dosing by care-givers and the lack of stability data for these preparations makes it 
difficult to estimate the shelf-lives of these preparations under the variety of storage conditions to 
which they are exposed. Furthermore, prolonged KTZ therapy is associated with risks of 
hepatotoxicity. Novel drug delivery systems, that have well-defined stability limits, exhibit 
enhanced stability for KTZ and can minimize the risks of systemic adverse effects, are therefore 
required to facilitate the management of mycoses treated using KTZ. Therefore, the objectives of 
this study were: 
1. To gather data relating to the physicochemical properties of KTZ that would assist in the 
development of novel drug delivery systems using empirical studies and literature 
sources.  
2. To review current colloidal drug delivery systems and propose the need for oral lipid-
based formulations such as solid lipid microparticles (SLM) formulations for KTZ. 
3. To develop, optimize and validate a simple, selective, sensitive, precise and accurate 
reversed phase high performance liquid chromatographic method that was suitable for the 
quantitative analysis of KTZ in pharmaceutical formulations and the analysis of KTZ in 
aqueous dispersions of KTZ-loaded SLM.  
4. To establish the thermal stability, polymorphic behaviour and crystallinity of KTZ and 
Labrafil
®
 M2130 CS used for the manufacture of micro-particulate delivery systems.  
5. To investigate the feasibility of incorporating KTZ into a SLM formulation. 
6. To characterize the KTZ-loaded SLM formulations during formulation development and 
optimization studies.  
7. To establish the stability of the KTZ-loaded SLM formulations developed in these 
studies.   
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CHAPTER ONE 
KETOCONAZOLE 
 
1.1. Introduction 
Ketoconazole (KTZ) is a synthetic imidazole antifungal molecule with a broad spectrum of 
antimicrobial activity. KTZ has been used for the management of a variety of systemic and 
topical fungal infections [1-7]. KTZ was the first azole antifungal agent of the dioxolane series to 
be introduced for clinical use, and was the first orally active azole type compound reported [1]. 
The development of KTZ stemmed from an attempt to vary the spectrum, specific level of 
antifungal activity, routes of administration and potential use of imidazole compounds [1, 8]. 
KTZ forms part of the N-substituted (mono) imidazole series in which substitutions are made at 
one of the two nitrogen atoms in the molecule whilst the imidazole ring is left intact [1, 8]. The 
incorporation of a dioxolane ring and a variety of side chains at the N-substituted imidazole of 
econazole and miconazole led to the discovery of KTZ in 1976 [9]. The dioxolane series of the 
azole compounds originated from substitutions made at the 1, 3-dioxolane configuration joined to 
the nitrogen atom [1].  
 
Extensive studies were conducted on KTZ in the late 1970s following identification of its 
antifungal efficacy subsequent to oral administration [2, 3, 10-12]. It has been reported that KTZ 
is effective in the management of a range of fungal infections of the skin, fingernails, gastro-
intestinal tract, respiratory tract and mucous membranes amongst others [5, 7, 11-17]. In 1981, 
Janssen Pharmaceutica introduced Nizoral
®
 200 mg tablets and received approval from the Food 
and Drug Administration (FDA) for the clinical use of KTZ as a prescription drug [18]. In 
recognition of his role in the discovery of KTZ in 1982, Jan Heeres was awarded the IUPAC-
Richter Prize in 2008 for his work on azole chemistry, most specifically on KTZ [19]. KTZ is 
now widely used to treat fungal infections in adult and paediatric patients that do not respond to 
topical treatment and is occasionally used for the prophylaxis of fungal infections in immuno-
compromised patients [7, 15]. Solid oral dosage forms of KTZ are usually crushed to produce 
extemporaneous preparations due to the dearth of antifungal medicine in liquid form. The lack of 
quality control in extemporaneous compounding makes it difficult to estimate the stability of such 
KTZ preparations. Therefore, the aim of this research was to investigate the feasibility of 
incorporating KTZ into a novel drug delivery system that possesses well-defined stability limits.
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1.2. Physicochemical properties   
1.2.1. Description  
The chemical name of KTZ as defined by the IUPAC system is 1-Acetyl-4-[4[[(2RS, 4SR)-2-(2, 
4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1, 3-dioxolan-4-yl]methoxy]phenyl]piperazine 
[20]. KTZ is also known as (±)-cis-1-acetyl-4-{4-[2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-
ylmethyl)-1, 3-dioxolan-4-yl-methoxy]phenyl}piperazine [15]. The structure of KTZ is depicted 
in Figure 1.1. 
  
Cl
N
O
O
ONN
O
CH
3
H
N
Cl
 
Figure 1.1 Ketoconazole  
 
KTZ occurs as a white or almost white powder with a molecular formula and mass of 
C26H28Cl2N4O4 and 531.4 g/mol respectively. One gram (1 g) of anhydrous KTZ contains not less 
than 99 % (0.99 g) and not more than 101.0% (1.01 g) ketoconazole.  
 
1.2.2. Solubility  
KTZ is practically insoluble in water, is sparingly soluble in ethanol, is soluble in toluene, ether 
and acetone and is freely soluble in methanol, chloroform and dichloromethane [15, 20, 21]. KTZ 
has been found to have an aqueous solubility of 0.017 mg/ml at 25°C [22]. KTZ is classified as a 
BCS Class II compound  as it exhibits high permeability and low solubility in the gastrointestinal 
tract (GIT) [23]. The aqueous solubility of KTZ at pH 7.4 is 5.2 µM (0.0028 mg/ml) and 5.6 µM 
(0.0030 mg/ml) for the crystalline and amorphous forms, when measured using the shake flask 
method [24]. Amorphous KTZ, although known to be unstable, is more soluble than the 
crystalline form [25]. The dissolution of KTZ has been reported to be significantly reduced in 
solutions of  pH > 5 [26]. 
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1.2.3. Dissociation constant  
The dissociation constant or pKa, is a property of ionisable substances and expresses the ratio of 
ionized and unionized forms of a substance at equilibrium in water [27]. KTZ is a dibasic drug 
and therefore has two pKa values viz., 6.51 and 2.94 which are a consequence of the protonation 
of the imidazole and piperazine moieties respectively [28-30]. Ionisation of the piperazine group 
in the presence of gastric acid is vital for dissolution and subsequent absorption of KTZ [28-30]. 
 
1.2.4. Partition coefficient  
The partition coefficient or log Po/w of a compound is a thermodynamic measure of the  
hydrophilic-lipophilic balance of the compound [31]. The log Po/w value of KTZ is 3.73 which is 
an indication that it is lipophilic and in part explains the poor water solubility of KTZ at neutral 
pH [29, 30]. Methods other than the traditional shake-flask method have been used to determine 
the partition coefficient of KTZ, including planar chromatography and the calculated log P value 
for KTZ is 4.45 [32]. Other reported values of log P for KTZ are 3.84 and 4.35 [33, 34].  
  
1.2.5. Ultraviolet Absorption Spectrum  
Ultraviolet/visible (UV/Vis) spectroscopy is widely used in qualitative and quantitative analysis, 
the determination of dissociation and equilibrium constants, trace analyses and photometric 
titration [35-37]. The range of wavelengths for UV/Vis spectroscopy is between 190 nm to 800 
nm and although this range may seem limited, UV/Vis spectral studies can be of great value for 
the generation of information about molecules since most organic compounds and functional 
groups are transparent in this portion of the electromagnetic spectrum [35, 36]. 
 
UV studies were conducted to determine the λmax of KTZ for high-performance liquid 
chromatographic analysis of KTZ coupled with UV detection. Since KTZ is insoluble in water 
and in the mobile phase constituents for analysis (§ 3.3.2.8), the UV absorption spectrum of KTZ 
in water or mobile phase was not assessed and the ultraviolet absorption spectrum of KTZ in a 
methanolic solution at a concentration of 10 µg/ml is depicted in Figure 1.2. The spectrum was 
generated using a double beam UV Vis spectrophotometer (GBC Scientific Equipment Pty Ltd, 
Melbourne, Victoria, Australia). The spectrum reveals a peak maximum at 205.9 nm and a minor 
peak at 247.8 nm. Shoulders at 217.4 nm and 221.5 nm were also noted in the spectrum.  
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Figure 1.2 Ultraviolet spectrum of ketoconazole 
 
1.2.6. Infrared Spectrum 
Infrared (IR) spectroscopy is a useful and relatively easy technique that may be used to acquire 
structural information about a molecule and to identify unknown substances that may be present 
in a molecule [35, 36]. Molecules with covalent bonds that exhibit dipole moments absorb 
electromagnetic radiation in the infrared region of the electromagnetic spectrum and 
Consequently, display different natural vibration frequencies [35, 36]. Although different 
molecules might possess similar bonds, no two molecules will have the same infrared spectrum, 
as different molecules have different dipole moments [35, 36]. The IR spectrum of KTZ was 
generated using a Perkin-Elmer 100 FTIR spectrometer (Waltham, Massachusetts, USA) 
equipped with universal Attenuated Total Reflectance (ATR) technology in the range of 515-
4000 cm
-1
. The IR spectrum and relevant band assignments for KTZ are shown in Figure 1.3 and 
summarized in Table 1.1.  
 
Wavelength (nm) 
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Figure 1.3 Infra-red spectrum of ketoconazole 
 
Table 1.1 Major infra-red band assignments for KTZ  
Band position (cm
-1
) Assignment 
3177 sp2 C-H stretch 
2976 sp3 C-H stretch 
1645 C=O stretching of the ketone (conjugation with imidazole ring) 
1458 C-N stretching of the imidazole 
1256 C-O stretching of the cyclic ether group 
1240 C-C=O bend of the ketone 
    NR  
1031 Ar-C-O stretching of the ether 
737 C-Cl stretching of chlorine 
 
The FTIR spectrum of KTZ reveals characteristic peaks showing the C=O stretching vibration of 
its carbonyl group, C-O stretching of its aliphatic ether group and C-O stretching of its cyclic 
ether at 1645 cm
-1
, 1031 cm
-1
 and 1240 cm
-1
 respectively.  
1.2.7. Stereochemistry and structure activity relationship 
KTZ is the cis diastereomer of 1-acetyl-4-[4[[2-(2, 4-dichlorophenyl)-2-(1H-imidazole-1-
ylmethyl)-1, 3-dioxolan-4-yl]methoxy]phenyl]piperazine, which has two centres of asymmetry 
and exists as two enantiomeric pairs of diastereomers [38]. KTZ is the most active antifungal 
agent of the diastereomers and is available commercially, as a racemic mixture with the R, S and 
S, R diastereomers in a 1:1 ratio [38]. The racemic mixture of KTZ is known to possess broad 
anti-infective properties and is effective against a large number of fungi, yeasts and 
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dermatophytes [38]. The racemic mixture of KTZ can be produced using the method described by 
Heeres et al. in in § 1.3 and individual diastereomers may be obtained following resolution with 
an optically active acid such as tartaric acid [38, 39]. The racemate of KTZ, albeit the most potent 
antifungal of the diastereomers, is associated with adverse effects such as hepatotoxicity of KTZ 
[40].  
 
The development of KTZ commenced after an evaluation of miconazole revealed that it  
possessed certain key features responsible for antifungal activity [8]. Chemical modifications 
whilst maintaining the fundamental pharmacophore were introduced to generate azole compounds 
that were active against a wide range of mycoses [8]. The functional pharmacophore of KTZ is 
comprised of an imidazole ring joined to an asymmetric carbon atom to which a 2, 4-dihalogen-
substituted benzene moiety is attached (Figure 1.1) [8]. During the early stages of azole drug 
development, chlorine atoms were attached to the benzene moiety whilst for the newer analogues, 
the chlorine atom has been substituted with fluorine atoms that result in increased potency [8].  
  
The introduction of a dioxolane ring in KTZ improved the configuration of KTZ. Further 
substitutions of the dioxolane ring in addition to the introduction of a piperazine moiety, not only 
improved the antifungal efficacy of KTZ, but also enhanced oral activity [8]. The piperazine 
moiety is basic and is thought to be responsible for the water solubility and antimycotic activity 
of KTZ which is dependent on the extent of protonation of the piperazine group [41]. Increased 
protonation of the piperazine moiety leads to enhanced water solubility and antimycotic activity 
of KTZ and occurs when the pH of the medium is lower than the isoelectric point of the 
piperazine group substantiating the need for a low pH for adequate solubility and subsequent 
absorption of KTZ [41-43].  
 
1.2.8. Specific rotation  
The specific optical rotation of a 0.04 µg/ml KTZ solution in methanol at 20°C is between -1.0° 
and +1.0°.  
 
1.2.9. Melting characteristics 
The melting range of KTZ is 148°C and 152°C [20]. Changes in the melting behaviour of KTZ 
were investigated using Differential Scanning Calorimetry (DSC). The DSC thermogram of KTZ 
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was generated using a Perkin-Elmer DSC-7 Differential Scanning Calorimeter (Norwalk, 
Connecticut, USA) in a sealed aluminium pan, and is depicted in Figure 1.4. The DSC curve for 
KTZ reveals an endothermic peak of fusion at 149.27°C indicating that KTZ melts at this 
temperature. The melting range of KTZ was established as 146.42°C to 151.72°C.  
 
 
Figure 1.4 DSC curve for ketoconazole 
 
1.3. Synthesis 
The synthetic pathway for the manufacture of KTZ is illustrated in the reaction scheme depicted 
in Figure 1.5 [39]. The initial step in the synthesis of KTZ involves ketalisation of 2, 4-
dichloroacetophenone (I) with glycerine in the presence of a benzene-1-butanol medium and p-
toluenesulfonic acid. The ketal (II) is then brominated) at 30°C to form bromo ketal (III). Product 
III is then subjected to benzoylation in pyridine to form a cis/trans mixture, from which the cis 
form (IV) is isolated by recrystallization in ethanol. Coupling of product IV with imidazole in dry 
dimethylamine (DMA) produces an imidazole derivative and ester (V). Saponification of product 
V by refluxing in sodium hydroxide and dioxane-water leads to the formation of the alcohol (VI). 
Conversion of product VI to methylsulfonate (VII) followed by coupling with the sodium salt of 
VIII results in the production of ketoconazole (IX). 
 
 
8 
 
Cl
Cl
CH
3
O
OH
OH
OH
Cl
ClO
O
CH
3
OH
Cl
ClO
O
BrCH
2
OH
O
N
H
N
O
H
Cl
ClO
O
BrCH
2
O
H
Cl
ClO
O
O
N
N
H
Cl
ClO
O
OH
N
N
H
Cl
ClO
O
O
N
N
SO
2
CH
3
OH N N
CH
3
O
Cl
N
O
O
ONN
O
CH
3
H
N
Cl
+
Benzene-1-butanol
Br2
1. PhCOCl, pyridine
2. EtOH
p-toluenesulfonic acid
   DMA
NaOH
Dioxane
H2O
Pyridine
CH3SO2Cl
NaH, 50%, Me2SO
I
II
III
IV V
VIVII
VIII
XI cis-ketoconazole
 
 Figure 1.5 Synthesis of cis-ketoconazole adapted from [39] 
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1.4. Stability 
1.4.1. Hydrolysis 
KTZ undergoes hydrolysis at low pH [44]. Hydrolytic degradation is enhanced between pH 1-4 
and the degradation rate has been found to be highest at pH 1 suggesting that KTZ is subject to 
specific acid catalysis in aqueous solution [44]. KTZ undergoes little hydrolysis at alkaline pH 
and optimum physical and chemical stability are observed at pH 7 [44]. It has been reported that 
KTZ may be subject to slow hydrolysis when heated under reflux conditions for 10 hours in a 
10% v/v methanolic solution of sodium hydroxide [45]. 
 
1.4.2. Oxidation 
KTZ is known to degrade through oxidation particularly in aqueous media [44]. It has been 
reported that the oxidation of KTZ is much higher at low pH [44]. In addition KTZ is subjected to 
chemically irreversible oxidation in solutions of pH 8-12 when it exists in the un-protonated form 
that exhibits an increased susceptibility of the imidazole and piperazine rings to oxidation [46-
48]. KTZ has been found to undergo the least oxidation in the protonated form and is reported to 
be stable in a pH range of 4-7 [46-48]. 
 
1.4.3. Temperature  
Accelerated stress studies conducted at 25°C and 50°C revealed that KTZ is relatively stable in 
aqueous media for approximately three months [44]. However, after three months pronounced 
degradation occurs at 50°C whereas only minimal degradation was noted at 25°C [44]. These 
results imply that KTZ is chemically stable in aqueous media at temperatures not exceeding 50°C 
for a maximum period of three months [44]. Moreover, it has been reported that there is no 
significant effect on the concentration of KTZ in ethanolic solution when stored at ambient 
temperature or under refrigerated conditions over a twenty-nine day period [49].  
 
1.4.4. Light 
Stability studies conducted in ethanolic solutions of two different concentrations of KTZ stored in 
clear and amber glass containers exposed to light over a period of twenty-nine days. The samples 
were analyzed on days 0, 1, 2, 3, 5, 8, 15, 22 and 29 using UV spectroscopy [49] and the results 
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revealed that exposure to light had no significant impact on the concentration of KTZ. No 
difference was observed between the UV spectrum of the test and reference samples revealing no 
sign of degradation [49].  
 
1.5. Clinical Pharmacology 
1.5.1. Mechanism of action 
Azole compounds such as KTZ are known to exert their antifungal action by inhibiting sterol 
14α-demethylase, a microsomal cytchrome P450-dependent enzyme system [4, 50-55]. This leads 
to the inhibition of ergosterol biosynthesis for the cytoplasmic membrane and results in the 
accumulation of lanosterol and other 14α-methylsterols [10, 50-52, 54]. The closely-packed 
arrangement of the acyl chains of the phospholipids is subsequently disturbed, thereby impairing 
the function of membrane-bound enzymes such as ATPase and the electron transport system [10, 
50-52, 54]. The depletion of ergosterol therefore interferes with fungal cell growth and 
proliferation and inhibition of CYP P450 results in sensitization of fungal cells to oxidative 
metabolites produced by phagocytes [50]. 
 
KTZ also inhibits the biosynthesis of steroidal hormones in humans and specifically impacts the 
synthesis of testosterone and glucocorticoids [50]. The plasma levels of testosterone and 
androstenedione have been found to be lower in patients treated with KTZ [52, 56-59]. In 
addition an increase in 17α-hydroxyprogesterone levels implies that KTZ has an inhibitory effect 
on the enzyme C17, 20-lyase [56-58]. The reduction in androgen levels has been reported to be 
beneficial in the treatment of prostatic carcinoma and precocious puberty [57, 58]. KTZ has also 
proved useful in the treatment of Cushing’s disease and adrenal adenoma due to its inhibition of 
adrenal 11β-hydroxylase and C17, 20-lyase leading to a reduction in the levels of cortisol and 
related corticosteroids produced by excessive adrenocorticotropic hormone (ACTH) secretion in 
these conditions [52, 56, 57]. KTZ has also been reported to inhibit cholesterol synthesis by 
blocking demethylation of lanosterol, leading to a marked decrease in low density lipoprotein 
(LDL) levels [60].  
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1.5.2. Spectrum of activity 
KTZ exhibits a broad spectrum of activity against a variety of pathogenic fungi including the 
Candida species, Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, 
Blastomyces dermatitidis, Paracoccidioides brasiliensis in addition to a wide range of 
dermatophytes or ringworm fungi [4, 11, 51, 61, 62]. The antibacterial and anti-parasitic activity 
of KTZ is restricted to protozoa of the Leishmania major species [4, 51]. 
  
1.5.3. Clinical use and indications 
KTZ has been shown to be beneficial in the treatment of topical and oral pathogenic mycoses [2, 
5, 7, 63]. The use of orally administered KTZ is required for the treatment of systemic mycoses 
such as paracoccidioidomycosis, blastomycosis, coccidiodomycosis, candidiasis and 
histoplasmosis [4, 7, 11, 14, 63-65]. KTZ may also be used to treat severe chronic muco-
cutaneous candidiasis and disabling candidal chronic paronychia [5, 66]. KTZ is useful for the 
management of serious mycoses of the gastrointestinal tract (GIT), chronic vaginal candidiasis 
and dermatophyte infections which are not responsive to other therapies [5, 7, 66]. KTZ has also 
been used as prophylactic therapy in immuno-compromised patients with neoplastic and/or other 
malignant conditions [67].  
 
High-dose KTZ has proved to be of therapeutic benefit in the treatment of metastatic prostate 
cancer since KTZ suppresses the biosynthesis of steroids and thus reduces androgen production. 
Topical KTZ is frequently used to treat ringworm, cutaneous candidiasis, pityriasis versicolor and 
seborrhoeic dermatitis and pityriasis capitis or dandruff caused by Pityrosporum spp. 
 
1.5.4. Resistance 
Over the years, resistant strains of Candida spp. to KTZ have emerged. The underlying 
mechanisms of resistance to azole antifungal agents involve gene overexpression and of efflux 
transport [50, 68-70]. Gene amplification or downregulation were found to be primary 
mechanisms of resistance in C. albicans [68]. Moreover, energy-requiring efflux pumps viz., 
ATP-binding cassette multidrug transporters may account for resistance towards azole antifungals 
such as KTZ [50, 68]. Overexpression or downregulation of transporter genes such as CDR1 or 
BEN appear to mediate azole resistance in species such as Saccharomyces cerevisiae [68].  
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Modifications to the ERG11 gene, which encodes the azole target enzyme in C. glabrata 
(CgERG11) up-regulates the CgCDR1 and CgCDR2 genes which in turn encode efflux pumps 
and are primary causes of resistance to azole antifungal drugs [70]. A further mechanism of 
resistance is a reduction in ergosterol biosynthesis as observed in a number of post-treatment C. 
albicans, C. neoformans and Histoplasma capsulatum species [69]. Furthermore, mutations have 
been reported in the CYP51A1 genes of resistant C. albicans isolates and it appears that an 
overexpression of CYP51A1 in C. albicans and C. glabrata may also contribute to reduced 
susceptibility to azole antifungal agents [69]. 
 
1.5.5. Dosage and administration 
KTZ is commercially available in South Africa as Nizoral
®
 200 mg tablets (Janssen-Cilag) and 
Ketazol
®
 200 mg tablets (Aspen Pharmacare) [61]. The adult dose for oral administration of KTZ 
for the management of chronic and recurrent vaginal candidiasis is 400 mg daily for five days 
[61]. Other indications usually require a dose of 200 mg KTZ daily which may be increased by 
200 mg to 400 mg twice daily if an adequate response is not achieved [61]. It is imperative that 
KTZ therapy is continued for at least one week after the symptoms of the condition have 
disappeared [61]. Treatment with KTZ is usually 14 days in duration and may be longer if the 
initial clinical response is poor [66].  
 
Topical preparations of KTZ include Nizcreme
®
 cream (2%) (Janssen-Cilag) and Ketazol
®
 cream 
(2%) (Aspen Pharmacare) [61]. In addition shampoo preparations of KTZ are also available for 
topical use and include Nizshampoo
®
 (2%) (Janssen-Cilag), Adco-Dermed
®
 shampoo (2%) (Adco 
Generics) and Kez
®
 liquid (2%) (Pharma Dynamics) [61]. Topical administration of KTZ 
involves application of the product to the affected area(s) twice a day until a few days after the 
symptoms have disappeared [61].  
 
There is a scarcity of appropriate paediatric formulations for KTZ in South Africa and 
extemporaneous preparations are generally manufactured and administered to paediatric patients 
in the public sector. These extemporaneous preparations of KTZ include suspensions that are 
manufactured by crushing KTZ tablets and mixing the resultant powder in a methylcellulose 
vehicle prior to administration. Limited data relating to the shelf-life and stability of these 
extemporaneous preparations is currently available and there is an increased potential for the 
stability of these extemporaneously prepared formulations to be adversely affected, thereby 
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possibly resulting in ineffective oral therapy with KTZ for the management of fungal infections in 
paediatric patients. Therefore, there is a need for the development of novel drug delivery systems 
for KTZ for paediatric use.  
 
1.5.6. Contraindications 
KTZ is contraindicated in patients with porphyria, pre-existing hepatic disease, hypersensitivity 
to imidazole drugs in pregnancy and nursing mothers [51, 61]. In mild liver disease it has been 
found that the pharmacokinetics of KTZ are not adversely affected, although the plasma levels of 
KTZ may be elevated due to impairment of metabolism [61, 71]. Hepatic damage is known to be  
a rare adverse effect of KTZ administration and may manifest itself with transient elevated levels 
of serum transaminase or fatal hepatitis [61, 71].  
 
1.5.7. Drug interactions 
Pharmacokinetic drug interaction studies revealed that KTZ may interact with a number of 
compounds as the molecule inhibits the cytochrome P450 isoenzyme 3A4 that is responsible for 
the hepatic metabolism of a large number of xenobiotics [53, 61, 72]. Animal studies have shown 
that KTZ inhibits N-demethylase and O-demethylase activity in hepatic microsomes as it binds to 
the CYP P450 component of the mono-oxygenase complex with little impact on NADPH-
cytochrome c P450 reductase activity [53]. This effect on hepatic microsomes has been shown to 
persist at low concentrations and over a long period of time [53]. The mechanism of interaction 
involves the formation of a nitrogenous ligand to cytochrome P450 as a direct interaction exists 
between the azole-nitrogen and the haem functional group of the cytochrome P450 enzyme [53]. 
It has been intimated that different P450 isoenzymes may have different binding affinities for 
KTZ and therefore KTZ may be a mixed inhibitor of hepatic N-demethylation [53]. 
 
The consumption of alcohol while on KTZ therapy may lead to a disulfiram-like reaction 
characterized by nausea, vomiting and facial flushing that may result in the induction of hepato-
toxicity [61, 73]. The anticoagulant effect of warfarin is known to be increased 3-fold with the 
concurrent administration of KTZ [61, 72]. The metabolism of compounds such as cyclosporine, 
tacrolimus and sirolimus are also known to be inhibited by KTZ resulting in elevated plasma 
concentrations of these compounds [61]. Raised levels of cyclosporine lead to nephrotoxicity and 
have been reported when cyclosporine and KTZ are co-administered. The mechanism of this 
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interaction is thought to be via inhibition of cyclosporine elimination by KTZ, increased 
absorption of cyclosporine or increased free cyclosporine caused by displacement from cell and 
protein binding by KTZ [72]. 
 
Drugs such as rifampicin, phenytoin, nevirapine and phenobarbitone are known to cause 
microsomal enzyme induction and have been reported to lower the plasma concentration of KTZ 
and therefore their concurrent use should be avoided [61, 72]. Conversely, the co-administration 
of protease inhibitors such as indinavir and ritonavir with KTZ may lead to increased levels of 
KTZ necessitating dose adjustment. The metabolism of corticosteroids is inhibited by KTZ and it 
is advised that the dose of corticosteroids such as methylprednisolone be halved when they are 
co-administered with KTZ [61, 72]. Other drugs for which a dose reduction may be necessary 
include calcium channel blockers such as dihydropyridines and verapamil that are metabolized by 
the CYP 3A4 system and the concomitant administration of KTZ with these compounds may lead 
to a marked antihypertensive effect in these patients [61].  
 
Ebastine, mizolastine, pimozide, cisapride and quinidine are contraindicated when using KTZ as 
the metabolism of these drugs is inhibited and increased plasma concentrations may result in 
cardiotoxicity characterized by torsade de pointes [61]. An increased risk of rhabdomyolysis is 
possible due to increased plasma concentrations of HMG CoA reductase inhibitors on co-
administration of KTZ and these drugs are therefore contraindicated when using KTZ [61]. A 
similar trend is observed with the concurrent administration of midazolam or triazolam which 
leads to a potentiation of the sedative effect of these compounds, therefore the oral use of these 
drugs is usually contraindicated and careful monitoring is necessary if used during KTZ therapy 
[61].  
 
1.5.8. Adverse effects 
The most common dose-dependent adverse effects of KTZ include nausea, dyspepsia, abdominal 
pain, diarrhoea, anorexia and vomiting [15, 51, 61]. The administration of KTZ with food or at 
bedtime or in divided doses may help to alleviate these effects [51]. Uncommon side effects such 
as headache, menstrual disruption, dizziness, photophobia, paraesthesia, hypersensitivity 
reactions, rash, pruritus, fever and chills may also be observed during KTZ therapy [61]. 
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Since KTZ inhibits steroid biosynthesis in humans, endocrinologic anomalies such as 
gynaecomastia, erectile dysfunction, oligospermia and alopecia may be experienced during 
therapy [51, 61]. Hepatotoxicity whilst on KTZ therapy may be characterized by a mild and 
asymptomatic increase in serum aminoferase level which reverts to the normal range 
spontaneously or after a few days [51, 61, 74]. However, symptomatic KTZ-induced hepatitis 
may occur in rare cases and may be potentially fatal [15, 51, 61, 74]. It is advisable to perform 
liver function tests prior to and during long-term therapy with KTZ [15, 51, 61, 74]. The earliest 
symptoms of hepatitis include anorexia, malaise, nausea and vomiting with or without dull 
abdominal pain and liver function tests must be conducted and treatment with KTZ must be 
discontinued immediately [15, 51, 61, 74].  
 
1.5.9. High risk groups 
1.5.9.1. Pregnancy 
KTZ has been found to be teratogenic, exhibits embryo-toxicity in animals and has been 
classified as a Category C compound [7, 61]. Although placental transfer is low a dose of 80 
mg/kg/day of KTZ reduced the pregnancy rate in female Wistar rats and when administered on 
days 6 to 15 of gestation a decrease in body weight and consumption of food was also observed 
[7, 75]. Post-natal studies performed on the rats indicated that a dose of 40 mg/kg/day induced 
maternal toxicity and 50% of the litter were stillborn [7]. High doses of KTZ administered in food 
(160 mg/kg/day) produced small litter sizes with very few live births [7]. The newborn rats were 
small at birth showing signs of toxicity and were unable to gain weight which resulted in death a 
few days after birth [7]. In addition 60% of the pups had cleft palates, reduced ossification of 
skull bones and axial skeletal defects [75]. 
 
The effect of oral administration of KTZ on birth outcomes in human subjects has been 
investigated but failed to establish an increased risk for congenital malformation in infants that 
were born from mothers who received 200 mg oral KTZ once or twice daily during their second 
and third months of pregnancy [76]. Consequently, the in utero exposure of the human embryo to 
low doses of KTZ (<400 mg/day) during pregnancy is thought to be safe [75, 76]. 
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1.5.9.2. Lactation 
Breast-feeding is contraindicated in patients taking KTZ as the drug is excreted in breast milk and 
may cause kernicterus in the nursing infant [61]. It is advised that nursing mothers should express 
and discard the milk during and for 24 to 48 hours after treatment with KTZ [61]. Studies 
performed on dogs have reported that KTZ has been detected in the breast milk at a level that is 
22% of the peak plasma concentration and KTZ use is therefore contraindicated during lactation 
[66]. 
 
1.5.9.3. Paediatric use 
The safety of KTZ in children under two years of age has not yet been established. However, 
since the mid-1980s KTZ has been used to treat paediatric patients including infants [7, 61]. 
Extemporaneous suspensions are prepared by crushing KTZ tablets for administration to 
paediatric patients. A dose of between 3 mg/kg/day and 6.5 mg/kg/day has been administered 
orally for the management of fungal infections in paediatric patients [61, 66] and paediatric doses 
of KTZ are based on body weight. The recommended dosage regimen is 50 mg once daily for 
children weighing 20 kg or less, 100 mg once daily for children weighing between 20 kg and 40 
kg and 200 mg once daily for children weighing more than 40 kg [7]. 
 
1.5.9.4. Geriatric use 
It has been reported that normal doses of KTZ may be used in elderly patients [66]. Dosage 
adjustments of KTZ are therefore not required in the geriatric population unless underlying 
conditions necessitating such changes exist [66]. Caution should be exercised when treating the 
elderly, particularly if there is a history of hepatic disease or in case of poly-pharmacy, since 
elderly patients frequently have multiple chronic medical conditions for which they are prescribed 
medicines. 
 
1.5.9.5. Renal impairment 
The use of KTZ in patients with renal impairment is not contraindicated since KTZ is not 
eliminated via the kidneys [66]. Urinary excretion of unchanged KTZ was nominal in subjects 
with renal insufficiency compared to that observed in healthy subjects [7]. Renal elimination is 
not considered to be clinically relevant in patients with renal disease and in healthy subjects. In 
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patients with severe renal insufficiency the absorption of KTZ has been reported to be slower 
with peak plasma levels being lower than that observed in healthy subjects [7]. Nonetheless the 
extent of absorption did not differ between the two groups and the initial differences noted in 
absorption were not statistically significant [7]. It has been reported that renal failure does not 
affect the peak plasma concentrations or the elimination half-life of KTZ as the drug is 
extensively metabolized by the liver [77]. 
 
Consequently, dosage adjustments in patients with renal impairment are not required with KTZ 
[7, 66]. Studies performed in patients on continuing ambulatory peritoneal dialysis (CAPD) 
demonstrated minimal penetration into the CAPD fluid, thereby indicating that KTZ is unlikely to 
be effective in the treatment of fungal peritonitis [66].  
 
1.6. Pharmacokinetics 
Pharmacokinetic studies on KTZ suggest that KTZ exhibits linear kinetics over the dose range of 
50 mg to 200 mg whilst higher doses of 400 mg to 600 mg exhibited non-linear kinetics [77]. The 
non-linear pattern noted in the kinetics of KTZ could be attributed to complete absorption, non-
linear elimination, saturation of a first-pass effect or a reduction in the volume of distribution 
[77]. Single-dose administration of KTZ reveals no evidence of non-linear kinetics whereas 
multiple-dose administration of KTZ suggests some degree of non-linearity in the disposition of 
KTZ following oral administration [77]. Routine therapeutic drug monitoring of plasma or tissue 
concentrations achieved during treatment with KTZ may be unnecessary as there seems to be no 
correlation between peak plasma levels of KTZ and the clinical response in patients with 
superficial or deep mycoses [7, 72]. 
 
1.6.1. Absorption 
KTZ, unlike miconazole and econazole, is known to be well absorbed following oral 
administration. The absorption of KTZ is usually complete within two to four hours after 
ingestion. Peak plasma concentrations after administration of 200 mg and 400 mg doses have 
been found to be 3 to 4.5 µg/ml [7] and 5 to 7µg/ml respectively [78]. It is worth noting that 
higher and more consistent plasma concentrations are observed when KTZ is administered with a 
meal which may be due to the highly lipophilic character of the molecule (log Po/w = 3.73) [7, 77, 
79]. The acidic environment of the stomach plays an important role in facilitating the dissolution 
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and subsequent absorption of KTZ [42, 44, 78]. Concomitant therapy with drugs that interfere  
with gastric pH or acid production in the stomach, including antacids such as sodium bicarbonate, 
aluminium oxide and H2-receptor antagonists such as cimetidine can therefore markedly reduce 
the absorption of KTZ following oral delivery [7, 28, 80].  
 
Other drugs that reduce gastric acidity include sucralfate, ranitidine, anticholinergic drugs and 
proton-pump inhibitors such as omeprazole [7, 51, 81]. Didanosine formulations in which 
antacids or buffers have been incorporated to prevent acid degradation of didanosine have also 
been shown to exert a similar effect on gastric pH [61]. Moreover, the concurrent administration 
of KTZ with Maalox
®
, an antacid preparation containing magnesium and aluminium hydroxide 
resulted in variable effects on plasma levels of KTZ [77]. It has been suggested that drugs or 
formulations that may impair the absorption of KTZ should be taken at least two hours before or 
after KTZ administration to ensure that an optimal therapeutic effect can be achieved [61, 66]. 
 
 It has been postulated that the absorption of KTZ may be impaired as a result of a reduction in 
gastric acid secretion caused by gastrointestinal tract abnormalities in patients infected with HIV 
[82]. It has been suggested that the co-administration of KTZ with 200 ml of 0.1 M hydrochloric 
acid (HCl) can improve the absorption of KTZ although the administration of HCl can be 
problematic due to its effect on dental enamel and potential irritation of the oesophagus [83]. In 
addition the preparation and administration of HCl may not always be convenient and therefore 
alternatives to HCl, viz., glutamic acid have been used in conjunction with KTZ administration 
[83]. Glutamic acid is available as glutamic acid hydrochloride which reacts with the aqueous 
contents of the stomach to release HCl following oral administration and it has been reported that 
glutamic acid hydrochloride exhibits fewer adverse effects than HCl [84]. The bioavailability of 
KTZ after oral administration of a 200 mg single-dose tablet was found to be approximately 75%, 
which may suggest that KTZ undergoes first-pass metabolism or significant pre-systemic 
metabolism during the absorption phase [7, 66].  
 
1.6.2. Distribution 
The distribution of KTZ is wide (99%) as KTZ is extensively bound to plasma proteins (84%) 
and erythrocytes (15%), although the volume of distribution is only 0.361 Lkg
-1
 for persons 
weighing 70 kg [61, 66]. Obesity does not have a significant impact on the distribution pattern of 
KTZ [66]. The distribution of KTZ, albeit extensive in the body, appears to be poor in respect of 
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the cerebrospinal fluid (CSF) and detectable levels of KTZ have been observed in the CSF of 
patients with inflammation of the  meninges [5, 61, 66, 85]. Therefore, the concentrations of KTZ 
that are likely to be achieved in the CSF are insufficient for the effective treatment of fungal 
meningitis [66, 72, 85]. However, the penetration of KTZ into saliva, urine, sebum and the 
cerumen has been found to be high and the drug can therefore be used to treat fungal conditions 
associated with these secretions [77]. 
 
1.6.3. Metabolism 
KTZ undergoes extensive hepatic metabolism and  major metabolites are excreted in the bile [7, 
77]. Various metabolic pathways have been identified for the metabolism of KTZ in humans. The 
main metabolic reaction includes oxidation of the imidazole ring followed by degradation of the 
oxidized imidazole [66]. Other pathways for the metabolism of KTZ include oxidative O-
dealkylation, oxidative degradation of the piperazine ring and aromatic hydroxylation. The 
metabolites of KTZ are not pharmacologically active [7, 66]. KTZ inhibits the metabolism of 
substrates of P450-dependent oxidation, viz., the P450 III A isoenzyme which appears to be 
responsible for the oxidation of KTZ [66]. Therefore, compounds that are inducers of P450 IIIA 
are capable of causing a reduction of plasma concentrations of KTZ and conversely, concomitant 
administration of KTZ with drugs metabolized by P450 III A may lead to increased levels of 
these molecules with the consequence of adverse drug reactions [51, 61, 66].  
 
1.6.4. Elimination  
The elimination half-life (t1/2) of KTZ has been reported to be between six and ten hours [66]. It 
has been suggested that the t1/2 of KTZ increases with dose and that after repeated dosing it may 
take between eight and ten hours for elimination to occur [51, 72, 79, 86-88]. In patients with 
neoplastic disease a mean t1/2 of 3.7 hours has been reported [67], contrary to a t1/2 of 55 minutes 
observed in severely immuno-compromised patients administered 400 mg KTZ on a daily basis 
[89]. KTZ has been shown to exhibit slow and dose-dependent elimination at concentrations of 
less than 0.1 mg/ml. The elimination half-life (t1/2β) of KTZ following administration of single 
oral doses of 100 mg, 200 mg and 400 mg was found to be 6.5, 8.1 and 9.6 hours respectively 
implying that the pharmacokinetics of KTZ may be best fitted to a 2 body-compartment (2-BCM) 
model [7, 79].  
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The excretion of KTZ in man occurs mostly in the faeces (57%) and in the urine (13%) [7]. 
Unchanged KTZ accounts for 20% to 65% of the drug recovered in the faeces and for 
approximately 2% to 4% of that in the urine [7]. The metabolites of KTZ in the urine include 
basic, polar acidic and conjugates of polar acidic compounds [7]. In cancer patients it was 
reported that less than 1% of the KTZ administered could be recovered in the urine six hours post 
administration [67]. The urinary excretion of KTZ is therefore minor and this is considered to be 
an insignificant route of elimination of the drug.  
 
1.7. Conclusions 
A review of the literature on ketoconazole including the description, physicochemical properties, 
stereochemistry and structure-activity-relationships, clinical pharmacology and clinical 
pharmacokinetics has been presented. The chemical name of KTZ is 1-Acetyl-4-[4[[(2RS, 4SR)-
2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl) 1, 3-dioxolan-4-yl]methoxy] 
phenyl]piperazine. The molecular formula of KTZ is C26H28Cl2N4O4 and its molecular weight is 
531.4. KTZ is a synthetic imidazole antifungal agent of the dioxolane series and occurs as a white 
or almost white powder.  
 
KTZ exhibits poor water solubility and is a dibasic compound with two pKa values of 6.51 and 
2.94 that are due to the ionisable imidazole and piperazine groups respectively. The piperazine 
moiety is ionized at low pH and thus the solubility of KTZ in an acidic environment is enhanced, 
which is essential for the absorption of the drug. The lipophilic nature of KTZ can be explained 
by the relatively high octanol/water partition coefficient or log P of 3.73 and the even higher 
calculated log P values. KTZ is soluble in organic solvents such as ethanol, toluene, ether, 
acetone, methanol, chloroform and dichloromethane.  
 
The ultraviolet (UV) absorption spectrum of KTZ reveals that KTZ has a wavelength of 
maximum absorption (λmax) of 205.6 nm. Infrared spectral studies reveal characteristic bond 
stretching in KTZ specifically for the C=O, C-Cl, C-O, C-C and C-N bonds. The stereochemistry 
of KTZ is particularly important for optimal antifungal activity and the cis-ketoconazole is 
thought to be the most potent antifungal of the four possible diastereomers of KTZ. It has been 
found that the pharmacophore of KTZ responsible for antifungal action consists of an imidazole 
ring joined to an asymmetric carbon atom to which a 2, 4-dichlorobenzene moiety is attached. 
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Introduction of a dioxolane ring and piperazine moiety in the KTZ structure are thought to 
improve the oral and antimycotic activity of the drug. 
 
A Differential Scanning Calorimetry (DSC) thermogram for KTZ reveals that the melting range 
is 146.42°C to 151.72°C and that the melting point of KTZ was found to be 149.27°C. An 
understanding of the DSC thermogram for KTZ is essential to elucidate the melting behaviour of 
KTZ prior to and after exposure to heat during formulation and manufacturing to identify if any 
polymorphic forms of KTZ may arise as a result of these processes. KTZ has been found to 
undergo increased hydrolysis at low pH and irreversible oxidation in aqueous media when it is in 
the un-protonated form in solution of pH between 8 and 12, whereas at temperatures < 50 °C 
there does not appear to be an impact on KTZ stability in solution. The mechanism of action of 
KTZ involves inhibition of sterol 14α-demethylase, a microsomal cytchrome P450-dependent 
enzyme system that leads to depletion of ergosterol in fungal cells, thereby affecting cell growth 
and proliferation. KTZ has also been found to inhibit the biosynthesis of steroids in humans that 
in turn impacts on the synthesis of testosterone and glucocorticoids.  
 
The broad spectrum of activity of KTZ makes it suitable for the treatment of a variety of fungal 
conditions including oral and topical infections. Systemic mycoses requiring oral KTZ therapy 
include paracoccidioidomycosis, blastomycosis, coccidiodomycosis, candidiasis, histoplasmosis, 
chronic mucocutaneous candidiasis, candidal paronychia, mycoses of the GIT, vaginal 
candidiasis and dermatophyte infections. KTZ is also useful for prophylaxis when treating 
immuno-compromised patients suffering from neoplastic disease or malignant cancer. High-dose 
KTZ may also be used for the treatment of metastatic prostate cancer. KTZ is also used for 
topical application for the treatment of ringworm, cutaneous candidiasis, pityriasis versicolor and 
seborrhoeic dermatitis and pityriasis capitis. Resistance to azole antifungals over the years has 
been found to be the consequence of overexpression of genes and efflux pump activity.  
 
KTZ is contraindicated in hepatic disease, porphyria, pregnancy and nursing mothers. Drug 
interactions have been noted with the concomitant use of compounds such as cyclosporine, 
tacrolimus, sirolimus, rifampicin, phenytoin, nevirapine,  phenobarbitone, indinavir,  ritonavir, 
corticosteroids such as methylprednisolone, calcium channel blockers, verapamil, ebastine, 
mizolastine, pimozide, cisapride, quinidine, HMG CoA reductase inhibitors, midazolam and 
triazolam with KTZ. Therefore, dosage adjustments and careful monitoring are often required 
during concurrent therapy.  
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Pharmacokinetic studies of KTZ reveal that it exhibits linear kinetics at doses of between 50 mg 
and 200 mg, whereas non-linear patterns have been observed at higher doses. The absorption of 
KTZ has been reported to be impaired by drugs such as antacids, H2-receptor antagonists, proton 
pump inhibitors and sucralfate which reduce gastric acidity, thereby indicating that a low pH is 
essential for the absorption of KTZ. This may be explained by the protonation of the piperazine 
group of KTZ at pH < 3, which increases the solubility and subsequent absorption of KTZ. It has 
been found that KTZ is extensively distributed in the body and it binds to plasma proteins and red 
blood cells. KTZ is metabolized in the liver and a number of different metabolic pathways for 
KTZ exist. Renal excretion is not a major elimination route of KTZ as it is mostly excreted in the 
faeces as unchanged drug. 
 
KTZ has physicochemical and pharmacological properties such as a high lipophilicity and oral 
antifungal activity, making it a suitable candidate for inclusion in an oral lipid formulation. Since 
there is a dearth of appropriate paediatric formulations, in particular for KTZ, it was deemed 
important to develop oral paediatric formulations of KTZ to optimize antifungal drug therapy in 
such patients. A liquid dosage form of KTZ with well-defined stability limits would be an 
advantage in antifungal therapy as it would circumvent the need for extemporaneous 
compounding by care-givers thus minimizing the risks associated with the lack of quality control 
of such preparations. Solid lipid microparticles (SLM) are novel solid lipid carriers that have been 
found to possess advantages over traditional colloidal carriers and therefore, it may be considered 
appropriate to develop SLM carriers for the delivery of KTZ to paediatric patients. 
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CHAPTER TWO 
SOLID LIPID MICROPARTICLES AS A DRUG DELIVERY SYSTEM FOR 
KETOCONAZOLE 
 
2.1. Introduction 
The development of advanced drug delivery systems is a challenging interdisciplinary field 
integrating areas of research such as pharmaceutics, biochemistry and physical chemistry, 
amongst others [90, 91]. Colloidal drug delivery systems (CDDS) have been investigated 
intensively over the past thirty years and delivery technologies viz., liposomes, polymeric 
nanoparticles and solid lipid nanoparticles have since been commercialized for therapeutic use  
[90-102]. With increasing numbers of lipophilic compounds emerging through drug discovery 
studies, it has become crucial that pharmaceutical scientists develop novel drug delivery systems 
that improve the aqueous solubility, increase dissolution rates and subsequently enhance oral 
bioavailability of hydrophobic drugs [103-105]. Furthermore, during the development of novel 
drug delivery systems important delivery considerations such as the toxicity of the system and 
protection of the active pharmaceutical ingredient (API) against chemical degradation must not be 
overlooked [93, 101, 106-108]. In addition an essential requirement of modern drug therapy is 
that controlled delivery of an API to the site of action in therapeutic concentrations is desired 
[109-112].  
 
A number of CDDS have been reported over the years and include liposomes [92-94, 113-120], 
nanoemulsions (NE) [121, 122], nanosuspensions (NS) [123-125], nanocapsules (NC) [126-131], 
polymeric particles [98, 111-113, 124, 128-130, 132-143] and solid lipid particles for which the 
dimensions are in the micrometeter and nanometer ranges [100-102, 106, 110, 144-157]. 
Although liposomes, NS and NE technologies have been successfully introduced commercially, 
there are major obstacles associated with the use of such CDDS that include costly excipients and 
equipment. In addition sustained drug release from formulations is not always possible through 
the use of  CDDS [90, 94, 158]. The use of polymeric nano- and microparticles has been 
associated with numerous challenges including the lack of large scale production methods that 
yield products of appropriate quality and that are acceptable to regulatory authorities [159-162]. 
In contrast, the use of CDDS consisting of lipids that are physiologically well tolerated and have 
a Generally Regarded as Safe (GRAS) status, have been deemed advantageous and lipid 
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formulations appear to be an attractive delivery system since they have the potential to modify 
drug release profiles and prolong drug release due to slower degradation of the lipid and 
protection of API from chemical degradation [101, 102, 163-166]. In addition lipid formulations 
have been used as an approach to solubilize hydrophobic drug candidates with the aim of 
enhancing oral bioavailability of poorly soluble compounds [103, 104, 123, 125]. The 
incorporation of a model lipophilic drug such as KTZ into a CDDS that possesses the ability to 
control the release of the API may not only assist in reducing the incidence of systemic adverse 
effects associated with long-term antifungal therapy but may also lower the frequency of dosing 
which would be beneficial in the treatment of immunocompromised and paediatric patients who 
are often unable to swallow large solid dosage forms and require intravenous therapy or 
extemporaneous preparations made by care-givers. Solid lipid particles in the nanometer or 
micrometer range have been shown to possess advantages of other CDDS in addition to being 
physiologically compatible, sustaining drug release and having the ability to be manufactured 
using large-scale production methods [99, 101, 102, 106, 163, 164, 166]. KTZ is known to be 
highly lipophilic and thus may be a good candidate for inclusion into a solid lipid carrier. 
Furthermore, the encapsulation of KTZ into a solid lipid carrier prior to incorporation into a 
liquid dosage form intended for paediatric use may offer a promising alternative drug delivery 
system for this population as KTZ is susceptible to chemical degradation.  
 
2.2. Description of colloidal drug delivery systems  
Liposomes have been extensively studied during the development of CDDS as the formulations 
are known to achieve a high drug loading, have low inherent toxicity and immunogenicity and are 
biodegradable [90, 93, 116, 118, 167]. However, liposomes tend to exhibit limited 
physicochemical stability on storage and undergo degradation in the gastrointestinal tract (GIT) 
following oral administration [94, 102, 162, 168]. Liposomal formulations have therefore not 
been considered promising systems for oral drug delivery and have rather been used for cosmetic 
applications [90, 125]. Cosmetic liposomal formulations have been successfully introduced into 
the clinical and pharmaceutical markets, despite limited data and information relating to these 
systems being available [90]. Furthermore, the excipients used in the manufacture of liposomes 
tend to be expensive and the possibilities for large-scale production of liposomal formulations are 
often limited [90, 125, 167, 169, 170].  
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Nanoemulsions (NE) were initially used as CDDS for the purposes of parenteral nutrition and 
were later applied to the intravenous administration of hydrophobic molecules [101, 122, 157, 
171-173]. As the extent of haemolysis and pain experienced at the site of injection are reduced 
with NE formulations such preparations have proved to be beneficial when administered 
intravenously [173]. One of the challenges of using NE as CDDS is the possibility of partitioning 
an API from the dispersed oil droplets into the continuous aqueous phase, which may impact on 
the stability of the API if it is susceptible to degradation in an aqueous environment [173, 174]. In 
addition the potential for controlled drug delivery is restricted in NE formulations as the API may 
easily diffuse from dispersed oil droplets [121, 175, 176].  
 
Another CDDS used for the formulation of poorly soluble drugs are nanosuspensions (NS), which 
were developed to enhance the oral bioavailability of hydrophobic compounds. The formulation 
of NS does not require the use of a matrix material and no excipients besides a vehicle comprised 
of oils or liquid polymers are required. Consequently, NS are relatively simple systems that can 
be produced on a large-scale using high pressure homogenization [123, 125]. A major 
disadvantage of liposomes, NE and NS is their inability to protect an API against chemical 
degradation due to the absence of a matrix material to encapsulate the API [125, 127, 140, 177]. 
 
Nanocapsules (NC) and polymeric nanoparticles (PN) were developed in an attempt to 
incorporate an API into a matrix in order to prevent the compound from being exposed to a 
hostile environment that may precipitate hydrolytic or light-induced degradation [127, 140, 177]. 
The presence of a polymeric membrane in NC and PN not only physically impedes the movement 
of an API within the matrix but also offers possibilities of retarding or modifying drug release 
from the matrix system [127, 140, 141, 177]. Although the polymeric membrane offers the 
advantage of a solid matrix and allows flexibility in the control of drug release and protection of 
the API against chemical degradation, PN have not been extensively commercialized due to the 
challenges associated with polymer chemistry, toxicity and the lack of possibilities of industrial 
scale production of PN [132, 178-180]. In addition the production of PN tends to be covered by 
broad patents which do not guarantee exclusivity and it may not always be profitable for research 
groups working in collaboration with pharmaceutical industries to develop PN products [90].  
 
Müller and his research group developed solid lipid nanoparticles (SLN™) [164] that were 
designed to avoid the shortcomings of existing technologies [164, 173, 181-187]. SLN are 
promising particulate carrier systems that are biodegradable, physico-chemically stable, have low 
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toxicity and can be manufactured on a large scale using high pressure homogenization [101, 108, 
110, 173, 182]. SLN are manufactured using biocompatible lipids which may be used to 
incorporate lipophilic, hydrophilic and poorly water-soluble drugs [101, 102, 108, 110, 173, 182]. 
Another advantage of SLN is that they exist in the solid state and therefore, can protect an 
incorporated API against chemical degradation and further offer possibilities of modifying drug 
release profiles [101, 108, 110, 165, 173, 182]. In addition the degradation velocity of SLN in 
vivo is slower than that observed for traditional colloidal systems [166]. SLN are known to be in 
the sub-micron size range of between 50 and 1000 nm, whilst solid lipid microparticles (SLM) 
range in size between 10 and 1000 µm [91, 99]. The qualitative composition of SLM is known to 
be equivalent to that of SLN and therefore, SLM may also be considered physiologically 
compatible, biodegradable, non-toxic and may be produced on a large scale [99, 188]. The 
respective size ranges of SLN and SLM essentially account for the differences in the applications 
and routes of administration applicable for both types of delivery system [99, 188]. The use of 
SLM in drug delivery has not been comprehensively explored, although SLM may have some 
applications for the in vivo targeting and selective administration of some therapeutic compounds 
[91, 99]. A broad list of drugs, miscellaneous and macrocyclic entities that have already been 
incorporated into SLM by various research groups, has recently been published [102, 139, 143, 
189-204]. However, no attempts have been made to incorporate ketoconazole (KTZ) into SLM 
for the purposes of oral drug delivery. Therefore, this project involved an investigation into the 
feasibility of incorporating KTZ into solid lipid microparticles (SLM) in an attempt to improve 
oral drug delivery of the compound for paediatric patients. Consequently, aqueous dispersions of 
KTZ-loaded SLM were developed, optimized and characterized during these studies.  
 
2.3. Solid lipid microparticles  
2.3.1. Overview 
Innovative solid lipid carriers have a wide range of applications including topical [205, 206],  
intravenous [207, 208] and solid lipid formulations for parenteral [207, 208], oral [209, 210], 
dermal [206], ocular [211, 212], pulmonary [163, 204, 213, 214] and rectal [215] routes of 
delivery. One of the major advantages of SLM over polymeric nanoparticles and o/w fat 
emulsions is the high degree of tolerability and the good oral bioavailability associated with these 
drug delivery systems when compared to polyester PN [101, 209]. Cosmetic and pharmaceutical 
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agents may be formulated into SLM in order to protect these compounds from the surrounding 
and potentially hostile environment [173, 174, 212, 216].  
 
In essence, SLM consist of an oil-in-water emulsion, similar to the emulsions used for parenteral 
nutrition except for the substitution of a liquid lipid or oil with a lipid that is solid at both room 
and body temperatures and that forms solid lipid microparticles [166]. Solid lipid carriers such as 
SLN and SLM consist of a lipid matrix manufactured by using physiologically well-tolerated 
lipids or a mixture of lipids viz., fatty acid esters of glycerol and polyglycerol, fatty acids, fatty 
alcohols, hydrogenated fatty acid esters and polar wax, amongst others [143, 189-204, 217]. The 
use of solid lipids or solid lipid mixtures with relatively different molecular structures has been 
reported to increase the drug loading capacity (DLC) and encapsulation efficiency (EE) of these 
technologies [108, 173]. SLM may be manufactured using a variety of manufacturing techniques 
as described in § 2.4, vide infra. However, small particles made from glycerides with short-chain 
fatty acids may not easily be produced as these often do not recrystallize during the 
manufacturing process [100, 218].  
 
Various liquid media such as highly ethylcellulose solutions and non-aqueous or aqueous media 
of PEG-600 have been used as the outer or dispersed phase for SLM dispersions [166, 219]. 
Aqueous dispersions of SLM may be stabilized using a single or combination of surfactants by 
means of electrostatic interaction using ionic surfactants such as sodium dodecyl sulphate (SDS) 
or by steric hindrance using non-ionic surfactants such as Tween 80 and/or Poloxamer 188 
(Pluronic
®
 F68) [220, 221]. The aqueous drug-loaded SLM dispersions may be used as a 
granulating fluid and incorporated in the manufacture of traditional dosage forms such as tablets 
or pellets that are designed to release SLM in a completely non-aggregated form following 
disintegration [166]. In addition SLM can be dried by spray-drying or lyophilization to enhance 
their long-term stability. The dry powder may be reconstituted with water to produce a 
suspension that would be useful as a paediatric dosage form  [102, 166, 173]. 
 
The use of SLM has been associated with shortcomings such as particle growth particularly on 
ageing and storage, unpredictable tendencies to gel, cream or coalescence. Furthermore, limited 
DLC and drug expulsion may occur on prolonged storage and can be attributed to dynamic 
changes within the lipid structure during polymorphic transitions following production [102, 151, 
222]. The burst release associated with SLM has also been reported as a result of phase separation 
during cooling in production of SLM with drug-enriched shells (Figure 2.1. III) [102, 108]. 
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Consequently, there is an urgent need for research to be undertaken to develop SLM carriers that 
circumvent these challenges and enhance the potential for oral drug delivery using such carriers.  
 
     Solid solution           Soft drug-enriched shell             Hard drug-enriched shell                 Lipid shell 
 
 
Drug molecularly dispersed          lipid core                                  lipid core                      Drug-enriched core         
in a matrix                                                                                                                             
               I                                            II                                            III                                          IV 
 
Figure 2.1 Proposed models of drug incorporation into SLN: (I) Homogenous matrix with molecular 
dispersion of the drug. (II) Lipid core surrounded by soft drug-enriched shell. (III) Drug-free lipid core 
surrounded by a hard shell consisting of lipid-drug mixture at eutectic concentrations. (IV) Lipid shell 
being drug-free or having low drug content surrounding the drug-enriched core [166, 173] 
 
2.3.2. Drug distribution in SLM matrices 
Drug distribution within  SLM matrices may influence drug release performance of the SLM 
formulation [188]. Incorporation of a drug into the SLM matrix may be complex and can be 
affected by several factors, including the solubility of the drug in the lipid and the 
physicochemical characteristics of the drug or the lipid carrier and stabilizer used in the 
production of the SLM. Furthermore, the techniques used to manufacture the SLM may impact on 
the model of drug incorporation into the SLM and production parameters may need to be altered 
to achieve appropriate loading for the desired model [166, 223]. A diagrammatic representation 
of four different models of drug incorporation into SLM postulated by Müller et al., is depicted in 
Figure 2.1 [166, 173, 188].  
 
These models include a homogenous matrix model, the soft and hard drug-enriched shell models 
and the drug-enriched core model. The proposed models of drug incorporation are applicable to 
ideal situations and in practice may occur concurrently [188]. The structure of the SLM matrix is 
chiefly influenced by the chemical nature of an API, the excipients used and associated 
interactions also depend on production process parameters [166, 173, 188]. However, it may not 
be feasible to observe the physical distribution of a drug in an SLM matrix since lipid excipients 
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are soft and have a low melting point [188]. Therefore, other means of visualization using 
computer simulation may have to be used to explore the microstructure of SLM systems [188]. 
 
2.3.2.1. Homogenous matrix model 
The homogenous matrix model (Figure 2.1 I) refers to a situation in which the drug is 
molecularly distributed or forms amorphous clusters within a solid lipid matrix [101, 166]. This 
model may be produced when highly lipophilic drugs are incorporated into a solid lipid matrix 
using hot high-pressure homogenization (HPH) or when cold HPH is used to produce drug-
loaded SLM [101]. No phase separation of the lipid and the API occurs during the production 
process and the homogenous matrix is formed following cooling and recrystallization of the oil 
droplets obtained from the homogenization of the drug-loaded micro-emulsion using HPH [101]. 
Drug release from these systems is determined by the rate of diffusion of the drug within the solid 
lipid matrix and this model has been reported to be ideal for sustaining and controlling drug 
release [166]. 
 
2.3.2.2. Soft and hard drug-enriched shell models 
In contrast, drug-enriched shell models (Figure 2.1 II and III, respectively) are produced when 
phase separation occurs during the production process and may be described as a solid lipid core 
surrounded by an outer shell enriched with drug [101, 166]. Models II and III are also produced 
using hot HPH and re-partitioning occurs during the cooling process [101]. However, the soft 
shell model (Figure 2.1 II) consists of a drug-enriched outer shell due to lipid precipitating 
initially, thereby forming a drug-free lipid core during cooling of the crude drug-containing 
micro-emulsion [166]. The rest of the drug-lipid mixture is continuously enriched with drug 
content until eutectic concentrations are reached and simultaneous crystallization of the lipid and 
the drug occurs leading to the formation of a soft shell surrounding the lipid core [166]. 
Conversely, the hard drug-enriched shell model (Figure 2.1 III) may be obtained when the API 
and the lipid have structural characteristics enabling them to fit together to form a layered solid 
brick-like structure [166]. The API fits into the imperfections of the lipid lattice thus forming a 
hard outer shell [166]. Burst release is observed from soft and hard drug-enriched shell models as 
the drug has a relatively short diffusion distance for release [166].  
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2.3.2.3. Drug-enriched core 
The drug-enriched core model (Figure 2.1 IV) is formed when a drug precipitates as it reaches its 
saturation solubility and a drug-enriched core and a poorly enriched shell is formed on cooling 
[166]. The liquid mixture is enriched within the lipid until eutectic concentrations are reached and 
on further cooling a mixture of drug and lipid precipitate simultaneously [166]. This model 
describes a situation in which the drug precipitates prior to crystallization of the lipid and oil 
droplets surrounding the drug-enriched core subsequently recrystallize to form a solid lipid shell 
that serves as a membrane through which the drug must diffuse, from the inner core [166]. The 
drug-enriched core model has been used to describe the incorporation of an API into SLM which 
demonstrates an initial burst release followed by controlled release of the API from the SLM 
[166]. This model therefore describes a situation where membrane-controlled release occurs in 
accordance with Fick’s first law of diffusion [166, 188]. 
 
2.4. Manufacture of solid lipid microparticles 
Solid lipid carriers such as SLM consist of a lipid matrix manufactured using physiologically 
well-tolerated lipids such as mono-, di- and/or triglycerides composed of fatty acid esters, fatty 
alcohols or fatty acids, waxes, cholesterol and phospholipids, amongst others [102, 139, 143, 189-
204]. The SLM matrices are produced and stabilized using surfactants such as poloxamers, 
polysorbates, lecithin amongst others and water which comprises the aqueous vehicle of the 
dispersion [102, 139, 190, 192, 199-201, 204]. Perusal of the literature reveals extensive lists of 
lipids and emulsifiers that may be used for the manufacture of SLM [102, 139, 143, 189-204]. 
The typical excipients used for the manufacture of SLM usually have a GRAS status and  
suggesting that SLM formulations are of suitable quality, are acceptable to international 
regulatory authorities and do not show signs of acute and/or chronic toxicity during in vivo use 
that have been observed when polymeric particles, particularly those made of polyester 
derivatives, are used [102, 164].  
 
SLM may be manufactured from solid lipids or a mixture of solid lipids using different 
manufacturing techniques (§ 2.5 vide infra). Solid lipids or solid lipid mixtures with different 
molecular structures may be used to increase the drug loading capacity and encapsulation 
efficiency of SLM [108, 173]. One of the crucial steps in the manufacturing process of SLM 
includes the dissolution or dispersion of a drug into a lipid to achieve controlled release profiles 
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for the SLM formulations [102, 207, 224]. Therefore, physical mixing of a drug and a lipid phase 
is not sufficient if drug release is to be prolonged and the melting of the lipid to incorporate the 
API is an essential requirement for the successful manufacture of sustained released SLM [102, 
207, 224]. Another important step in the manufacture of SLM is the dispersion of a molten lipid 
phase into an aqueous medium which may be undertaken using either mechanical or 
thermodynamic methods to promote the formation of SLM [102, 207, 224]. The emulsifying 
agent or stabilizer may be added either to the lipid or aqueous phase to produce a 
thermodynamically stable system depending on the predominant properties of the surfactant used 
and include hydrophilicity or lipophilicity, which may be deduced from its hydrophilic lipophilic 
balance (HLB) value of the compound [166].  
 
2.5. Production of solid lipid microparticles (SLM) 
2.5.1. Overview 
A number of methods have been used for the production of SLM viz., high pressure 
homogenization [164, 225], micro-emulsion formation [183, 225, 226], solvent evaporation [151, 
160, 193, 225, 227, 228], micro-channel emulsification [229, 230], cryogenic micronization 
[196], spray congealing [139, 143, 195, 198, 199, 203, 217, 231] and spray drying [203, 231]. 
High pressure homogenization (HPH) is preferred as it is efficient, reliable and does not involve 
the use of toxic organic solvents. In addition HPH does not require the use of large volumes of 
water for dilution of micro-emulsions compared to the other methods of production of SLM 
[102]. Nevertheless, HPH requires the use of costly equipment often not routinely available in 
small-scale laboratories [102]. An alternative method of production of SLM that does not require 
complex equipment and toxic organic solvents was therefore selected for the laboratory-scale 
production of SLM. A micro-emulsion technique was selected for use due to its simplicity and 
involves the use of high shear devices such as an Ultra Turrax
®
 homogenizer that is routinely 
available in research laboratories. 
 
2.5.2. High-pressure homogenization (HPH) 
High-pressure homogenization (HPH) has been used for a number of applications for many years 
for the production of emulsions and suspensions [102, 125]. HPH has also been used in the food 
industry for the homogenization of food products such as milk and in the pharmaceutical industry 
to produce parenteral emulsions [125]. The major advantage associated with the use of HPH is 
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the ease of scale-up of batch sizes, which makes it valuable in the large-scale production of solid 
lipid nano- or microparticles depending on the formulation composition and process parameters 
required [125]. The method of producing SLM by HPH is similar to that used for  the production 
of parenteral oil-in-water (o/w) emulsions [101, 125]. The underlying principle of HPH is based 
on the fact that the pre- or crude micro-emulsion is passed through a small gap, the piston-gap, 
which is approximately 10 µm, at a high velocity and pressure. Particle size is reduced due to 
shear force, cavitation and impaction [125]. Instead of using a piston-gap homogenizer, a jet-
stream homogenizer may also be used for particle size reduction. In such homogenizers the 
impact of two colliding high-velocity streams of the micro-emulsion results in particle diminution 
[125]. The jet stream homogenizer is preferred for the production of nano-crystals [125]. HPH 
can be conducted at high temperatures viz., hot HPH or at lower temperatures viz.,  cold HPH 
[101, 125]. In both cases an API is dissolved or solubilized in a lipid at a temperature 
approximately 5-10°C above its melting point [101]. A schematic representation of the 
manufacture of SLN or SLM using cold and hot HPH is shown in Figure 2.2. 
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Figure 2.2 Schematic representation of hot and cold homogenization for the manufacture of SLN and SLM 
adapted from [102] 
HOT 
HOMOGENIZATION 
TECHNIQUE 
COLD 
HOMOGENIZATION 
TECHNIQUE 
 
Melting the lipid and 
dissolving or dispersing the 
drug in the molten lipid 
Dispersion of the drug-loaded lipid 
mixture into a hot aqueous 
surfactant solution 
Dispersing the powder in an 
aqueous surfactant dispersion 
medium 
Solidification of the hot 
emulsion by cooling to room 
temperature 
Aqueous dispersion of 
solid lipid nanoparticles (SLN™) or 
solid lipid microparticles (SLM) 
Solidification of the drug-loaded 
lipid in liquid nitrogen or dry ice 
Grinding in a ball, mortar or 
powder mill to ≈ 50-100µm 
Pre-mixing using a stirrer to form a 
coarse pre-emulsion 
High pressure homogenization at a 
temperature above the melting 
point of the lipid 
Hot o/w micro- or nano-emulsion High pressure homogenization at 
room temperature or below 
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2.5.2.1. Hot high-pressure homogenization 
In the hot HPH technique, a drug-lipid molten phase is dispersed in a hot aqueous surfactant 
solution heated to the same temperature as the lipid phase whilst stirring to form a micro- or pre-
emulsion [102]. The pre-emulsion is homogenized using a high-pressure homogenizer such as a 
piston-gap homogenizer or a jet stream homogenizer to produce a nano- or micro-emulsion [101, 
102, 125]. The emulsion is subsequently cooled to room temperature (25ºC)
 
to allow 
crystallization of the dispersed lipid droplets in the nano- or micro-emulsion to form nano- or 
microparticles, respectively [101, 102].  
 
Hot HPH is associated with major shortcomings such as temperature-induced degradation of API, 
partitioning of drug into the aqueous phase during homogenization and the complexity of the 
crystallization process of the micro-emulsion, which may result in lipid modification and/or the 
formation of super-cooled melts [102]. Therefore, hot HPH is ideal for the production of SLM 
containing lipophilic and thermostable drugs. In addition coalescence of particles may occur 
during homogenization due to the high kinetic energy of the particles if the homogenization 
pressure is too high or the number of homogenization cycles is excessive [125, 187]. It has been 
reported that the use of 3-5 homogenization cycles at a homogenization pressure between 500-
1500 bar tends to produce SLN or SLM products of high quality [100, 225].  
 
2.5.2.2. Cold high-pressure homogenization 
Cold HPH involves rapid cooling of a drug-lipid molten phase with dry ice or liquid nitrogen in 
order to increase the brittleness of the lipid to permit uniform distribution of the API throughout 
the lipid. The drug-containing solid lipid is then ground to form lipid particles of sizes ranging 
between 50 and 100 µm [102]. The lipid particles are dispersed in a cold surfactant solution using 
a high speed stirrer to form a pre-suspension which may then be homogenized at or below room 
temperature [102]. The cold HPH technique is preferred for thermolabile drugs as the exposure to 
high temperature during the dispersion of the drug in the lipid is relatively short [102]. 
Furthermore, cold HPH may be used for hydrophilic drugs since this technique minimizes the 
partitioning of hydrophilic molecules from the lipid phase into the aqueous phase of the 
dispersion, during the high pressure homogenization process [102, 232]. However, a major 
drawback of cold HPH is that the method increases the fragility of the lipid at low temperatures 
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that  may lead to particle aggregation and result in the formation of relatively large particles with 
a wide particle size distribution [101]. 
 
2.5.3. Micro-emulsion formation 
The micro-emulsion technique, developed and patented by Gasco [183, 184], involves the 
formation of a micro-emulsion at a temperature above the melting point of the lipid used. The 
micro-emulsion may be produced by heating a mixture of water, surfactant and co-surfactant to 
the same temperature as the molten lipid phase [102]. The lipid phase containing the drug is then 
mixed under mild stirring conditions with the aqueous surfactant solution [102]. The micro-
emulsion formed is then dispersed in a cold (2-3°C) aqueous medium under mild mechanical 
stirring to promote precipitation of nano- or microparticles [102]. The volume ratio of hot micro-
emulsion to cold water is usually in the range of 1:25 to 1:50 [102]. Micro-emulsions already 
contain droplets of submicron size which are formed spontaneously without application of energy 
[102, 183] and it has been reported that the particle size is influenced by the velocity of the 
distribution processes [233]. The process of producing the micro-emulsion may be modified to 
produce different products variants, including oil-in-water and water-in-oil melt dispersions and 
water-in-oil-in-water multiple emulsions [200, 201].  
 
2.5.3.1. Oil-in-water melt dispersion 
An oil-in-water (o/w) melt dispersion technique, also known as hot melt microencapsulation is 
generally used when lipophilic drugs are to be included in the product and it is similar to the 
micro-emulsion technique [160, 190, 191, 193, 194, 200, 204, 228]. The drug to be included is 
dissolved in molten lipid at a temperature of 5-10 ºC above the melting point of the lipid and the 
drug-lipid mixture is subjected to emulsification in an aqueous surfactant solution at the same 
temperature using a high-shear device such as an Ultra-Turrax
®
 or Silverson
®
 mixer [160, 191, 
193, 200, 204, 228]. The o/w emulsion, that is produced, may then be dispersed into a large 
volume of an ice-cooled aqueous phase to produce SLM in an aqueous dispersion [160, 191, 193, 
200, 204, 228]. The hardened microparticles are harvested following filtration, rinsing with water 
and drying using a vacuum desiccator [200].  
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2.5.3.2. Water-in-oil melt dispersion 
The water-in-oil (w/o) melt dispersion technique is a variation of the o/w melt dispersion 
approach and is used for the incorporation of hydrophilic API into SLM [199]. The w/o 
dispersion method avoids the use of water to prevent the drug from partitioning into the external 
aqueous phase that results in low drug loading in the microparticles [199]. The API and the 
surfactant are dispersed into the molten lipid, followed by addition of a hot non-aqueous 
continuous phase such as silicone oil to produce a w/o dispersion [199]. The w/o dispersion is 
subsequently subjected to rapid cooling by immersion in an ice bath and cold oil is incorporated 
into the mixture as it cools, to form solid lipid microparticles [199]. Centrifugation may be used 
to separate the microparticles from the oil followed by washing and drying to obtain the SLM 
[199].  
 
2.5.3.3. Water-in-oil-in-water multiple emulsion 
The water-in-oil-in-water (w/o/w) multiple emulsion technique is preferred for water-soluble 
drugs [201]. The lipid is melted and the API is dissolved in an aqueous surfactant solution which 
is heated to the same temperature as the lipid phase [201]. The aqueous solution is then 
emulsified with the molten lipid to produce a primary w/o emulsion which is then mixed in an 
external aqueous phase to generate the w/o/w emulsion [201]. The dispersion obtained is cooled 
in an ice bath [201] or at room temperature [228] prior to filtering, rinsing and drying the particles 
that are produced in a vacuum desiccator.  
 
2.5.4. Solvent evaporation 
The solvent evaporation technique, also known as solvent emulsification, was developed by 
Sjöström and Bergenståhl and involves the formation of solid lipid nano- or microparticles by 
precipitation from o/w emulsions [227]. A water-immiscible organic liquid such as chloroform is 
used to dissolve the lipid and the drug is incorporated as a solid which has been finely ground 
using liquid nitrogen or as an aqueous solution [160, 193]. The drug-containing organic phase is 
then subjected to emulsification with an aqueous phase containing an emulsifying agent [102]. 
The solvent is subsequently evaporated and the emulsion produced is transferred into an ice-
cooled aqueous phase and stirred to induce precipitation of lipid microparticles from the aqueous 
phase [102]. Evaporation can be performed under low pressure, for example between 4-6 kPa 
[234]. The major advantage of this technique is that it precludes the drug and the lipid carrier 
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from being exposed to high temperatures as experienced in high-pressure homogenization and 
melt dispersion approaches to manufacture. However, the use of organic solvents limits the use of 
the method particularly in development of parenteral and paediatric formulations and it was 
therefore not selected for the manufacture of SLM in these studies.  
 
2.5.5. Micro-channel emulsification 
Micro-channel emulsification is a novel technique used to manufacture mono-disperse o/w and 
w/o emulsions without the need for high mechanical shear and requires lower energy inputs 
compared to traditional emulsification processes [229, 230]. This is achieved by use of a silicon 
micro-channel plate through which the dispersed and continuous phases are forced to generate 
mono-disperse emulsion droplets [229, 230]. The sizes of these droplets are controlled by the 
structure of the micro-channel plate and the SLM aqueous dispersion is obtained on cooling the 
emulsion to room temperature [229, 230]. 
 
2.5.6. Cryogenic micronization 
The cryogenic micronization technique requires the use of drug-containing lipid matrices formed 
by melt dispersion or solvent stripping for the production of SLM. The drug may be dispersed 
into the molten lipid using a magnetic stirrer or the drug and the lipid may be dispersed into an 
organic solvent mixture to produce the lipid matrices. These lipid matrices are stored at 
temperatures as low as -80ºC and are micronized in an apparatus through which liquid nitrogen is 
purged to produce finely divided powders. These may be sieved using an automatic sieving 
apparatus [196]. The SLM particles obtained may vary from 5-5000 µm in diameter, depending 
on the sieve selected to segregate the powders [196]. 
 
2.5.7. Spray congealing 
The spray congealing method of producing SLM is often referred to as spray chilling. The API is 
initially dissolved in a lipid carrier that has previously been heated to a temperature above its 
melting point and the drug-lipid melt is subsequently atomized, with a pneumatic nozzle, into a 
vessel that is placed into a dry ice bath, prior to drying using vacuum at room temperature for 
several hours [139, 143, 198, 199, 203, 217, 231]. The drug-lipid mixture may also be atomized 
by use of ultrasound to generate small droplets that fall freely and solidify upon cooling at room 
temperature [195, 198, 199]. An alternative means of producing the SLM particles may involve 
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the use of a high-speed rotating disc onto which the drug-lipid melt is poured [143]. The rotation 
of the disc in a cooling chamber causes the drug-lipid mixture to spread evenly and spray from 
the peripheral edges of the disc onto a chiller, which forms a surface from which the 
microparticles may be collected [143]. 
 
2.5.8. Spray drying 
This technique is often used for the production of SLM containing lipophilic drugs as it is a 
relatively simple process [203, 231]. The lipid and hydrophobic API are dispersed concurrently 
into an organic solvent to form a drug-containing lipid mixture [203, 231]. The mixture produced 
is then spray-dried, resulting in the formation of microparticles [203, 231]. The major drawback 
of this technique is the use of organic solvents which is not desirable in the formulation of SLM 
intended for oral drug delivery, particularly for paediatric patients.  
 
2.6. Characterization of SLM 
2.6.1. Overview 
The characterization of aqueous dispersions of SLM is an important step in the formulation 
development and assessment process as it gives the formulation scientist an opportunity  to make 
predictions regarding the physical stability, release kinetics and quality of the resultant product 
[101, 102]. Nonetheless, it is worth noting that owing to the small colloidal particle size range of 
SLM systems and the multiple dynamic phenomena involved with the use of lipids viz., the 
kinetics in hysteresis and the super cooling phenomena, characterization of SLM dispersions can 
be complicated [102]. Sample preparation may for instance, result in changes in the physical 
properties of SLM such as the kinetics, crystallization patterns or lipid modification of the 
particles which in turn, may produce erroneous results [102]. Subsequently, such physical 
changes may lead to spontaneous gelation or other macroscopically visible changes in the SLM 
formulation [102]. It is therefore imperative that samples be handled with care, particularly 
during sample preparation during analysis of SLM formulations. Acquaintance with techniques 
used in sample manipulation is essential for optimal results to be derived from characterization 
studies. Typical performance characteristics of SLM systems that must be evaluated include 
particle size and zeta potential. However, it should be borne in mind that other parameters such 
as the degree of crystallinity and lipid modification, in addition to the possibility of coexistence 
of multiple colloidal systems, must also be assessed. 
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2.6.2. Image analysis 
2.6.2.1. Overview 
Image analysis provides direct information about the size, shape and surface morphology of SLM, 
which may not be accessible when techniques that measure the particle diameter such as for 
example laser diffraction (LD) and/or photon correlation spectroscopy (PCS) that rely on light 
scattering effects are used [102]. In addition, image analysis allows the type of particle surface to 
be evaluated from direct observation with microscopic methods. Image analysis may be performed 
using light and electron microscopy. Light microscopy permits the visualization of particles with 
sizes in the micrometer range and high-resolution microscopy such as electron microscopy using a 
scanning electron microscope (SEM) and/or a transmission electron microscope (TEM), are 
required to view particles in the micrometer or nanometer range [102].  
 
The main disadvantage of image analysis is the need for pre-treatment of samples prior to 
visualization. This may result in particle aggregation or solvent removal and thus may adversely 
affect the size and/or shape of the SLM [102, 235]. Image analysis methods are complementary, 
and each approach has advantages and disadvantages [102]. Different information may therefore 
be extracted from each of the methods and different characteristics of the microparticles may 
subsequently be elucidated [102].  
 
2.6.2.2. Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) allows for visualization of microparticles under dehydrated 
conditions since the preparation of samples prior to analysis involves drying using either an oven 
or a vacuum pump. Imaging is performed at high voltages under high vacuum [235]. The sample 
is deposited on a graphite strip and allowed to air- or oven-dry for a few minutes, after which it is 
metalized with gold and viewed under an accelerating voltage of approximately 10-20 kV [235]. 
SEM produces three-dimensional images of microparticles which facilitates the viewing of 
surface morphology. However, shrinking of the microparticles may occur as a result of drying of 
the sample under high vacuum or removal of the solvent which may change the molecular 
structure of the microparticles [235].  
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2.6.2.3. Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) can be used to investigate the size, shape and surface 
morphology of a variety of colloidal particles [236]. TEM generally has a higher resolution than 
SEM and provides a better indication of the particle size distribution of colloidal dispersions. 
Samples may be prepared prior to TEM analysis using techniques such as staining, freeze-
fracturing or cryo-electron microscopy. Staining is generally sufficient to obtain accurate 
information relating to particle size, shape and surface morphology of aqueous SLM dispersions. 
The sample is usually plated on a copper grid coated with a carbon film and is left to dry for 30 
seconds prior to staining with a dye such as phosphotungstic acid or uranyl acetate. The stained 
sample is dried at room temperature for approximately 30 seconds prior to visualization using 
TEM [236]. 
 
2.6.2.4. Atomic force microscopy 
Atomic force microscopy (AFM) is another imaging technique used to visualize the shape and 
surface morphology of colloidal particles. AFM monitors the force acting between a surface and a 
probe tip to obtain spatial resolution of 0.01 nm, which is then used for imaging [102]. AFM is an 
imaging technique that does not require sample pre-treatment and the need for sample 
conductivity [102, 235]. The hydrated sample is usually plated onto a microscope slide or a mica 
plate and since this approach permits rapid visualization of SLM,  in situ changes which occur at 
the interface of the particles may also be observed [102]. A fine AFM probe is used to assess the 
outer layer of the particle. The hardness of the particle surface can be determined by contact AFM 
by comparing it to that for a standard silicon surface [166, 221]. Therefore, the model of drug 
incorporation into the SLM matrices may be predicted using AFM analysis [102]. Immobilization 
of particles by contact AFM can be easily accomplished for particles in the micrometer range due 
to their higher rate of sedimentation [101]. However, smaller particles that are inherently in 
constant and rapid motion may not be accurately viewed using contact AFM without removal of 
the solvent in which they are dispersed. In addition it has been established that solvent removal 
may distort the shape of SLM as well as their molecular structures [102, 235]. AFM was not used 
in these studies. 
 41 
 
2.6.3. Particle size analysis 
Photon correlation spectroscopy (PCS) and laser diffraction (LD) are routine approaches for the 
assessment of particle size in colloidal dispersions. PCS may also be used in conjunction with LD 
to determine the polydispersity indices of colloidal dispersions [102]. Both LD and PCS do not 
directly measure particle size but measure the light scattering effects of colloidal dispersions, 
which may then be used to calculate particle size [102]. Inaccurate data may be obtained in cases 
where non-spherical or platelet-like particles are present in a colloidal dispersion [237]. The use 
of LD and PCS may not provide an exact representation of the size of SLM for samples with 
large particle size distribution (PSD) or polydispersity indices (PI) and in such cases, the use of 
electron microscopy may be more appropriate. PCS, also known as dynamic light scattering, 
measures the intensity fluctuations of scattered light upon particle movement and allows the 
measurement of particles in the size range of a few nanometers to approximately 3 µm. PCS is 
more likely to detect nanoparticles than microparticles. LD is generally used to characterize 
particles in the micrometer range and covers a broad range from nanometer to the lower 
millimeter  size range [102]. Since LD technology was not available in our laboratory, particle 
size analysis was performed using imaging analysis coupled with Soft Scanning Imaging 
Software (SSIS) as PCS was deemed inappropriate for measuring SLM particles, which were 
larger than 3 µm in diameter. 
 
2.6.4. Zeta potential analysis 
The zeta potential (ZP) of a colloidal dispersion represents the electric potential at the 
hydrodynamic plane of shear and is a key property of a dispersion that is used to predict the 
physical stability of  dispersions, particularly during and following storage for extended periods 
of time [102, 148, 238, 239]. The ZP of SLM depends not only on particle charge but also on the 
dispersant used [235, 238]. It has been established that small changes in pH or ionic strength of a 
medium may have an impact on the ZP of SLM and may result in the interaction of particles 
according to their zeta potential and not according to their surface charge [235, 238]. A large 
negative or positive zeta potential results in mutual repulsion of particles, thereby enhancing the 
physical stability of a colloidal dispersion by preventing aggregation of the particles [238]. The 
ZP of SLM dispersions may be determined using Laser Doppler Anemometry (LDA) coupled 
with a zetasizer and subsequently applying the Helmholtz-Smoluchowsky equation (Equation 
2.1) to the resultant data [235, 239]. 
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                          Equation 2.1 
 
where, 
    electrophoretic mobility 
ε = dielectric constant  
ξ = zeta potential 
η = viscosity of the dispersion medium 
 
The measurement of the ZP of particles in distilled water or water with low conductivity provides 
a comprehensive assessment of the dispersion or aggregation behaviour of colloidal particles. The 
ZP of a colloidal dispersion, stabilized by electrostatic stabilizers alone, indicates stability of the 
dispersion if the ZP is ≤ -30 mV or ≥ +30 mV [238]. A zeta potential of magnitude < -30 mV or < 
+30 mV is indicative of a stable colloidal dispersion when steric stabilizers are used in 
combination with electrostatic stabilizers, since steric stabilizers decrease the ZP due to a shift in 
the shear plane of a particle [235, 238]. The measurement of ZP was therefore used to predict the 
stability of the SLM dispersions throughout the formulation development process and following 
storage of the dispersions. 
 
2.6.5. Crystallographic analysis 
2.6.5.1. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) is used to establish the melting point(s) and melting 
enthalpies of different modifications of solids including lipids and may therefore be used to 
predict the stability associated with different modifications of a lipid [102, 148, 240, 241]. The 
principles of DSC are described in detail in Chapter 4, § 4.1.1, vide infra. DSC was used in 
preformulation studies to assess the polymorphism of KTZ and solid lipids prior to the production 
of KTZ-loaded SLM. The melting enthalpies observed following DSC analyses of aqueous SLM 
dispersions may be used to calculate the recrystallization index (RI) of SLM formulations. The RI 
value may be used as a measure of the percentage lipid that has recrystallized during  storage of  
aqueous SLM dispersions and may be calculated using Equation 2.2 [240].  
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              Equation 2.2 
where RI = recrystallization index 
           ΔH   molar melting enthalpy 
 
2.6.5.2. X-ray diffraction  
X-ray diffraction (XRD) assesses the dimensions and length of the long and short spacing within 
a lipid lattice [102]. Synchrotron radiation can be used to avoid the long measurement times and 
associated sensitivity issues of conventional X-ray determinations. Wide-angle X-ray diffraction 
(WAXD) may be used to establish the lamellar arrangement of lipid molecules, elucidate the 
polymorphic behaviour and degree of crystallinity of fatty acid chains in triacylglyceride 
compounds [241, 242]. WAXD measures the length of long and short spacings between alkyl side 
chains in a triglyceride lipid layer such that discrimination between crystalline and amorphous 
substances may be made based on the number of reflection bands in the WAXD spectrum [243]. 
WAXD may be used to fully elucidate the polymorphism and crystallinity of lipids, SLM or an 
API in a SLM dispersion. It is a powerful tool when used in conjunction with DSC for the 
characterization of SLM [244, 245]. Accessibility of WAXD equipment remains a challenge for 
the routine characterization of lipids [102] and the method was therefore not used in the analysis 
of SLM dispersions. Crystallographic analyses were performed during preformulation studies 
using DSC only.  
 
2.6.6. Drug loading and encapsulation efficiency  
The drug loading capacity of a carrier system for a specific API determines the suitability of the 
carrier system. It is a crucial parameter that needs to be evaluated during formulation 
development and optimization studies [101, 207, 246]. CDDS such as SLM are expected to 
protect an API from chemical and light-induced degradation and therefore, the API should remain 
encapsulated within the lipid matrix [207]. Furthermore, it is desirable that such delivery systems 
have a high encapsulation efficiency (EE) and long-term retention of the entrapped drug [207].  
Consequently, DLC and EE are essential characteristics of SLM which need to be assessed during 
formulation development as these may impact on the drug release characteristics of SLM 
formulations. Drug loading capacity (DLC) is generally expressed as the amount of drug added to 
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a colloidal dispersion relative to the total amount of lipid phase used [101, 247] and  includes the 
lipid and API. DLC is calculated using Equation 2.3. 
 
            
                        
                             
             Equation 2.3 
 
Several factors affect the drug loading capacity of SLM including the solubility of the API in the 
molten lipid, miscibility of the drug melt and molten lipid, the chemical and physical structure of 
the solid lipid matrix and the polymorphic state of the lipid material (s) [101]. In order to achieve 
a high drug loading capacity, a drug needs to be sufficiently soluble in the lipid melt and 
demonstrate a higher solubility than required in the melt as solubility decreases on cooling and 
may therefore be lower in the solid lipid form [101]. Solubilizers may be used to increase the 
solubility of a drug in the lipid phase. The use of lipids with a mixture of mono-, di- and 
triglycerides increases the solubilization of a drug [101]. In addition the use of lipid mixtures may 
promote the formation of imperfections in a crystal lattice, thereby creating more space to 
accommodate the drug within the lipid matrix [101]. The polymorphic form of a lipid may also 
dictate whether drug will be retained in the lipid matrix or expelled following crystallization and 
during storage [101].  
 
The encapsulation efficiency of a drug depends on the total amount of drug added to the lipid. 
The higher the drug content, the higher the theoretical EE [248]. EE is usually expressed as the 
amount of drug entrapped in the particles relative to the total amount of drug added and can be 
calculated using Equation 2.4 [246, 247]. The extent of drug incorporation into the SLM may be 
quantified using analytical techniques such as UV spectrophotometry or high performance liquid 
chromatography (HPLC). The DLC and EE of KTZ-loaded SLM were investigated using a RP-
HPLC method that was developed, optimized and validated as described in Chapter 3, vide infra. 
 
                                                      
                        
                    
                 Equation 2.4  
 
2.7. Conclusions 
The development of advanced colloidal drug delivery systems (CDDS) stemmed from attempts to 
address challenges in drug delivery such as enhancing the bioavailability of hydrophobic drugs, 
protecting API from chemical degradation and achieving controlled drug delivery to the site of 
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action. Colloidal systems such as liposomes, nano-emulsions, nanosuspensions, nano-capsules, 
polymeric particles and solid lipid carriers have been developed and these CDDS demonstrate 
advantages and limitations which restrict their application in human and veterinary drug delivery. 
In an attempt to minimize the shortcomings of the existing systems, novel drug delivery systems 
such as solid lipid nano- (SLN) and microparticles (SLM) have been developed using 
physiologically compatible lipids such as glycerides of fatty acids. The major difference between 
SLN and SLM is directly related to their respective size ranges. SLN are known to range between 
50 and 1000 µm in size whereas SLM range between 10 and 1000 µm in diameter. SLN or SLM 
dispersions are suspended in an aqueous medium and are formulated using lipid(s) that are solid 
at room temperature and a surfactant or combination of surfactants to stabilize the resultant 
particles.  
 
The use of solid lipid carriers has numerous advantages over other CDDS technologies such as 
polymeric nanoparticles and liposomes, including their biocompatibility, good oral 
bioavailability, possibility of drug targeting to various parts of the body and large-scale 
production. In addition it is possible to control or modify drug release profiles as the degradation 
velocity of solid lipid carriers in vivo is slower than that of other colloidal systems. Furthermore, 
the solid lipid matrix provides excellent protection against chemical or light-induced degradation 
and SLN and SLM carriers have been shown to exhibit the potential for drug delivery via the oral, 
topical, parenteral, dermal, ocular, pulmonary and rectal routes of administration. Drug 
incorporation into SLM matrices depends on a number of factors including solubility of the drug 
in the lipid melt, physicochemical properties of the drug, lipids and surface active agents in 
addition to production parameters used in the manufacture of SLM formulations. Three models of 
API incorporation have been proposed for SLM matrices although in practice, these may occur 
simultaneously. The models of drug incorporation include a homogenous matrix, soft and hard 
drug-enriched and the drug-enriched core models. 
 
The production of SLM may be achieved using different approaches including high pressure 
homogenization, micro-emulsion techniques, solvent evaporation, micro-channel emulsification, 
cryogenic micronization, spray congealing and spray drying. The quality of SLM formulations 
must be evaluated during formulation development and optimization and parameters such as 
particle size (PS), shape, surface morphology, zeta potential (ZP) and lipid polymorphism must 
be determined. SLM formulations may be characterized using photon correlation spectroscopy 
(PCS) which can be used in conjunction with laser diffraction (LD) to measure the particle size of 
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SLM. The physical stability of an aqueous SLM dispersion may be assessed using Laser Doppler 
Anemometry (LDA) to determine the zeta potential of the SLM which enables predictions to be 
made regarding the long-term stability of the SLM dispersion. It is important to note that PCS and 
LD provide information only on the particle size of the SLM which is indirectly measured from 
light scattering effects. Information relating to shape and surface morphology are not obtained 
from PCS and LD analysis. Imaging analysis is required to elucidate the shape and surface 
morphology of SLM and is usually achieved using high-resolution microscopy such as SEM and 
TEM.  
 
Crystallographic analysis of SLM dispersions may be performed using complementary techniques 
such as differential scanning calorimetry (DSC) and wide-angle X-ray diffraction (WAXD) 
which reveal polymorphic modifications and the presence of crystalline structures. The stability 
associated with lipid modifications may be deduced from DSC analyses which may therefore be 
used to predict the behaviour of a lipid after being exposed to heat and the extent of 
recrystallization during storage.  
 
It is essential that the loading capacity of the SLM carriers be assessed to determine the suitability 
and usefulness of a specific drug carrier system. Analytical techniques such as UV 
spectrophotometry and high performance liquid chromatography (HPLC) may be used to 
determine the drug loading capacity (DLC) and the encapsulation efficiency (EE) of SLM for an 
API.  
 
The feasibility of incorporating the hydrophobic drug, KTZ into SLM as potential drug carriers 
was investigated and is reported in Chapter 5, vide infra, where aqueous dispersions of KTZ-
loaded SLM were developed using a micro-emulsion technique. The KTZ-loaded SLM 
formulations were characterized in terms of PS, particle shape and morphology and ZP using 
some of the techniques reviewed in this chapter. In addition the DLC and EE of the SLM 
preparations were established using RP-HPLC during formulation development and stability 
studies.  
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CHAPTER THREE 
DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC METHOD FOR THE ANALYSIS OF KETOCONAZOLE 
 
3.1. Introduction 
3.1.1. Overview 
The quantitative analysis of ketoconazole (KTZ) in biological fluids [249-259] and 
pharmaceutical dosage forms has been accomplished using a variety of analytical techniques 
[260-269]. Analytical approaches such as microbiological assay [259, 269], capillary zone 
electrophoresis [270, 271], spectrophotometry [256, 263, 264, 267], TLC-densitometry [262] and 
high-performance liquid chromatography (HPLC) [249-258, 260-266, 268, 271] have been used 
for the quantitation of KTZ in a variety of matrices. Perusal of the literature reveals the inherent 
complexity of most of these methods and the high cost associated with the equipment required 
and that is often not available in many laboratories [262, 270, 271]. Techniques such as 
microbiological assay are neither adequately sensitive nor selective for the routine analysis of 
KTZ in biological fluids or pharmaceutical dosage forms [259, 269]. Previously reported HPLC 
methods demonstrated higher sensitivity and selectivity than microbiological assays for the 
analysis of KTZ but tend to involve complicated extraction procedures or require mobile phase 
compositions that are tedious to prepare due to the inclusion of hydrophobic ion-pair reagents or 
amine-containing mobile phase modifiers [253, 254, 260, 272, 273]. 
 
The objective of this study was to develop a rapid, cost-effective, simple, sensitive, selective, 
precise and accurate analytical method that could be used for the quantitation of KTZ for the 
routine in vitro analysis of KTZ containing pharmaceutical dosage forms. Reversed-phase high-
performance liquid chromatography (RP-HPLC) coupled with UV detection was selected as the 
preferred method of analysis for KTZ, based on the frequency of use reported in the literature, 
simplicity relative to other analytical techniques and the availability of equipment in our 
laboratory.  
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3.2. Principles of high performance liquid chromatography 
High performance liquid chromatography (HPLC) is an analytical technique used to separate and 
isolate compounds based on their physico-chemical properties. It is suitable for the analysis of 
macromolecular and/or thermolabile analytes that may not be readily analysed using gas 
chromatography (GC) [274-281]. HPLC analysis of low molecular weight compounds can be 
achieved using various approaches such as normal-phase or adsorption, ion-exchange and 
bonded-phase chromatography all of which require the compound of interest to have specific 
properties viz., polarity, electric charge amongst others [282-285].  
 
Adsorption chromatography is also known as liquid-solid or normal-phase chromatography and  
was the most widely used chromatographic technique until the development of derivatized silica 
for use as a stationary phase was initiated [286]. Normal-phase chromatography requires the use 
of polar stationary and non-polar mobile phases and is suitable for the chromatographic 
separation of polar compounds [281, 282, 286]. In contrast, ion-exchange chromatography 
involves the reversible exchange of ions between the mobile and stationary phases. Ion-exchange 
separations are based on the different strengths of solute-ion or resin-ion pair interactions. The 
solute-ion competes with the mobile phase ion for ionic sites in the ion exchange backbone [282, 
284, 286]. Bonded-phase chromatography was developed in the late 1960s to improve the 
efficiency and reproducibility of performance of stationary phases used in liquid chromatography. 
Functional groups are chemically bonded onto spherical silica particles through carefully 
monitored reaction conditions to produce highly efficient and reproducible stationary phases. The 
level of cross-linking and the amount of silane bonded to the surface are determined by the 
reaction conditions used to produce the column. The degree of silanization determines the surface 
chemistry of the stationary phase and therefore, the performance of separations on that stationary 
phase [286].  
 
Bonded-phase chromatography (BPC) can be of two types, viz., normal- and reversed-phase 
chromatography. In normal-phase chromatography the stationary phase is generally more polar 
than the mobile phase and the retention of solutes decreases with increasing solvent polarity [282-
284, 286]. In reversed-phase chromatography the stationary phase is non-polar whilst the eluent 
or mobile phase is polar and the strength of the mobile phase may be adjusted by the addition of 
polar organic solvents [286-288].  The mobile phases used in reversed-phase HPLC are optically 
transparent, are compatible with electrochemical detectors and biological samples and have weak 
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interactions with the stationary phase, thereby enhancing mass transfer during a separation and 
reducing equilibration times when solvent changes are made [283, 286, 287].  
 
Reversed-phase HPLC was selected for the analysis of KTZ as it has a number of advantages 
with respect to versatility, convenience and reproducibility of the analytical technique [275]. The 
use of hydrocarbon bonded phases such as octyl or octadecyl silica as the stationary phase in RP-
HPLC enhances the stability and lifetime of columns when compared to micro-particulate bonded 
phases as hydrocarbon phases are usually stable in aqueous solutions of pH < 8 [275]. RP-HPLC 
may be used for the chromatographic separation of a variety of compounds possessing different 
chemical properties using a broad range of solvents of varying strength that may be used in 
combination with complexation in the mobile phase [275]. The convenience associated with 
using RP-HPLC stems from the extended operational life of columns leading to the use of a 
single column for the analysis of a compound of interest over an extended period of time [275].  
 
Many theories to explain retention mechanisms of a solute in RP-HPLC have been postulated. 
The hydrophobic and/or solvophobic theory refers to the partitioning of a solute from a 
hydrophilic mobile phase onto a hydrophobic stationary phase which is not expected to retain the 
solute by ionic attraction, hydrogen bonding, formation of charge transfer complexes or any 
strong non-covalent interactions due to the non-polar nature of this phase [275, 289-291]. 
Another theory that explains the retention of large non-polar moieties in RP-HPLC may be 
attributed to silanophilic interactions with surface silanols [275, 289]. Interactions between the 
solute and residual silanol groups on the surface of a stationary phase involve hydrogen bonding 
and/or ionic interactions [275, 289-291]. 
 
RP-HPLC has been widely used  in pharmaceutical and drug analysis where the separation of 
compounds of interest or constituents from biological fluids, fatty acids, hydrocarbons with 
varying degrees of isotopic substitution and naturally occurring samples are performed routinely 
[283, 292-294]. BPC has been used for high precision analysis and trace analyses in 
environmental sample studies [283, 294]. In addition BPC has been widely used for the 
separation of excipients in pharmaceutical formulations, measurement of cations and anions after 
the formation of derivatives with appropriate reagents and characterization of some oligomeric 
mixtures [283, 292]. 
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3.3. HPLC method development  
3.3.1. Overview 
It is worth noting that many considerations drive the development of an analytical method viz., 
the physical and chemical nature of an analyte of interest, knowledge of the type of matrix from 
which the analyte is to be separated and the structure, stability and reactivity of the analyte [287, 
295-297]. The solubility and sensitivity of the analyte of interest to changes in pH, temperature, 
dissolved oxygen and light must be considered in addition to functional parameters such the 
accuracy and precision of the method, the complexity and time required for sample preparation, 
manipulation and analysis [287, 295]. Furthermore, the concentration range of the analyte and its 
chemical properties may influence detection and are important parameters that need to be 
established prior to commencing analytical method development [287, 295].  
 
Several HPLC methods have been reported for the analysis of KTZ [249-258, 260-266, 268, 271]. 
A summary of the methods published for the analysis of KTZ is listed in Table 3.1. Most of the 
methods involve the use of RP-HPLC coupled with UV detection for the analysis of KTZ in 
biological matrices [249, 253, 254, 272, 273, 298-300] or pharmaceutical dosage forms [260, 262, 
265, 268].  
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Column Mobile phase composition Sample 
matrix 
Flow rate 
(ml/min) 
Detection 
wavelength 
Retention 
time 
Internal 
standard 
Ref. 
Bakerbond
®
 C18  
(5µm, 4.6 × 250 mm I.D.) 
Diisopropylamine in MeOH (1:500) and 
ammonium acetate solution (1:200), 70:30  
Oral liquid 
mixture 
3.0 225 nm 3.1 -  [265] 
Interchrom Nucleosil
®
 C8  
(5µm, 4.6 × 250 mm I.D.) 
ACN and 0.025 M phosphate buffer, 45:55, pH 4. Shampoo  1.0 250 nm - Formaldehyde [268] 
RP-Hypersil
®
 BDS-C18  
(5µm, 4.6 × 150 mm I.D.) 
MeOH-water-diethylamine, 74:26:1  Canine plasma 1.0 240 nm 8.0 9-acetyl 
anthracene 
[253] 
RP-µ-Bondapak
TM
 C18 
cartridge column (10µm, 
4.6 × 250 mm I.D.) 
ACN and 0.025 M trishydroxymethyl 
aminomethane in phosphate buffer, 55:45, pH 7 
Formulations: 
Nizoral
TM
 
cream and 
tablets 
2.0 260 nm 5.7 Clotrimazole [262] 
Inertsil
®
 ODS-80A   
(5µm, 4.6 × 150 mm I.D.) 
ACN-water-tetrahydrofuran-ammonium 
hydroxide-triethylamine, 50.2:45:2.5:0.1:0.1, pH 
6.0 
Human plasma 1.0 206 nm 5.9 Clotrimazole [254] 
Hypersil
® 
ODS RP-column  
(5µm, 4.6 × 150 mm I.D.) 
ACN-0.1 Sorensen buffer, 60:40, pH 6.6  Human plasma - 206 nm 5.75 - [298] 
Beckman
®
 C18  
(5µm, 4.6 × 250 mm I.D.) 
ACN:50 mM phosphoric acid, 60:40, pH 2.2 Blood 2 207 nm - - [300] 
RP-µ-Bondapak
TM
 C18  
(5µm, 4.5 × 300 mm I.D.)  
MeOH:25 mM KH2PO4 and 4 mM 
heptanesulfonic acid buffer, 60:40, pH 8.0  
Blood 1.8 226 nm - Terconazole [273] 
Nova-Pak
®
 C18  
(5µm, 3.9 × 150 mm I.D.) 
MeOH:ACN:20 mM KH2PO4, 30:30:35, pH 6.8 Blood 2 254 nm 4.3 Clotrimazole [249] 
Hypersil
®
 ODS C18  
(5µm, 3 × 100 mm I.D.) 
ACN:water, 45:55, with 500 µL/L diethylamine, 
pH 8.0  
Blood 0.6 254 nm 5.0 Terconazole [272] 
Spherisorb
®
 CN  
(5µm, 4.6 × 250 mm I.D.) 
THF: phosphoric acid, 50 mM triethylamine, 
30:70, pH 3.0) 
Formulations: 
tablets and 
cream 
1 230 nm 7 Clotrimazole [260] 
Whatman
®
 RP-C18  
(5µm, 4.5 × 125 mm I.D.) 
ACN:10 mM KH2PO4, 65:35, pH 6.0 Human 
stratum 
corneum  
0.7 254 nm 8.6 - [299] 
Table 3.1 RP-HPLC methods used for the analysis of KTZ in dosage forms 
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3.3.2. Experimental 
3.3.2.1. Reagents 
All chemicals were at least of analytical reagent grade. HPLC-grade acetonitrile (UV cutoff at 
200 nm) was purchased from Romil-SpS
®
 Ltd. (Waterbeach, Cambridge, UK). Potassium 
dihydrogen phosphate and sodium hydroxide pellets were purchased from Associated Chemical 
Enterprises (Southdale, Gauteng, RSA). HPLC-grade water was prepared by reverse osmosis 
using a Milli-RO
®
 15 water purification system (Millipore Co., Bedford, MA, USA) consisting of 
a Super-C
®
 carbon cartridge, two Ion-X
®
 ion-exchange cartridges and an Organex-Q
®
 cartridge 
and the resistivity of the water was maintained at 18 MΩcm. The water was filtered through a 
0.22 μm Millipak® 40 stack filter (Millipore Co., Bedford, MA, USA) prior to use. Ketoconazole 
(KTZ) and clotrimazole (CLZ) were purchased from Sigma-Aldrich (Johannesburg, Gauteng, 
RSA). Ketazol
®
 tablets (Aspen Pharmacare, Port Elizabeth, Eastern Cape, RSA) were purchased 
from Wallaces Pharmacy (Grahamstown, Eastern Cape, RSA). 
 
3.3.2.2. HPLC system 
The modular HPLC system consisted of an Isochrom LC dual piston solvent delivery module 
(Spectra-Physics, San Jose, CA, USA), a WISP
™
 Model 712 Autosampler (Millipore
®
 Waters 
Associates, Milford, MA, USA) and a linear UV-100 detector (Spectrachrom, NV, USA) set at a 
λ   206 nm. Data acquisition was performed using an SP-4600 Integrator (Spectra-Physics, San 
Jose, CA, USA).  
 
3.3.2.3. Selection of an analytical column  
The analytical column is a significant component of any HPLC system [275, 282-284]. In RP-
HPLC the column packing is usually comprised of spherical or irregularly shaped silica particles 
which form the surface of the support to which organic ligands containing functional groups viz., 
n-octadecyl or n-octyl are covalently bonded [275, 282-284]. The column surfaces are known to 
possess favourable kinetic properties for mobile phase equilibration and eluent adsorption and 
exhibit relatively good stability in respect of hydrolytic decomposition. The particle shape, size 
and pore size distribution, nature of ligands, morphology of the bonded surface layer and the 
magnitude of surface coverage are responsible for the differences in retention behaviour exhibited 
by different commercial columns [275]. Most columns used in HPLC are generally 150 mm in 
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length, with an inner diameter of approximately 4-5 mm and a narrow particle size distribution 
with a mean diameter of < 10 µm [275, 282, 283]. Analytical columns are expected to display 
lasting efficiency, stability, rapid responses to changing conditions, reproducibility, reliability and 
durability during analysis [275].  
 
Ketoconazole is a dibasic imidazole compound with two pKa values of 2.91 and 6.54, 
respectively [29, 30, 301]. The lipophilic characteristics of the molecule are due to the presence 
of a benzene ring and hydrophobic alkyl chains, whilst the presence of nitrogen atoms in the 
piperazine and imidazole moieties account for a small degree of polarity of the molecule. These 
properties make KTZ a suitable candidate for separation using a reversed-phase packing material, 
as KTZ is expected to be retained on a hydrophobic stationary phase. A search of available 
literature revealed that liquid chromatographic studies of KTZ have been undertaken using a C18 
packed column for in vitro and in vivo analyses. A  Beckman
®
 Coulter ODS 5µm, 150 × 4.6 mm 
i.d. column was selected for these studies following efficiency testing to evaluate its performance.  
 
The most common measure of efficiency of a chromatographic system is the theoretical plate 
number, N, that is also known as the number of theoretical plates contained in a chromatographic 
column [284], a definition that has now become universally accepted. The plate number, N for a 
test substance under specified favourable conditions can be quantitatively expressed using 
Equation 3.1 [284].  
 
2
21
54.5









W
t
N R       Equation 3. 1 
where,  
tR = the retention time of a test peak 
W1/2 = the peak width at half peak height 
 
The assumption for the measurement of peak width in Equation 3.1 is that the peak is Gaussian in 
nature. This assumption is not often observed in practice, in particular for basic compounds which 
tend to show evidence of tailing as a consequence of the interaction with acidic silanol groups of 
the stationary phase [284, 289]. Nevertheless, the calculation of the theoretical plate number 
permits an analyst to select an appropriate analytical column based on the efficiency and 
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performance of that stationary phase. For the purposes of these studies only columns displaying 
plate counts of > 5000 were considered acceptable for use.  
 
In general, the smaller the diameter of particles of the support material or the adsorbent, the 
greater the separation efficiency and the higher the value for N is expected due to an increase in 
the associated surface area of the stationary phase, which in turn enhances the potential for 
interaction between the eluent and the compound(s) of interest [276, 279]. The smaller the 
particle diameter of a packing material the higher the inlet pressure and subsequently, high 
pressures and flow rates used for a separation may result in removal of the stationary phase from 
the support. Chemically bonded stationary phases have been developed to avoid the stripping of 
the stationary phase from the column, particularly when highly polar solvents are used to elute 
strongly retained sample components [276].  
 
Column packing and preparation is a critical step for the optimization and efficiency of a 
separation and for prolonging the column life during use. When packing the stationary phase it is 
vital that the support is packed optimally with solid adsorbents to avoid the development of 
stagnant pools and to allow the pores of the support to be completely filled with the stationary 
phase [276, 302]. Equilibration of a column with mobile phase at a flow rate of 1 ml/min for 
approximately one hour is also important to allow the adsorbent material to equilibrate to the 
mobile phase and to remove entrapped air from the packing material. It has been reported that a 
properly packed HPLC column should provide an efficiency of at least 6000 theoretical plates 
with 5-10 µm particles [276]. Packing materials of 5 μm diameter have been reported to double 
column efficiency when compared to 10 μm packing materials although system back pressures at 
higher flow rates are significantly greater for these systems [279]. 
 
The efficiency of a chromatographic column is best evaluated using an ideal test system under 
specified conditions, rather than using the analyte of interest for which the method is to be 
developed using the conditions for HPLC method development. The use of small, neutral test 
compounds such as toluene or naphthalene, a flow rate of 1 ml/min and a mobile phase with a 
viscosity (η) of less than 1 cP, with a composition of 0 to 100% acetonitrile-water mixtures kept 
at temperatures < 20˚C are ideal test conditions [284].  
 
The efficiency of the 5µm, 150 × 4.6 mm i.d. Beckman
®
 Coulter ODS column was assessed by 
performing replicate injections (n=6) of a test mixture containing uracil, acetophenone, benzene, 
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toluene and naphthalene at room temperature (22˚C). A wavelength of 254 nm and a mobile 
phase composition of acetonitrile-water (70:30) at a flow rate of 1 ml/min were used for the 
separation. A typical chromatogram of the separation of the test mixture using these conditions is 
depicted in Figure 3.1. 
 
 
Figure 3.1 Typical chromatogram of a test mixture containing uracil (1), acetophenone (2), benzene (3), 
toluene (4) and naphthalene (5) after separation on a Beckman
®
 Coulter ODS column 
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The theoretical plate number for the Beckman
®
 column was found to be 7544 ± 532 (n=6). Such a 
column with a particle size diameter of 4 µm and a length of 150 mm is expected to give a 
theoretical plate number of more than 10 000. However, since the column had been used, it was 
regarded as suitable for use in development and validation of a method for the analysis of KTZ 
using low flow rates.  
 
3.3.2.4. UV detection of KTZ 
The selection of a detector is an important consideration for quantitative analysis by HPLC, as the 
detector is used to monitor the concentration of a solute in a mobile phase when it leaves the 
stationary phase and column [303]. It is desirable that detectors used in liquid chromatography 
show a response that increases linearly with solute concentration and displays a broad range of 
linearity with high sensitivity and predictable specificity [303, 304]. Ideal HPLC detectors should 
be able to respond to all solutes universally without contributing to extra-column band 
broadening, be non-destructive of the solute molecules, have a reasonably fast response 
independent of the mobile phase and be unaffected by changes in temperature and mobile-phase 
flow rates [303-306]. The HPLC detector should be able to operate under moderate pressures, be 
versatile, reliable, convenient to use and easy to maintain. In practice, no currently available 
detector possesses all these characteristics and the selection of an HPLC detector is based on the 
characteristics of the solute, sensitivity and specificity required in addition to the convenience and 
versatility necessary to facilitate analysis [304, 306]. 
 
Since the late 1960s, UV detection has been the most commonly used method of detection in 
HPLC analysis [304, 307]. The measurement of the ultraviolet (UV) absorbance of a solute in the 
mobile phase is achieved using either a variable-wavelength spectrophotometric or diode-array 
detector [304]. UV detectors offer a number of advantages over other detection systems as they 
are simple to use, relatively cheap to purchase, trouble-free to operate, easy to maintain, are 
sensitive and non-destructive to solute molecules [308, 309]. UV detection is generally selected 
as the detection method of choice, particularly if samples to be analyzed absorb light in the UV or 
visible region of the electromagnetic spectrum between 190-600 nm unless analyte concentrations 
are too low for detection, sample interference is significant or qualitative structural information 
for the analyte is needed [304]. KTZ is an imidazole antifungal compound whose chemical 
structure consists of light-absorbing chromophores including an aromatic ring, an imidazole and a 
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piperazine moiety, double bonds (π electrons) including C O, thereby making it a suitable 
candidate for UV detection following separation using HPLC.  
 
The principle of UV detection is based on the Beer-Lambert law which states that the analyte 
concentration, C,  is proportional to the fraction of light transmitted through the detector flow 
cell, 





I
I 0
 and is related to absorbance, A, molar absorptivity or molar extinction coefficient of 
the analyte,  and the path length, L, of the flow cell as shown in  Equation 3.2 [304, 307, 310].    
 
CL
I
I
A 





 0log    Equation 3.2 
 
where, 
          A = absorbance  
          I0 = intensity of the incident light 
          I = intensity of the transmitted light 
           = molar absorptivity or molar extinction coefficient of absorbing species 
          C = analyte concentration  
          L = path length of flow cell  
 
Successful chromatographic monitoring using UV detection can only be achieved if the 
wavelength of detection is carefully selected since it can potentially impact the sensitivity, 
selectivity and baseline noise of a detector [310]. A good understanding of the UV spectrum of 
the sample to be analyzed is therefore required prior to selecting a wavelength of detection for use 
during method development studies.  
 
A review of the literature indicated that different wavelengths have been used for RP-HPLC 
analysis of KTZ and include 206 nm [254, 298], 207 nm [300], 225 nm [265], 226 nm [273], 230 
nm [260], 240 nm [253], 250 nm [268], 254 nm [249, 272, 299] and 260 nm [262]. The 
differences in the wavelengths used for HPLC analysis may be due to the fact that the λmax is also 
in part a function of the solvent which is used to dissolve KTZ. The wavelength of maximum 
absorption (λmax) was found to be 206 nm following assessment of the UV absorption spectrum of 
KTZ in methanol (§ 1.2.5) and was therefore selected as the wavelength of choice for maximal 
sensitivity during the analysis of KTZ. The use of higher wavelengths has been previously 
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reported for the analysis of KTZ and this choice may have been based on the need to exclude the 
likelihood of interference from other compounds at wavelengths close to 200 nm. In these studies, 
high selectivity for KTZ was obtained at 206 nm without any significant interference from the 
solvent or excipients observed. Although the RP-HPLC method involved the use of the internal 
standard, clotrimazole, the eluent was monitored at 206 nm and not at the λmax of clotrimazole as 
it is possible to include adequate amounts of the internal standard during analysis with 
appropriate attenuation to ensure that a satisfactory response from the analyte(s) of interest is 
generated. 
 
3.3.2.5. Choice of internal standard 
The use of an internal standard (IS) improves the accuracy of an analytical method and minimizes 
system and procedural deviations that may result in variations in precision as a function of sample 
size or instrumental response [278, 311]. An internal standard is usually structurally similar to the 
analyte of interest and is added to a sample mixture during the preparation of standards and 
solutions of unknown concentration [282, 284, 311]. The unknown concentration of a compound 
of interest is calculated following the measurement of the peak area or peak height ratio of the 
analyte and IS  [280]. In these studies, peak height ratio was chosen over peak area as the 
measurement criteria since the amount of tailing observed during the analysis of KTZ was not 
considered substantial.  The internal standard method compensates for sample volume changes 
and day-to-day changes in chromatographic conditions, which may affect the IS and the sample 
of interest uniformly [280, 312]. The choice of an internal standard is therefore crucial to 
facilitate the optimization of the analytical method.  
 
An internal standard should be well resolved from the API and should as far as possible be 
commercially available [278, 282, 284]. In addition the IS must not be a potential impurity or 
degradation product of the analyte of interest. The most important consideration while selecting 
an IS is to ensure that it has similar physicochemical characteristics and chromatographic 
behaviour to the analyte of interest, although it might not be structurally related to the compound 
of interest [284]. Therefore, the method developed for the compound of interest must be suitable 
and applicable for the quantitation of both the compound of interest and the IS.  
 
Perusal of the literature revealed that imidazole antifungals agents are often used as IS for the 
HPLC analysis of KTZ. Potential internal standards investigated included clotrimazole (CLZ), 
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econazole (ECZ) and miconazole (MCZ). Separation was achieved using a mobile phase 
composition of acetonitrile and 50 mM phosphate buffer (pH 6) in a ratio of 65:35 at a flow rate 
of 1 ml/min and detected at 206 nm. The retention times of the potential IS are listed in Table 3.2. 
Table 3.2 Retention times of KTZ and potential internal standards 
Compound Retention time of KTZ (min) Retention time of IS (min) 
Clotrimazole 3.8 6.7 
Econazole 3.9 8.7 
Miconazole 3.8 14.1 
 
MCZ eluted at a retention time of 14.1 min which was considered too long for routine analysis of 
KTZ and was therefore not considered further as an IS. The retention times of CLZ and ECZ 
suggest that these compounds may be appropriate for use as IS for the analysis of KTZ. The peak 
for ECZ however exhibited considerable tailing and as ECZ eluted at 8.7 min, the run time may 
be prolonged, which was again considered undesirable. Conversely, the peak for CLZ was sharp, 
with good baseline resolution and a retention time of 6.7 min, therefore CLZ was selected as the 
IS for this analysis.  
 
3.3.2.6. Mobile phase selection 
Mobile phases used in HPLC analyses offer a series of challenges and often differ in respect of 
their spectral, chemical and chromatographic separation performance. Based on the retention 
characteristics of the analyte of interest when a particular solvent mixture, organic solvent 
concentration or choice of organic solvent is made further adjustment to modify retention times 
may be necessary [283]. 
 
It is desirable that the solvents used in liquid chromatography are miscible with all components of 
the mobile phase. In addition they should be of appropriate purity and stability, have acceptable 
toxicity, possess low viscosities to reduce pressure drops and have high diffusivities to produce 
sharper peaks. Solvents used in HPLC with UV detection must be UV transparent and solvents 
transparent below 220 nm are preferred. It is particularly important to avoid contamination of 
solvents as impurities are known to make the solvent opaque, or shift the UV cut off to higher 
wavelengths. It is preferred that solvents used in HPLC have boiling points below 100°C to 
ensure high sample recovery and if mass spectrometry detectors are to be used, low molecular 
weight solvents are preferred [281].  
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The most commonly used solvent mixtures for RP-HPLC include water-methanol (MeOH) or 
water-acetonitrile (ACN). The optimum mobile phase composition is often found by trial and 
error and a convenient approach for method development is to start with 1:1 water-MeOH or 
water-ACN mixtures [283, 296]. Methanol is widely used for reversed-phase separations as it has 
a hydroxyl functional group which can act as a hydrogen bond donor and/or acceptor. 
Furthermore, MeOH is readily available as a high-purity liquid, is chemically stable, possesses 
minimal health and safety hazards when handled carefully, is usually miscible with a wide range 
of solvents and is relatively inexpensive [287]. MeOH is more polar than other solvents due to its 
hydrogen-bonding properties and its ability to form hydrogen bonds with a stationary phase may 
influence adsorption of the solvent and partitioning of the solute with a resultant impact on the 
chromatographic separation [313].  
 
In contrast, acetonitrile is a moderately polar and weak hydrogen bond acceptor as it is an aprotic 
compound. ACN offers a unique combination of properties that distinguish it from other HPLC 
solvents. ACN is known to be a solubilizing solvent that typically produces sharp well-defined 
peaks and is miscible with a wide range of organic solvents. Moreover, ACN-water mixtures have 
a low viscosity in comparison to analogous hydro-alcoholic solutions such as water-MeOH 
mixtures. ACN also has a midrange solvent strength and has a very low UV cutoff, making it 
suitable for use in systems in which low wavelength UV detection is essential [287].  
 
KTZ is a lipophilic compound that is practically insoluble in aqueous solution, whilst it is freely 
soluble in methanol and solvents such as chloroform and dichloromethane (§1.2.2). HPLC 
methods for the analysis of KTZ have been developed using bonded phase columns (C18) and 
mobile phases consisting of ACN and sometimes MeOH as the organic modifier (Table 3.1). A 
mixture of water and MeOH was used as the mobile phase for the analysis of KTZ and produced 
broad, asymmetric peaks with tailing and poor baseline resolution. Conversely, binary mixtures 
of ACN and water produced well-defined sharp peaks with good baseline resolution and reduced 
tailing. Therefore, ACN was selected as the organic solvent of choice for further method 
development studies for the analysis of KTZ.  
 
3.3.2.7. Preparation of buffer 
Buffer solutions of 20, 30, 40, 50, 60 and 70 mM were prepared by accurately weighing 
appropriate amounts of potassium dihydrogen phosphate into a 1 litre A-grade volumetric flask 
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and making up to volume with HPLC grade water. The resulting solution was then adjusted to the 
desired pH using a 1.0 M NaOH solution that had been prepared by accurately weighing 4.0 g of 
sodium hydroxide pellets into a 100 ml A-grade volumetric flask and making the solution up to 
volume with HPLC grade water.  
3.3.2.8. Preparation of mobile phase 
Solutions of mobile phase were prepared by adding the desired volume of HPLC-grade 
acetonitrile and buffer to a glass Duran
® 
Schott solvent mixing bottle (Schott Duran GmbH, 
Mainz, Germany). The mixture was allowed to equilibrate to room temperature and the mobile 
phase was then filtered through a 0.45 μm Millipore® HVLP filter (Millipore, Bedford, MA, 
USA) and degassed under vacuum using a Model A-2S Eyela Aspirator (Rikakikai Co., Ltd, 
Tokyo, Japan) prior to use. Freshly prepared mobile phase was used daily and mobile phase was 
not recycled during use. It is necessary to degas the mobile phase as dissolved gases may lead to 
the formation of small air bubbles in the flow cell of a detector or in the connecting tubing at high 
inlet pressures subsequently causing chromatographic interference. The more polar the mobile 
phase, the more likely it is to dissolve air and degassing aids in the removal of oxygen which may 
react with the stationary phase. Air bubbles disrupt detectors, particularly those used to monitor 
eluent by detection of optical properties of solutes. The presence of dissolved gasses may result in 
baseline drift and random noise which in turn could affect the sensitivity and reproducibility of a  
system [282]. 
 
3.3.2.9. Preparation of stock solutions and calibration standards 
Standard stock solutions of KTZ (250 µg/ml) and CLZ (200 µg/ml) were prepared by accurately 
weighing approximately 25 mg of KTZ and 20 mg of CLZ using a Model AG-135 Mettler Toledo 
top-loading analytical balance (Mettler Instruments, Zurich, Switzerland) directly into 100 ml A-
grade volumetric flasks and dissolving in 20 ml of MeOH. The stock solutions were placed in a 
Model 8845-30 ultrasonic bath (Cole-Parmer Instrument Comp. Chicago, IL, USA) for 2 min in 
order to ensure complete dissolution of the analytes after which samples were made up to volume 
with MeOH. Stock solutions were stored in a refrigerator (4˚C). Stock solutions were used within 
a maximum period of one (1) week, based on stability study data generated as described in § 
3.4.7.2 vide infra. Calibration standards of KTZ were prepared by serial dilution of the stock 
standard solution on a daily basis to produce solutions of 2, 10, 20, 40, 60, 80, 100 and 120 μg/ml 
concentration and were made up to volume using MeOH. 
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3.3.3. Optimization of the chromatographic conditions  
3.3.3.1. Mobile phase selection 
The mobile phase in RP-HPLC has a significant influence on sample retention and separation 
characteristics. Separation selectivity in RP-HPLC can be altered by changing the concentration 
of the organic modifier or altering the pH of the mobile phase if the sample components are 
acidic or basic in nature. The use of buffers or pH adjustment can lead to ion suppression and 
hence reduce peak tailing if the analyte is in the non-ionised form. For strongly basic analytes, 
basic modifiers viz., tertiary amines such as triethylamine may be added to the mobile phase to 
eliminate peak tailing. Furthermore, the addition of salts or ion-pair reagents may affect the 
solubility of the analyte and hence influence retention and selectivity characteristics of that 
compound.  
 
3.3.3.1.1. Effect of concentration of organic modifier 
The influence of the concentration of ACN on the retention times of KTZ and CLZ was assessed 
using binary mixtures of ACN and 50 mM phosphate buffer in different proportions at pH 6.0. 
The mixtures ranged between 55 and 75% ACN and the results are depicted in Figure 3.2. 
 
Figure 3.2 Effect of ACN composition on the retention times of KTZ and CLZ (n=6) 
 
It was observed that the retention time (Rt) of KTZ was shorter than that for CLZ with any of the 
ACN/water binary mixture used. This can be explained in part by the lipophilic characteristics of 
CLZ enhancing the hydrophobic interactions between CLZ and the stationary phase used. It was 
also observed that the retention times of both KTZ and CLZ were inversely proportional to the 
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ACN concentration in the mobile phase, implying that an increase in ACN concentration in the 
mobile phase would lead to a shorter retention time for KTZ and CLZ. This reduction in retention 
time may be due to an increase in the extent of interactions between the solute and the solvent and 
a decrease in the extent of interaction between the solute and the stationary phase.  
 
These studies were conducted to determine an optimal concentration of ACN for use in the 
mobile phase such that reasonable retention times for both KTZ and CLZ were possible. 
Retention times considered acceptable were approximately 4 min for the first peak of interest and 
an approximate difference of 2-6 min between the elution of the first peak and second peaks, 
giving rise to a run time of approximately 10-12 min. A binary mixture consisting of ACN and 50 
mM phosphate buffer (pH 6.0) in a ratio of 60:40 was selected as the mobile phase of choice for 
the separation of KTZ and CLZ based on criteria set in our laboratory. The retention times for 
KTZ and CLZ using this particular mobile phase were 3.7 and 8.7 min, respectively.  
 
3.3.3.1.2. Effect of flow rate 
One of the aims of these studies was to develop an HPLC method with a run time of 
approximately 10-12 min for the analysis of KTZ in pharmaceutical dosage forms. Therefore, the 
influence of flow rate on the retention times of KTZ and CLZ was also evaluated. The effect of 
changing flow rate is depicted in Figure 3.3. These studies indicate that the retention times of 
KTZ and CLZ decrease as the flow rate of the mobile phase increases. A flow rate of < 1.0 
ml/min resulted in a retention time of > 10 min for CLZ, which was considered undesirable since 
the method would be time-consuming. 
 
Figure 3.3 Effect of flow rate of the mobile phase on the retention times of KTZ and CLZ (n=6)
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The use of high flow rates such as 1.5 ml/min and 2 ml/min resulted in short retention times for 
KTZ and CLZ which were considered too close to the solvent front for quantitation in addition to 
back pressures exceeding 2000 psi (13.8 MPa). Moreover, the resolution of the peaks was not 
adequate at high flow rates. A flow rate of 1.0 ml/min produced sharp, well-resolved peaks with 
acceptable retention times for KTZ and CLZ (Figure 3.4). The mobile phase flow rate selected for 
further use was 1.0 ml/min. 
 
Figure 3.4 Typical chromatogram of a mixture of the internal standard, clotrimazole (CLZ, 80 µg/ml) and 
ketoconazole (KTZ, 120 µg/ml) using a mobile phase of 60% v/v ACN (60% v/v) and 50 mM phosphate 
buffer (pH 6.0) (40% v/v) at a flow rate of 1.0 ml/min 
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3.3.3.1.3. Effect of buffer pH 
The effect of the pH of the buffer, used to prepare the mobile phase, on the retention times of 
KTZ and CLZ is depicted in Figure 3.5. These studies were conducted using a mixture of ACN 
(60% v/v) and 50 mM phosphate buffer ranging from pH 4.0 to 7.0. No difference was noted in 
the retention times of KTZ and CLZ as the pH of the buffer was increased. However, poor 
resolution was noted at pH < 5.  
 
Figure 3.5 Effect of buffer pH used for the preparation of the mobile phase (comprising of 60% v/v ACN: 
phosphate buffer, 50 mM) on the retention times of KTZ and CLZ (n=6) 
 
Close inspection of the chromatograms revealed slight shouldering and an increase in tailing of 
the peaks at higher pH, e.g. pH 7.0. Buffers of pH > 7.0 were not used as silica-based columns 
such as the Beckman
®
 ODS column may undergo hydrolysis at pH ≥ 8. The increased 
shouldering and tailing observed at high pH was attributed to the poor performance of the column 
and a pH of 6.0 resulted in sharp and well-resolved peaks.  
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3.3.3.1.4. Effect of buffer molarity  
The effect of buffer molarity on the chromatographic separation of KTZ and CLZ was also 
investigated and studies were conducted over the range of 20 to 100 mM using potassium 
dihydrogen phosphate buffer (pH 6.0). The influence of buffer molarity on the retention times of 
both KTZ and CLZ is shown in Figure 3.6.  
 
Figure 3.6 Effect of buffer molarity used for the preparation of the mobile phase (comprising of 60% v/v 
ACN: phosphate buffer, pH 6.0) on the retention times of KTZ and CLZ (n=6) 
 
No significant differences were observed in the retention times of KTZ and CLZ as the buffer 
molarity was increased from 20 to 100 mM. However, poorly resolved asymmetric peaks were 
observed when buffers of low and high molarity were used. A buffer of intermediate molarity of 
50 mM was therefore selected for further optimization studies. 
 
3.3.3.1.5. Optimal mobile phase composition  
The mobile phase selected for further investigation for the analysis of KTZ using CLZ as an IS 
was comprised of a binary mixture of ACN and 50 mM phosphate buffer (pH 6.0) in a ratio of 
60:40. The KTZ peak was well resolved from the CLZ peak when the optimal mobile phase was 
used and sharp well-defined peaks were observed. A typical chromatogram generated using these 
separation conditions and a flow rate of 1.0 ml/min is depicted in Figure 3.4. The peaks for KTZ 
and CLZ eluted at 3.7 min and 8.7 min, respectively. A total run time of 12 min was selected for 
the analysis, which resulted in a relatively low volume of mobile phase and solvent use for the 
analysis of KTZ in test samples.  
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3.3.3.2. Chromatographic conditions 
The final chromatographic conditions selected for validation of the HPLC analysis of KTZ are 
summarized in Table 3.3. 
Table 3.3 Optimized chromatographic conditions 
Column Beckman
®
 Coulter ODS column (5µm, 150 × 4.6 mm I.D.) 
®
 
Flow rate 1.0 ml/min 
Detection wavelength 206 nm 
Injection volume 10 µL 
Temperature Ambient 
Mobile phase composition  ACN:50 mM phosphate buffer, pH 6.0 (60:40) 
Sensitivity 2.0 AUFS 
Recorder SP-4600 Integrator (Spectra-Physics, San Jose, CA, USA) 
Integrator speed 0.25 mm/min 
 
 
3.4. Method validation 
3.4.1. Overview 
The validation of an analytical method is a critical process that is used to establish the 
performance characteristics of a method and to establish whether the method meets the 
requirements for its intended purpose [314-319]. The validation process provides significant data 
with respect to the reliability, accuracy and precision of an analytical method and enables the 
analyst to identify or foresee potential problems [320, 321]. Nevertheless, it may not be possible 
to identify all potential problems of a particular analytical method during the validation process 
and only common problems such as column degeneration, changes in column behaviour and co-
elution of impurities may be identified [318, 322]. Method validation is therefore a distinct 
process that is used to certify that the analytical method performs in a specific manner for the 
purpose for which it was developed [315, 318, 319].  
 
Guidelines outlining the validation of analytical methods used for the routine analysis of 
pharmaceutical dosage forms have been published in the United States Pharmacopoeia (USP), by 
FDA, regulatory authorities in Europe and the International Conference on Harmonization (ICH) 
[314, 315, 323-325]. All provide useful information on the type of studies to be conducted and 
define key validation parameters to be investigated [314, 315, 323-325]. However, these 
guidelines fail to provide information with respect to how the validation studies must be 
conducted, and therefore, perusal of the literature for published approaches to analytical method 
validation is essential.  
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It is imperative that the objective of the intended method is established before proceeding with a 
particular validation protocol even if validation procedures for HPLC methods essentially include 
similar parameters [321, 322]. A Level I or quantitative assay method is usually applied to the 
determination of potency, evaluation of drug release, monitoring of drug levels in blood or 
assessment of impurities or contaminants in human drug products [321]. On the other hand, a 
Level II or qualitative assay method is intended for qualitative analyses for the purposes of 
identification. The FDA for instance recommends that an analytical method developed for a 
pharmaceutical product be validated with regard to accuracy, precision, sensitivity, specificity 
and reproducibility [320]. The USP and ICH guidelines include validation parameters such as 
accuracy, precision, specificity, limits of detection (LOD) and of quantitation (LOQ), linearity, 
range and sample stability [314, 315, 323-325]. In addition the ICH guidelines also include an 
evaluation of robustness and system suitability [323, 324]. The validation of a RP-HPLC method 
for the analysis and quantification of KTZ from pharmaceutical dosage forms during formulation 
development and assessment was therefore performed as detailed in the FDA [316, 325] and USP 
[314] guidelines with reference to the ICH recommendations [323, 324].  
 
3.4.2. Linearity and range 
The evaluation of linearity is vital to demonstrate whether proportionality exists between a 
quantitative response and the concentration of the analyte within the range of analysis [314, 317, 
326]. The range of analysis refers to the inclusive interval between the upper and lower levels of 
analyte concentration that have been quantitated with the necessary accuracy, precision and 
linearity [282, 283, 295, 323, 324]. The linearity of the analytical method was assessed within the 
range of concentrations expected, using a standard calibration curve which was evaluated by 
calculation of a least squares linear regression curve [327]. Linearity must be established when 
using UV spectrophotometry as it is fundamental that the absorptive response follows the Beer-
Lambert law over the range of concentrations analyzed [274, 283, 284]. 
 
A minimum of five concentrations spanning the concentration range to be analyzed must be used 
for the assessment of linearity. Linearity studies were therefore conducted by performing 
replicate measurements (n=6) at eight concentration levels covering the concentration range of 2-
120 µg/ml for KTZ. The mean peak height ratio of KTZ and internal standard was plotted against 
concentration to produce the calibration curve. The acceptability of the linearity data was judged 
from an examination of the correlation coefficient (R
2
) for the regression line of the standard 
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calibration curve. An R
2 
value of between 0.999 and 1 was considered to be adequate to 
demonstrate the linearity of the method and to show the presence of a direct response-
concentration relationship [317, 323, 324]. A typical calibration curve for the analysis of KTZ is 
depicted in Figure 3.7.  
 
Figure 3.7 Typical calibration curve constructed for KTZ using peak height ratio of KTZ and CLZ versus 
concentration  
 
3.4.3. Precision 
Precision is a measure of the extent of closeness of data from repeated analysis of an homogenous 
sample [326, 328]. Precision quantifies the variability of an analytical method on account of the 
performance of the analyst, manipulations made in performing the analysis and day-to-day 
environmental changes [315, 328]. All official or approved analytical methods are required to 
include an assessment and quantification of precision, which indicates the repeatability and 
reproducibility of a method. The ICH guidelines recommend that precision be assessed at three 
levels viz., repeatability, intermediate precision and reproducibility [315, 323, 324]. Precision is 
usually expressed as the percent relative standard deviation (% RSD) and a percent RSD of ± 5% 
was set as the acceptable tolerance for precision studies in our laboratory.  
 
3.4.3.1. Repeatability 
The repeatability of a method of analysis is a measure of the intra-day variation and expresses the 
ability of the method to withstand small experimental variations over a short time interval under 
the same operating conditions [323, 324]. Repeatability studies therefore need to be conducted by 
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the same analyst, in the same laboratory using the same equipment on the same day [323, 324, 
328]. A minimum of nine determinations spanning the range of analysis or a minimum of six 
determinations at 100 % of the expected test concentration are suggested in the ICH guidelines as 
adequate for repeatability evaluation. The % RSD for an assay method must be ≤ 2 % [320], 
whereas the % RSD for the determination of impurities at trace levels must be ≤ 10 % [329].  
 
The repeatability of the analytical method was assessed through replicate analysis (n=6) of 
samples at low, medium and high concentrations interpolated from the calibration curve and 
which were within the range of concentrations analyzed. Analyses were performed at 
concentrations of 5, 45 and 115 µg/ml. The % RSD values obtained for the intra-day precision 
were ≤ 2% indicating that the analytical method was repeatable. The results from repeatability 
studies (n = 6) are summarized in Table 3.4.  
Table 3.4 Intra-day precision data for HPLC analysis of KTZ 
Concentration (µg/ml) Mean Peak Height Ratio Standard Deviation (SD) % RSD 
5.00 0.058 0.0006 0.960 
45.0 0.572 0.0049 0.853 
115 1.454 0.0061 0.417 
 
3.4.3.2. Intermediate precision 
Intermediate precision is also expressed as the ruggedness of an assay and refers to the ability of 
an analytical method to withstand variations within a laboratory and therefore, assesses the 
reliability of the procedure when conducted on different days using different analysts and/or 
instruments [314, 320, 323, 330]. The assessment of inter-day precision is important to establish 
the long-term variability of an analytical method within the same environment and to ensure the 
validity of the method once method development has been completed [320, 328]. The 
intermediate precision of this method was determined by performing replicate analyses (n=6) of 
samples of concentration 5, 45 and 115 µg/ml on three consecutive days. The intra-day precision 
data, expressed as the coefficient of variation or % RSD of the mean peak height ratio of KTZ to 
internal standard are summarized in Table 3.5. The criterion for acceptable intermediate precision 
was set at ≤ 2% for each concentration level. The data reveal that the % RSD values were < 2%, 
thereby indicating that the day-to-day precision of the analytical method was acceptable.  
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Table 3.5 Intermediate precision data for HPLC analysis of KTZ 
Day Concentration (µg/ml) Mean Peak Height Ratio Standard Deviation (SD) % RSD 
1 5.00 0.059 0.0011 1.931 
 45.00 0.584 0.0111 1.792 
 115.00 1.460 0.0098 0.670 
2 5.00 0.059 0.0001 0.297 
 45.00 0.591 0.0068 1.159 
 115.00 1.461 0.0122 0.833 
3 5.00 0.061 0.0001 0.149 
 45.00 0.595 0.0012 0.197 
 115.00 1.461 0.0063 0.435 
 
3.4.3.3. Reproducibility  
The reproducibility of an analytical method refers to the ability of the method to maintain 
precision when used in different laboratories. Reproducibility tests should be performed using 
homogenous samples by different analysts in different laboratories to establish whether the 
method can be transferred from one laboratory to another [328]. It is not usually expected to 
perform reproducibility tests if intermediate precision has been established unless the analytical 
method is intended for a standardized procedure which is to be published in an official 
compendium [324]. Tests for reproducibility were therefore not conducted in these studies as all 
analyses were performed by the same analyst in the same laboratory.  
 
3.4.4. Accuracy 
The accuracy of an analytical method refers to the closeness of results of an analysis to a known 
standard or reference value within the established range of analysis [314, 317, 326]. Accuracy 
and precision are two most important validation tests, as they are used to determine the error of an 
analytical procedure [317, 331, 332]. As recommended by the ICH, accuracy may be established 
by performing replicate analysis of samples containing known amounts of the analyte of interest 
and comparing the experimentally determined values to the nominal theoretical values. Another 
approach that can be used to investigate the accuracy of an analytical method involves comparing 
analytical results from a new method to the results from an existing or well-established 
procedure, or by spiking known amounts of the API of interest into blank matrices and 
establishing and evaluating the percent recovery from that matrix [320]. Statistical analysis of the 
data generated may also be used to demonstrate accuracy [315]. A two-sided t-test may be 
performed to determine whether significant differences exist between the mean data generated by 
a test method and a nominal value with a 95% level of confidence [317, 320]. FDA requires that 
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recovery values > 90% be demonstrated for biological samples if the analytical method is to be 
approved and recommends that accuracy be investigated at 80%, 100% and 120% of label claim 
for analytical methods used for analysis of drug substances or products [321, 332]. 
 
The accuracy of the HPLC method was determined by performing triplicate analyses (n=3) of 
samples containing known amounts of KTZ viz., 5, 45 and 115 µg/ml analyzed in replicates of 
six. The accuracy of the analytical method was represented as the percent recovery, % RSD and 
% bias. Bias reflects the influence of an analyst on the performance of the method and hence the 
accuracy of sample preparation prior to analysis [326]. By definition, bias refers to the deviation 
from the mean value determined for the API of interest [326]. FDA recommends that the 
acceptance criteria for recovery and % RSD be 100 ± 2% and ≤ 2% respectively at each 
concentration level studied over the range 80-120% of the target concentration. The tolerance 
limit for percent bias was set to 5% in our laboratory.  
 
The data generated during accuracy studies are summarized in Table 3.6. The percent bias was < 
5% for all samples tested. Based on the acceptable test criteria for our laboratory, the analytical 
method was considered accurate.  
Table 3.6 Accuracy data for HPLC analysis of KTZ (n = 3) 
Theoretical 
concentration (µg/ml) 
Actual 
concentration (µg/ml) 
SD % RSD % Bias % Recovery 
5.00 4.96 0.0907 1.829 -0.867 99.28 
45.00 45.30 0.5240 1.164 +0.674 100.67 
115.00 115.51 1.1410 0.986 +0.443 100.44 
 
3.4.5. Limits of quantitation (LOQ) and detection (LOD) 
The LOQ, sometimes termed the lower limit of quantitation or LLOQ, refers to the lowest 
concentration of an analyte that can be accurately and precisely quantitated under the stated 
operational conditions of an analytical method. The LOD refers to the lowest concentration that 
will yield an identifiable or detectable peak that might not necessarily be quantifiable under the 
stated operational conditions of the analytical method [295]. UV detectors may not have the 
highest precision at low analyte concentrations as a result of a loss of sensitivity of the detector 
lamp on ageing or due to variations in the noise levels of the detector, particularly if it has been 
acquired from a different manufacturer or has a different model number [321]. The LOQ is 
generally taken to be the lowest concentration level of  the calibration curve, whereas the LOD is 
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a limit test that enables the analyst to determine whether the concentration of an analyte is above 
or below a specific level or amount [314, 333].  
 
The ICH outlines different approaches that can be used to establish the LOQ and LOD of an 
analytical method. The different approaches yield similar results and none have similar 
identifiable trends that are a specific characteristic of the method. The LOQ and LOD can be 
determined by visual evaluation of the data. Another commonly used approach used in the 
determination of LOQ and LOD is the signal-to-noise ratio approach that may However, only be 
used in analytical methods that display significant baseline noise. The LOQ is said to have a 
signal to noise ratio of 10:1, whereas the LOD is established at a signal to noise ratio of 3:1 when 
measured signals from samples with known low analyte concentrations are compared [324]. This 
approach, albeit recommended by the USP, is not very practical as noise levels vary from detector 
to detector. Another technique used for the assessment of LOQ and LOD involves the calculation 
of the standard deviation of the response and slope of the line using Equations 3.3 and 3.4 to 
determine the value for these limits [286].  
 
                                                                 
   
 
                                                        Equation 3.3 
 
                                                                
     
 
        Equation 3.4 
 
where, 
σ = standard deviation of the response 
           S = slope of the calibration curve 
 
A fourth approach, where a plot of standard deviation versus concentration is constructed and the 
equation of the line determined, may be used. The LOQ and LOD are then calculated by 
multiplying the y-intercept by 10 and 3 respectively. The LOQ can also be taken as the lowest 
concentration with a % RSD of < 5% following multiple injection. The LOD can subsequently be 
taken as 30% of the LOQ [333]. The % RSD approach was used in these studies for the 
determination of LOQ and LOD. Six concentrations of KTZ were selected as potential LOQ 
values and analyzed in replicates of six. The results generated for this approach are listed in Table 
3.7. Using this technique, the LOQ was found to be 2.5 µg/ml with a % RSD of 2.13%. By 
convention, the LOD was calculated to be 0.75 µg/ml. 
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Table 3.7 LOQ data for HPLC analysis 
 
3.4.6. Specificity and selectivity 
The specificity or selectivity of an analytical method is defined as the ability of an analytical 
method to accurately and specifically determine the concentration of the analyte of interest in the 
presence of other components of a mixture or a sample matrix [318, 321, 334-336]. For the 
analytical method to be considered specific and selective, the analyte of interest must be well 
resolved from extraneous components of that mixture or matrix [284, 314, 321, 324]. For the 
chromatographic analysis of pharmaceutical dosage forms, it is important that the analytical 
procedure exhibits good resolution of the peak of interest from possible excipients or 
contaminants that might be present in dosage forms.  
 
3.4.6.1. Analysis of KTZ in tablet dosage forms 
The specificity and selectivity of the RP-HPLC method developed for the analysis of KTZ can be 
demonstrated from the chromatogram depicted in Figure 3.8, which was generated following the 
analysis of Ketazol
®
 200 mg tablets. A composite of 20 tablets was prepared by grinding the 
tablets into a fine powder and accurately weighing aliquots of the powder (n = 3), each of which 
was equivalent to the average weight of a single tablet. The powders were transferred into three 
respective volumetric flasks containing the IS and made up to volume using methanol. The 
solution was filtered through a 0.22 µm Millipore
® 
membrane filter and appropriate aliquots were 
analyzed using the validated HPLC method. No interference from tablet excipients or 
contaminants was observed. The drug of interest, i.e. KTZ, eluted at 3.7 min and was well 
resolved from the internal standard, CLZ, which in turn eluted at 9.0 min. 
Concentration (μg/ml) Mean Peak Height Ratio (n = 6) SD % RSD 
2.50 0.0375 0.0008 2.13 
2.00 0.0292 0.0015 5.24 
1.50 0.0289 0.0025 8.57 
1.00 0.0184 0.0014 7.44 
0.75 0.0099 0.0006 6.32 
0.50 0.0068 0.0006 8.92 
0.25 0.0029 0.0005 18.82 
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Figure 3.8 Typical chromatogram obtained following analysis of Ketazol
®
 200 mg tablets using 
clotrimazole (CLZ) as internal standard. 
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3.4.7. Sample stability studies 
3.4.7.1. Overview 
Part of a validation process necessitates an evaluation of the stability of analytes in the sample 
matrix and solvents used under the conditions to which the analytical samples will be subjected 
during analysis [321]. A compound may be considered stable under certain conditions for a 
specified period of time when there is no significant difference between the detector response for 
the API of interest following analysis of stored samples, compared to the response produced from 
freshly prepared solutions of that drug in a similar matrix or solvent [317]. Drugs that undergo 
hydrolysis, photolysis or that are sequestered onto glassware may need to be investigated for 
stability under normal laboratory operating conditions or following storage. It has been suggested 
that the stability of standard stock solutions used for the preparation of calibration curve standards 
should be assessed over the duration for which these solutions will be stored, under the same 
conditions of light or dark, at the same temperature(s) and in the same solvent(s) and container(s) 
that will be used prior to and during analysis [317, 337, 338].  
 
The stability of KTZ in the standard stock solution used to prepare the calibration standards (§ 
3.3.2.9) was assessed over a one week period as this was the maximum period over which the 
sample was likely to be stored. The aim of these stability studies was to establish whether KTZ 
degrades during this time i.e. from sample preparation through storage and to ensure that the 
integrity of the samples is maintained until analysis is performed [337-339]. In cases where data 
on stability are not available, it is recommended that standard stock solutions be prepared on a 
daily basis during sample analysis. Failure to prepare fresh solutions may result in the 
construction of a calibration curve from standards that do not reflect the true concentration of 
drug and therefore, leads to an inaccurate estimation of the drug concentration in unknown 
samples [338].  
 
3.4.7.2. Stability data analysis 
A systematic statistical procedure was used for the analysis of data generated during stability 
studies. This statistical approach is particularly useful since it accounts for the influence of the 
analytical method. In addition any error that may be associated with the procedure has been 
reported. The method, initially developed for the determination of stability of drugs in biological 
fluids, is based on the calculation of a 90 % confidence interval (C.I.) for the difference in 
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concentration or detector response (D) generated from replicate analysis of stored and freshly 
prepared samples. The true percentage change in response between stored and freshly prepared 
samples lies within a limit defined by the lower limit (L.L.) and the upper limit (U.L.) with 90% 
certainty [340]. 
 
According to this approach, a change may be statistically significant albeit not 
pharmacokinetically relevant i.e. a change may be regarded as significant if the C.I. does not 
include zero and relevant if the U.L. and L.L. of the C.I. are > 10% or < 10% respectively. This 
concept is illustrated in Figure 3.9, which displays the possible results that could be obtained 
from the analysis of stored samples using the approach described by Timm et al., for stability data 
assessment [340].  
 
 
The bars represent the C.I. for the possible scenarios: 
a) change of response, not significant and not relevant 
b) decrease of response, significant but not relevant 
c) decrease of response, significant and possibly relevant 
d) decrease of response, significant and relevant 
e) decrease of response, not significant but possibly relevant 
f) increase of response, significant 
 
Figure 3.9 Interpretation of stability data, as described by Timm et al. [340] 
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3.4.7.3. Stability of stock solutions 
The stability of KTZ stock solutions prepared, as previously described in § 3.3.2.9, was assessed 
during storage for one week at 4°C. Aliquots of 400 and 4800 µl of KTZ stock solutions were 
measured using single-channel model electronic pipettes (Hamilton Soft Touch ™, Nevada, US) 
covering the volume range of 50-1200 and 500-5000 µl respectively and these were transferred 
into 10 ml A-grade volumetric flasks and made up to volume with ACN to yield solutions of 10 
µg/ml and 120 µg/ml representing low and high concentrations respectively. Five replicate 
samples at each concentration were prepared for analysis on days 0, 1, 2, 3 and 7 following 
storage at 4°C. Consequently, a total of twenty-five separate samples were analyzed. Fresh 
samples of KTZ at each concentration studied were also prepared from a freshly prepared KTZ 
stock solution (§ 3.3.2.9) and analyzed on the same day as the stored samples on each day of 
analysis. A 40 µl aliquot of the internal standard (CLZ) stock solution measured using an 
electronic pipette (Hamilton Soft Touch™, 1-100 µl, Nevada, US) was added to the solutions 
prior to analysis and the peak height ratio of KTZ to internal standard was measured.  
 
The results obtained from stability studies of KTZ stock solutions at both the lower and upper 
concentrations stored at 4˚C for 1, 2, 3, 7 days are depicted in Figure 3.10. The data generated 
reveal that the change of response for KTZ was neither significant nor relevant at the lower (10 
μg/ml) and upper (120 μg/ml) concentration levels when stored at 4˚C for 7 days as the U.L. and 
L.L. of the C.I. were found to be within 5%. The wider C.I. calculated for both concentrations on 
day 3 could possibly be attributed to poor precision during sample preparation. However, the 
stability studies indicate that KTZ is stable in methanolic solution at 4°C following storage for 
one week. Therefore, it was acceptable to prepare stock solutions of KTZ in methanol and use 
them within one week prior to storage at 4°C.  
 79 
 
 
Figure 3.10 Interpretation of stability data for KTZ, as described by Timm et al. [340] 
 
3.4.8. Method re-validation 
Re-validation studies might have to be performed to ensure the validity of an analytical method 
when an original procedure has been changed or its validated operating conditions have been 
altered according to FDA guidelines. The extent of re-validation depends on the nature of the 
change to that analytical method and it might not be obligatory to re-validate the method 
completely if it has previously been validated according to the specifications of an international 
protocol [321]. Changes in the raw material or drug substance, changes in the manufacturing 
process of the raw material or in the composition of the product may require re-validation of the 
analytical method to ensure that the method continues to resolve the right strength, quality, purity 
and potency of the drug of interest and/or drug product. The re-validation process may only 
require an evaluation of performance characteristics likely to be affected by the change in the 
analytical method [315]. Nonetheless, it is advisable to conduct an evaluation of linearity, 
accuracy and precision of a method as an absolute minimum requirement should there be any 
change to the analytical method [315].  
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The RP-HPLC method developed for KTZ was revalidated since the column used initially in 
validation studies was replaced with a new column. Replacing a chromatographic column may 
lead to changes in specificity and resolution and quantitative aspects of the HPLC method [315]. 
Therefore, all method validation parameters were reassessed when the new column was installed 
for use. The definitions and accepted validation parameters of the performance characteristics 
discussed below have been described in § 3.4. In addition the column efficiency for the new 
column was evaluated using an ideal test system as described in § 3.3.2.3. The theoretical plate 
number for the new column was 13495 ± 742 (n=6). 
 
3.4.8.1. Linearity and range 
The linearity of the method was evaluated within the concentration range expected from the in 
vitro analysis of KTZ from lyophilized KTZ-loaded solid lipid microparticles that were to be 
developed. Calibration standards were prepared as previously described in § 3.3.2.9, and linearity 
was assessed as described in § 3.4.2. The calibration curve shown in Figure 3.11 was generated 
after replicate analysis (n=6) of samples in the range 2-120 µg/ml. The calibration curve 
represented by the equation y = 0.0124x + 0.0004, with a linear regression coefficient of 0.9998 
obtained after revalidation, indicates that the HPLC method is linear.  
 
Figure 3.11 Calibration curve constructed for KTZ following least squares linear regression analysis of 
peak height ratio of KTZ and CLZ  
y = 0.0124x + 0.0004 
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3.4.8.2. Precision 
The repeatability and inter-day precision of the analytical method were evaluated during the 
revalidation process as described in § 3.4.3. 
 
3.4.8.2.1. Repeatability 
The repeatability of the HPLC method was determined as described in § 3.4.3.1 at three 
concentration levels viz., 5, 45 and 115 µg/ml in triplicate. The results generated in this study 
reveal that the HPLC method is repeatable and are summarized in Table 3.8.  
Table 3.8 Intra-day precision data for HPLC analysis of KTZ during method revalidation 
Concentration (µg/ml) Mean Peak Height Ratio Standard Deviation (SD) % RSD 
5.00 0.059 0.0005 0.786 
45.00 0.601 0.0050 0.835 
115.00 1.461 0.0070 0.480 
 
3.4.8.2.2. Intermediate precision 
The inter-day precision was of the method was assessed as described in § 3.4.3.2, and was 
determined at three concentration levels viz., 5, 45 and 115 µg/ml in triplicate (n=3) for three 
consecutive days. The results of the intermediate precision studies are depicted in Table 3.9. The 
HPLC method was found to be precise over several days as the % RSD values observed were < 
5%.  
Table 3.9 Intermediate precision data for HPLC analysis of KTZ after method revalidation 
Day Concentration (µg/ml) Mean Peak Height Ratio Standard Deviation (SD) % RSD 
1 5.00 0.058 0.0011 1.879 
 45.00 0.593 0.0095 1.600 
 115.00 1.514 0.0089 0.590 
2 5.00 0.058 0.0001 0.117 
 45.00 0.587 0.0086 1.460 
 115.00 1.493 0.0097 0.653 
3 5.00 0.061 0.0001 0.176 
 45.00 0.565 0.0007 0.124 
 115.00 1.482 0.0064 0.423 
 
3.4.8.3. Accuracy 
The accuracy of the HPLC method was evaluated as described in § 3.4.4, and was determined at 
three different levels viz., 5, 45 and 115 µg/ml in triplicate (n=3). The results of these studies are 
summarized in Table 3.10 and reveal that the percent bias was < 5% at the concentration levels 
studied, thus the HPLC method can be said to be accurate.  
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Table 3.10 Accuracy data for HPLC analysis of KTZ (n = 3) after method revalidation 
Theoretical 
concentration (µg/ml) 
Actual 
concentration (µg/ml) 
SD % RSD % Bias % Recovery 
5.00 4.86 0.125 2.572 -0.028 97.20 
45.00 44.80 0.264 0.589 -0.005 99.60 
115.00 116.01 0.273 0.235 +0.008 100.88 
 
3.4.8.4. Specificity 
The specificity of the HPLC method developed for the analysis of KTZ was assessed using  
analysis of Ketazol
®
 200 mg tablets as described in § 3.4.6.1. The specificity of the analytical 
method for KTZ was also evaluated using Ketazol
®
 20mg/g cream. A typical chromatogram 
obtained from these studies is depicted in Figure 3.12, and reveals that there was no interference 
from the formulation excipients. KTZ eluted at 3.6 min and was well resolved from the internal 
standard, CLZ, which in turn eluted at 8.8 min.  
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Figure 3.12 Typical chromatogram obtained following analysis of Ketazol
®
 cream (2% w/w) using 
clotrimazole (CLZ) as internal standard. 
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3.4.8.5. Limits of quantitation and detection 
The LOQ was established using the % RSD method as described in § 3.4.5, and was found to be 2 
µg/ml with a % RSD of 3.38% after replicate analyses (n=6) of samples at that concentration. The 
LOD was therefore taken to be 30% of the LOQ by convention and was calculated to be 0.6 
µg/ml. The results obtained for LOQ determination are listed in Table 3.11.  
Table 3.11 LOQ data for HPLC analysis of KTZ 
Concentration (μg/ml) Mean Peak Height Ratio (n = 6) SD % RSD 
2.50 0.0361 0.0002 0.526 
2.00 0.0287 0.0010 3.380 
1.50 0.0211 0.0013 5.972 
1.00 0.0163 0.0010 6.319 
0.50 0.0061 0.0005 7.541 
0.25 0.0023 0.0004 17.826 
 
3.4.9. Application of the HPLC method 
Following development and validation studies, the RP-HPLC analytical method for KTZ was 
applied to the quantitative determination of KTZ in aqueous dispersions of solid lipid 
microparticles during drug loading capacity (DLC) and encapsulation efficiency (EE) studies.  
 
3.5. Conclusions 
A reversed-phase HPLC method has been developed for the analysis of KTZ and has been 
optimized and validated for use in the in vitro analysis of KTZ in solid lipid microparticles 
formulations. Method development studies reveal that the RP-HPLC method developed was 
relatively simple and convenient to use in comparison with those previously reported which are 
generally complicated and require mobile phase compositions that include the use of hydrophobic 
ion pair reagents or amine modifiers. 
 
UV detection was selected due to its versatility and simplicity. The choice of wavelength of 
analysis must take into account the need for maximum sensitivity and selectivity for the drug of 
interest. The ultraviolet absorption spectrum of KTZ revealed that the wavelength of maximum 
absorption of KTZ was 206 nm. The analytical column was selected based on the 
physicochemical characteristics of KTZ, the column length and the type and size of packing 
material. The efficiency of the column was evaluated using an ideal test system prior to selection 
of a particular column for analysis of KTZ. A 5µm, 150 × 4.6 mm I.D Beckman
®
 ODS column 
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was selected for use, based on these criteria before commencing method development studies for 
the analysis of KTZ.  
 
An internal standard (IS) was used during analysis of KTZ. A few azole antifungal agents were 
screened as potential IS prior to the selection of CLZ as the IS of choice. Optimization of a high-
performance chromatographic method was achieved by alteration of the pH and molarity of the 
buffer, and concentration of the organic modifier used in the mobile phase. The separation of 
KTZ was eventually achieved using reversed-phase HPLC on a non-polar n-octadecylsilane (C18 
or ODS) stationary phase, whilst the polarity of the mobile phase was adjusted using a mixture of 
acetonitrile (ACN) and phosphate buffer. ACN was preferred to methanol as the organic modifier 
since ACN possesses moderate polarity and produced sharp and well resolved peaks.  
 
During the analysis of basic compounds, such as KTZ, it is important to maintain the pH < 8 and 
conduct the analysis at an intermediate pH to avoid hydrolysis of silica-based columns [275, 284, 
289]. Since increased tailing was observed at pH values > 6.0 due to interactions of the basic 
KTZ and the acidic silanol groups, it was necessary to alter the pH of the buffer accordingly. The 
influence of parameters such as the mobile phase flow rate and the mobile phase composition on 
the retention times of KTZ and CLZ were also investigated. A binary mixture of ACN-50 mM 
phosphate buffer, pH 6.0 (60:40) was considered the most appropriate mobile phase composition 
for the separation of KTZ and CLZ when used at a flow rate of 1 ml/min. KTZ and CLZ eluted at 
3.7 and 8.7 min respectively and the total run time for the analytical procedure was approximately 
12 min. 
 
The HPLC method developed for the analysis of KTZ was validated in accordance with the 
recommendations specified in the United States Pharmacopeia (USP) and by the International 
Conference on Harmonization (ICH) [314, 323, 324]. Based on the criteria defined in these 
international protocols, the RP-HPLC method was found to be linear, precise, accurate, specific 
and sensitive. Stability studies indicated that KTZ is stable in methanol following storage at 4°C 
for at least 7 days. Since the analytical column was replaced by a new one, re-validation of the 
method of analysis was essential to ensure validity of the method and to evaluate the performance 
characteristics of the method with the new column [315]. The data generated during re-validation 
studies indicated that the HPLC method was linear, precise, accurate, specific and sensitive for 
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the analysis of KTZ from pharmaceutical formulations. A RP-HPLC method that is simple, rapid, 
linear, accurate, precise, sensitive and selective and has application for the in vitro analysis of 
KTZ-containing dosage forms has therefore been developed and validated.  
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CHAPTER FOUR 
EVALUATION OF POLYMORPHISM OF KETOCONAZOLE AND SELECTION AND 
CHARACTERIZATION OF SOLID LIPID FOR THE MANUFACTURE OF 
KETOCONAZOLE-LOADED SOLID LIPID MICROPARTICLES 
 
4.1. Introduction 
The manufacture of solid lipid microparticles (SLM) using hot high pressure homogenization and 
micro-emulsion techniques require the active pharmaceutical ingredient (API) to be subjected to 
high temperatures [341]. The hot high pressure homogenization (HPH) technique is associated 
with the formation of a pre-emulsion prior to homogenization using a piston gap homogenizer 
[99, 341]. Similarly, the micro-emulsion technique involves the formation of a micro-emulsion at 
temperatures above the melting point of the lipid [183]. The drug-lipid molten phase is formed 
following heating of the lipid to a temperature that is 5-10°C above its melting point and 
incorporating the API into the molten lipid [99, 341]. The melting process in these production 
techniques, albeit essential for the incorporation of the API into the bulk lipid, may precipitate 
temperature-induced degradation of the API or lipid carrier and may lead to changes in their 
physicochemical properties [183, 245, 342, 343]. 
 
Perusal of the literature reveals that KTZ melts at 146°C with no mass-dependent decomposition 
occurring in the range of 25-200°C supporting the fact  that KTZ is likely to be chemically stable 
under the production conditions used during the manufacture of KTZ-loaded SLM using hot HPH 
and micro-emulsion techniques [343]. The chemical degradation of KTZ leads to a change in 
colour from white to purple that is visible to the naked eye [343]. Therefore, for the purposes of 
this research visual assessment of the KTZ-loaded SLM formulations was deemed sufficient to 
detect signs of chemical instability and no colour changes were observed in any event.  
 
Investigating the solubility of KTZ in lipids prior to formulation of KTZ-loaded SLM is essential 
as the solubility of the API in lipids is likely to dictate the drug loading capacity (DLC) and 
encapsulation efficiency (EE) [99, 182, 341]. One of the phases of these studies therefore 
included an assessment of the solubility of KTZ in several lipids to determine the lipid excipient 
that should be used during formulation development and optimization studies. Preliminary 
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solubility studies were performed to select a solid lipid with the highest solubilizing potential for 
KTZ.  
 
It has been intimated that the methods used in the formulation of SLM may lead to changes in the 
polymorphic and crystalline states of the SLM in relation to those of the bulk lipid from which 
the microparticles were manufactured [241, 344]. The objectives of these studies were to 
establish the thermal stability, polymorphic behaviour and crystallinity of KTZ and Labrafil
®
 
M2130 CS used for the manufacture of micro-particulate delivery systems. These studies 
therefore included an investigation of the polymorphic and crystalline behaviour of the lipid 
carrier, Labrafil
®
 M2130 CS and KTZ and a 1:1 combination of Labrafil
®
 M2130 CS and KTZ 
prior to and after exposure to a temperature of 60°C for 1 hour using differential scanning 
calorimetry (DSC) in conjunction with Fourier-transform infra-red (FTIR) spectroscopy. The 
thermal and spectroscopic analyses of a mixture of KTZ and Labrafil
®
 M2130 CS were 
performed to establish whether Labrafil
®
 M2130 CS interacted with KTZ in any manner.  
 
4.1.1. Differential scanning calorimetry 
DSC is a simple thermo-analytical technique that is commonly used to assess the purity, thermal 
kinetic constants, phase equilibria and transitions of substances [345-349]. In addition DSC is 
used in the characterization of drugs and excipients during preformulation studies where it is 
applied to elucidate potential structural changes caused by solid-state interactions and polymorph 
formation [349-352]. Interactions such as drug-excipient incompatibility are easily detected using 
DSC which makes it a valuable tool during product development [351, 353-355]. Furthermore, 
due to its convenience and relative speed, DSC has been reported to have a wide scope of 
practical applications viz., the evaluation of thermal stability, chemical reactivity, decomposition 
behaviour and the qualitative and quantitative analysis of drugs and drug mixtures [351, 355-
358]. One of the main advantages of DSC is that small samples of between 2 and 5 mg are 
required for analysis [359]. A common application of DSC in the food and pharmaceutical 
industry includes the characterization and determination of the phase behaviour of lipids and 
starches such as in the discrimination of olive oil categories, determination of oil quality and 
stability with regards to lipid oxidation in vegetable oils, thermal analysis of starches and in the 
screening of lipid excipients which are of potential use in drug delivery [360-366].  
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The principle of DSC is based on the manipulation of temperature to obtain an indirect 
measurement of differential power during thermal events such as melting, dehydration, 
crystallization or glass transition phenomena [359]. DSC is a thermal analytical method in which  
two samples, the reference or control sample and the substance of interest are heated at a constant 
rate using a controlled temperature-heating programme in identical sample holders or cells [346-
348, 359]. In heat flux DSC the temperature of the reference sample and the substance of interest 
usually increase at the same rate during the controlled heating programme and under ideal 
conditions there are no differences between the temperatures of the two cells, provided no 
cooperative structural changes occur in the sample of interest [345, 346, 348]. Melting and 
crystallization are accompanied by the uptake and emission of heat respectively whilst 
polymorphic transitions may absorb or release heat into a system [345, 348, 359]. During such 
transitions the energy input into the system is used for the transition resulting in the sample 
temperature remaining constant [345, 348]. A temperature difference therefore exists between the 
reference and the sample cells and this temperature difference is measured using a thermal 
electric device for which the voltage is proportional to this temperature difference [348]. The 
voltage is subsequently converted to a differential heat flow signal through a calibration 
procedure and the signal obtained is plotted as a thermogram [348]. In power compensation DSC 
the two cells are heated by separate energy sources in a heat sink and the samples are maintained 
at a constant temperature by an automatic adjustment of the heating power in case of temperature 
differences  [347, 348, 367]. The amount of energy or heat required to attain the desired sample 
temperature is measured in both cells and is directly correlated to the heat flow into or out of the 
samples [347]. The heating power or energy input is lower in the reference sample compared to 
the material of interest and this differential heat flow may be plotted on a thermogram as a 
function of temperature or time [347]. The DSC curve may be used to retrieve the transition 
temperature and precisely calculate the standard enthalpy and entropy changes of the thermal 
event [348, 359, 367]. The standard enthalpy change may be determined from the integral of the 
signal obtained during a particular transition [348, 367]. 
 
Peak-shaped signals are generally obtained during first-order transitions such as melting, 
crystallization and polymorphic transitions [348, 367]. The shape of the DSC curve may also 
provide useful information about the presence of polymorphs and the character of the transition 
itself and indicate the presence of impurities which lead to broadening of the curve and in which 
case peak asymmetry may be indicative of the type of interaction of the impurity with the 
material of interest [348, 367]. Glass transitions tend to have a characteristic step-like deviation 
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from the baseline position [348]. Any large shift in melting point may be indicative of a strong 
solid-solid interaction although it may not necessarily indicate an incompatibility. Smaller peaks, 
extra-thermal effects or peaks which have completely disappeared may also indicate 
incompatibilities [347, 348]. In addition DSC may be used for the identification of solvates that 
are known to modify pharmaceutical properties such as solubility, dissolution rate, bioavailability 
and chemical stability and preformulation studies may have to include thermal characterization of 
the solvent of crystallization to determine the enthalpy of desolvation [346, 368, 369].  
 
DSC is a powerful screening tool in preformulation studies as it is possible to derive information 
relating to potential physical or chemical incompatibilities between an API and potential 
excipients, thereby facilitating the rational selection of materials for use in dosage form design 
and development [370]. However, it is worth noting that DSC alone may not be adequate in 
establishing solid-solid interactions arising from formulation processes which may only be 
conclusively identified using other supportive analytical techniques and long-term stability 
studies [367, 370]. Although it may be possible to monitor and quantify minute thermal events in 
a sample and the temperatures at which these occur, DSC may not definitely determine the cause 
of a thermal event and it may not be possible to clearly differentiate between certain thermal 
events. For instance, a shift in a melting endotherm may be due to degradation, polymorphism, 
presence of solvates, transformation or changes in the crystalline structure of the compound of 
interest which may be need to be substantiated using complementary methods such as 
thermogravimetric analysis, spectroscopic approaches and/or X-ray diffraction [348, 367, 370, 
371]. During thermal analysis of lipids, DSC may be used to predict the polymorphic behavior of 
lipids although X-ray diffraction techniques such as wide angle X-ray diffraction (WAXD) and 
small angle X-ray diffraction (SAXD) may be required to confirm the polymorphic states and the 
crystalline behaviour of the bulk lipid [363, 372, 373]. It was therefore deemed necessary to use a 
spectroscopic technique to rule out possibilities of degradation, transformation and presence of 
solvates in preformulation studies when the API and the lipid excipients are subjected to elevated 
production temperatures. Fourier-transform infra-red (FTIR) spectroscopy was considered an 
appropriate complementary technique for these preformulation studies and was used in 
conjunction with DSC to elucidate the thermal behavior of KTZ and lipid excipients. DSC 
provides thermodynamic data on the phase behaviour of lipids whilst FTIR spectroscopy provides 
molecular level details relating to interactions and changes occurring in lipids prior to and 
following exposure to heat [363, 374].  
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4.1.2. Fourier-transform infrared spectroscopy  
Fourier transform infra-red spectroscopy (FTIR) is commonly used in the characterization of the 
solid-state properties of solid dispersion co-precipitates in routine pharmaceutical analysis [369, 
375, 376]. FTIR analysis may be useful in identifying potential interactions between an API and a 
carrier from an assessment of the chemical bond shifts in the infra-red (IR) spectrum [355, 377, 
378]. In addition FTIR spectroscopy may be used to derive important structural information on 
chain conformation and packing arrangements in molecules such as lipids, polypeptides and 
polymers since IR absorption patterns are known to be different for all molecules even when 
similar frequencies of vibration are present [363, 379-382]. The use of FTIR in the study of fats, 
oils and solid lipids is common and invaluable for the determination and verification of organic 
structures as these molecules absorb electromagnetic radiation in the infra-red region (4000 and 
700 cm
-1
) resulting in differences in intensities and frequencies of absorption by different types of 
bonds [363, 380, 383-386].  
 
FTIR has been widely used in the characterization of pharmaceutical systems, particularly in raw 
material identification and qualification, solid-state characterization of drugs and physiochemical 
characterization of lipids and excipients for the identification of polymorphic and crystal forms 
[376, 380-383, 387-393]. FTIR spectrometers are usually preferred for IR analysis as they acquire 
data in a few minutes using only a few milligrams of sample and are accurate even in the 
presence of trace amounts of impurities which may also be identified [387, 394, 395]. 
Furthermore, FTIR spectrometers, particularly those equipped with attenuated total reflectance 
(ATR) technology are convenient, rapid and easy-to-use for routine fingerprinting of molecules 
[374, 379].  
 
The IR absorption process is based on the excitation of molecules to a higher energy state when 
they absorb IR radiation which is a quantized process leading to the stretching and bending of 
bonds in covalent molecules [367, 375, 394, 396, 397]. It is important to note that only bonds 
with a dipole moment are capable of absorbing IR radiation and therefore symmetrical bonds 
such as those of alkenes and alkynes do not absorb IR radiation [396, 397]. Analysis of solids 
using FTIR may be performed using different methods of sample preparation including the 
potassium bromide (KBr) pellet method and the Nujol mull method [367, 374, 375]. The KBr 
pellet approach involves finely grinding the solid substance with powdered KBr and pressing the 
mixture under high pressure which melts the KBr and incorporates the sample into a matrix 
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forming a KBr pellet [374, 396, 397]. The solid sample may also be ground with the mineral oil 
known as Nujol to form a suspension with the finely ground solid dispersed in the oil or dissolved 
in an organic solvent such as carbon tetrachloride prior to analysis [396-398]. These methods of 
sample preparation have limitations: for instance, KBr tends to be hygroscopic which may 
interfere with the spectrum and the use of Nujol oil or carbon tetrachloride during sample 
preparation may produce obscure spectra [374, 398]. An alternative to these techniques for IR 
analysis includes the use of attenuated total reflectance (ATR) technology which addresses the 
main challenges of IR analysis namely sample preparation and spectral reproducibility [374, 379, 
399]. FTIR coupled with ATR technology offers practical advantages over other spectroscopic 
methods as no sample preparation is required prior to analysis. In traditional FTIR spectroscopy 
sample preparation may induce solid-state transformations and introduce interferences as a result 
of environmental humidity [374, 379, 399]. Spectral bands obtained during FTIR analysis may be 
assigned to specific features of the molecule under investigation and the presence of polymorphic 
forms may be identified due to the appearance of unique bands or peak shifting in the IR 
spectrum [367]. Furthermore, the co-existence of amorphous states of the drug may be detected 
from broadening of the peaks in the IR spectrum [367, 396].  
 
The principle of ATR FTIR is based on the measurement of the changes that are produced when 
an IR beam is subjected to total internal reflection when it comes into contact with a sample 
placed on an optically dense crystal surface [399]. The quantum mechanical properties of light 
leads to an extension of the electromagnetic field beyond the crystal surface such that an 
evanescent wave, produced for approximately 0.5 to 5 µm above the surface, senses the IR-
absorbing sample [399]. The evanescent wave or field is subsequently attenuated or altered before 
returning to the IR beam producing the IR spectrum [399]. When using ATR technology it is 
imperative that the sample must be in direct contact with the crystal surface as the evanescent 
wave only protrudes above the crystal surface for a few microns [399]. In addition the refractive 
index of the crystal must be higher than that of the sample for total internal reflection to be 
produced and  ATR crystals typically have refractive indices between 2.38 and 4.01 at 2000  cm
-1
 
as solids and liquids tend to have lower refractive indices [399]. Crystal materials commonly used 
for ATR analysis include zinc selenide (ZnSe), germanium and diamond of which diamond has 
been reported to exhibit greater robustness and durability and exhibits minimal lifetime 
replacement costs [399]. However, ZnSe and germanium are often selected as crystal materials of 
choice for routine ATR sampling due to the high original purchase costs associated with diamond 
[399]. FTIR coupled with ATR technology was used in these studies to identify potential 
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molecular changes that may occur in KTZ and the lipid after exposure to high temperatures used 
during production of SLM.  
 
4.2. Materials 
4.2.1. Overview 
The materials that were used in solubility studies and thermal analyses are known to have GRAS 
status and are approved for oral and/or IV use in humans by one or more international regulatory 
authority  [400-402]. The physicochemical parameters of KTZ have been previously summarized 
in Chapter 1, § 1.2 vide infra. KTZ used during these studies was purchased from Oman 
Chemicals and Pharmaceuticals, Al Buraimi, Sultanate of Oman. The materials used in these 
studies were at least of analytical reagent grade and were used as received from the suppliers 
without further testing.  
 
4.2.2. Solid lipid excipients 
4.2.2.1. Precirol
®
 ATO5 
Precirol
®
 ATO 5 (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for 
glyceryl palmitostearate, which consists of a mixture of relatively short chain length acylglycerols 
of distearate, tripalmitin and tristearin [403, 404]. Precirol
®
 ATO 5 occurs as a fine white or 
almost white powder of well-controlled particle-size distribution with an indicative particle size 
of 50 µm and has a faint odour [403, 405, 406]. The melting point of Precirol
®
 ATO 5 lies 
between 52 and 55°C [403]. It has been reported that Precirol
®
 ATO 5 is freely soluble in 
chloroform and dichloromethane and practically insoluble in ethanol, mineral oil and water [403]. 
Precirol
®
 ATO 5 is classified as a non-ionic agent with a low HLB value of 2.0 [403-405]. It is 
advisable not to store Precirol
®
 ATO 5 at temperatures exceeding 35°C and Precirol
®
 ATO 5 
must be stored at a temperature of between 5 and 15°C in an airtight container protected from 
light and moisture [403]. Precirol
®
 ATO 5 has a hydroxyl value of 90-110, an acid number of <  
6, an iodine number < 3 and a saponification number ranging from 175 to 195 [404]. The 
manufacture of Precirol
®
 ATO 5 involves direct esterification of palmitic and stearic acids with 
glycerol without a catalyst  and Precirol
®
 ATO 5 is regarded as an essentially non-toxic and non-
irritant material, with a GRAS status [403]. The uses of Precirol
®
 ATO 5 are diverse, ranging 
from being used as a lipophilic agent, excipient, tableting binder to a lubricant for solid and 
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semisolid sustained release formulations [404, 406]. It has been reported that Precirol
®
 ATO 5 
protects drugs and improves the stability of  dosage forms [404]. 
 
4.2.2.2. Compritol
®
 888 
Compritol
®
 888 (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for glyceryl 
behenate [407]. Glyceryl behenate is described as a mixture of glycerides of fatty acids, mainly 
behenic acid with a content of 1-monoglycerides between 12.0 and 18.0% [407]. The non-
proprietary name for Compritol
®
 888 is glyceryl dibehenate and Compritol
®
 888 occurs as a 
mixture of diacylglycerols, mainly dibehenylglycerol, with varying amounts of mono- and 
triacylglycerols [408]. Compritol
®
 888 occurs as fine white or almost white to yellow powder or 
hard waxy mass or unctuous flakes with a faint odour and a low HLB value of 2.0 [404, 405, 407, 
408]. The melting point of Compritol
®
 888 falls between 65 and 77°C [407, 408]. Compritol
®
 888 
is practically insoluble in hexane, mineral oil and water and is soluble, on heating, in chloroform, 
dichloromethane and ethanol (96%) [404, 407, 408]. Compritol
®
 888 decomposes on heating to 
produce acrid smoke and irritating fumes [407]. It has been reported that Compritol
®
 888 has an 
acid number < 4, an iodine number < 3 and a saponification number between 145 and 165 [404].  
 
The production of Compritol
®
 888 occurs via esterification of glycerin by behenic acid (C22 fatty 
acid) without the addition of catalysts [407]. Raw materials of vegetable origin are used for the 
preparation of Compritol
®
 888 and the resulting esterified material is atomized by spray-cooling 
[407]. Compritol
®
 888 has a GRAS status and is generally regarded as a relatively non-irritant 
and non-toxic material [407]. Compritol
®
 888 should be stored in its original airtight container at 
a temperature < 35°C and it is recommended to prevent the exposure of Compritol
®
 888 to air, 
light, heat and moisture [404, 407]. Compritol
®
 888 has a hydroxyl value of 80-105 [238]. The 
fatty acid fractions of glycerol dibehenate, as determined by gas chromatography consist of 
palmitic, stearic, arachidic, erucic and lignoceric acids [408]. Compritol
®
 888 has been used in 
the formulation of modified release tablets, as a lubricant for tablets produced by direct 
compression and as a lipid excipient in melt processing techniques such as spray cooling and hot 
melt extrusion [409].  
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4.2.2.3. Labrafil
®
 M2130 CS  
Labrafil
®
 M2130 CS (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for 
lauroyl macrogol-6-glycerides EP or lauroyl polyoxyl-6 glycerides NF [410]. Labrafil
®
 M2130 
CS occurs as a pale yellow waxy semisolid with a relatively low HLB value of 4 [410]. The 
manufacture of Labrafil
®
 M2130 CS occurs via a trans-esterification procedure involving a C12-18 
glyceride and polyethylene glycol [411]. Labrafil
®
 M2130 CS has a melting range of 38 to 40°C 
[404, 410, 411]. Labrafil
®
 M2130 CS has a hydroxyl value of 90-110, an acid value < 2, a 
saponification value between 185 and  200 and an iodine value <  3 [411]. Labrafil
®
 M2130 CS is 
freely soluble in chloroform and dichloromethane, partly soluble in ethanol and practically 
insoluble in mineral oils and water [404]. Labrafil
®
 M2130 CS must be stored at a temperature of 
5-15°C in an airtight container protected from light and moisture and should not be stored at 
temperatures exceeding 35°C [410]. Labrafil
®
 M2130 CS is composed of well-characterized 
PEG-esters and a glyceride fraction and is regarded as an essentially non-toxic and non-irritant 
material with GRAS status [410]. The safety of use of Labrafil
®
 M2130 CS has been established 
by substantial toxicological data and its precedence of use in approved pharmaceutical 
formulations [410]. Labrafil
®
 M2130 CS may be used in oral and topical formulations as a 
solubilizer and is known to act as a bioavailability enhancer for oral formulations [410]. 
Furthermore, Labrafil
®
 M2130 CS is able to self-emulsify when in contact with aqueous media 
resulting in a coarse dispersion or a fine micro-emulsion and its surface-active properties improve 
the solubility of poorly soluble API in vitro and in vivo making it valuable in the formulation of 
self-emulsifying lipid formulations [410]. In topical ointments, microemulsions and emulsions, 
Labrafil
®
 M2130 CS is able to act as a water-in-oil surfactant which enhances drug penetration 
[410]. In addition Labrafil
®
 M2130 CS is also used in the formulation of tablets and hard and soft 
gelatin capsules [410].  
 
4.2.2.4. Gelucire
®
 44/14 
Gelucire
®
 44/14 (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for lauroyl 
macrogolglycerides or polyoxyglycerides [412]. Gelucire
®
 44/14 is produced from hydrogenated 
palm kernel oil and polyethylene glycol and is comprised of a mixture of polyethylene glycol 33 
(PEG 33, MW 1500), glycerides, glycerol and PEG mono- and diesters of fatty acids, with the 
most common fatty acid chain in the mixture being lauric acid in a proportion of 40-50% w/w, of 
which more than 80% are saturated [412, 413]. The final composition of Gelucire
®
 44/14 is 
 96 
 
approximately 72% w/w PEG esters, 20% w/w glycerides, 8% w/w pure PEG and 2% w/w 
glycerol [412, 413]. Gelucire
®
 44/14 occurs as a waxy solid with a faint odour and melts at 44ºC, 
with its drop point ranging between 42.5 and 47.5°C [404]. It has been reported that Gelucire
®
 
44/14 dissolves in chloroform, dichloromethane and ethanol but is insoluble in mineral oils [404]. 
The properties of Gelucire
®
 44/14 such as its high HLB value of 14 make it a good additive as a 
bioavailability enhancer and solubilizer for inclusion in the formulation of poorly soluble drugs 
[404, 412, 413]. The safety of Gelucire
®
 44/14 is substantiated by in-depth toxicological 
evaluations and precedence of use in approved pharmaceutical products [412]. Gelucire
®
 44/14 is 
often used to improve the release of poorly soluble API in a number of oral delivery systems such 
as granules, tablets, hard gelatin capsules, and self-emulsifying lipid formulations [404, 412, 
413]. Gelucire
®
 44/14 has an acid number < 2, an iodine number < 2, a saponification number 
between 79 and 93 and a hydration number between 36 and 56 [404]. Studies have shown that 
Gelucire
®
 44/14 is susceptible to hydration in the presence of at least 5% w/w water content at 
high humidity levels such as 75% RH [414]. It is therefore advisable to store Gelucire
®
 44/14 in 
its original airtight container away from air, light, heat and moisture [404, 412, 414]. 
 
4.2.2.5. Gelucire
®
 50/13 
Gelucire
®
 50/13 is the proprietary name for stearoyl macrogolglycerides or polyoxyglycerides 
[415]. Gelucire
®
 50/13 occurs as white waxy solid pellets with an HLB value of 13 [415]. 
Gelucire
®
 50/13 melts at 50ºC with a drop point ranging between 46 and 51°C [404]. Gelucire
®
 
50/13 is used in the formulation of a number of delivery systems such as capsules, granules, 
tablets and self-emulsifying lipid formulations as it forms a fine dispersion or micro-emulsion by 
self-emulsification when in contact with aqueous media [415]. Gelucire
®
 50/13 possesses surface-
active characteristics that enhance in vivo drug solubilization thus improving the bioavailability of 
poorly soluble drugs and facilitating their absorption [413, 415]. The use of Gelucire
®
 50/13 tends 
to result in immediate release preparations due to its high HLB value particularly when used in 
melt granulations [415]. However, Gelucire
®
 50/13 may also be used as an excipient in hard 
gelatin capsules as a controlled-release agent and to protect API [413, 415]. In addition Gelucire
®
 
50/13 exhibits good thermo-plasticity for use as a binder in melt processes and is a good excipient 
for use in melt processing approaches for capsule filling [415]. Gelucire
®
 50/13 has an acid 
number < 2, an iodine number < 2 and a saponification number between 65 and 80 [404]. 
Gelucire
®
 50/13 has GRAS status supported by toxicological data and precedence of use in 
approved products [404, 415].  
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4.2.3. Water 
Water used in these studies was of HPLC ultra pure grade and was prepared using a Milli-RO
®
 15 
water purification system (Millipore Co., Bedford, MA, USA) that consisted of a Super-C
®
 
carbon cartridge, two Ion-X
®
 ion-exchange cartridges and an Organex-Q
®
 cartridge. The water 
was filtered through a 0.22 μm Millipak® 40 stack filter (Millipore Co., Bedford, MA, USA) prior 
to use. 
 
4.3. Methods 
4.3.1. Characterization of KTZ 
4.3.1.1. DSC characterization of KTZ 
The melting range and changes in the melting behaviour of KTZ were determined using a Perkin-
Elmer DSC-7 Differential Scanning Calorimeter (Perkin-Elmer, Norwalk, Connecticut, USA). A 
2.6402 mg sample of KTZ was weighed using a Mettler Toledo top-loading analytical balance 
(Mettler Instruments, Zurich, Greifensee, Switzerland) and was hermetically sealed into a 
standard 40 µl aluminium pan. The instrument was calibrated for temperature using 5.0 mg high 
purity indium and DSC curves for KTZ samples were generated by heating the sample from 25ºC 
to 250ºC and subsequently cooling to 25ºC at heating and cooling rates of 10ºC/min. The 
reference standard used was an empty pin-holed aluminium pan sealed in a similar manner to the 
pan containing the sample. The DSC profile for KTZ was generated prior to and following  
exposure of the API to a temperature of 60ºC for 1 hour in order to determine the influence of 
heat on the physicochemical properties of KTZ. Parameters such as temperature onset, maximum 
peak and enthalpy were established using Pyris™ Thermal Analysis Manager software (Perkin-
Elmer, Shelton, Connecticut, USA) coupled to the Perkin-Elmer DSC-7 Differential Scanning 
Calorimeter. 
  
 98 
 
4.3.1.2. FTIR characterization of KTZ 
The FTIR spectra of KTZ prior to exposure to heat was generated as described in § 1.2.6 using a 
sample of KTZ weighing approximately 2 mg. FTIR analysis was also performed on a sample of 
KTZ following exposure to heat to identify any changes in chemical bond shifts, broadening of 
peaks or the presence of unique bands in the IR spectrum which might be indicative of 
polymorphic modifications that may have occurred following heating. A 10 mg sample of KTZ 
was weighed using a Mettler Toledo top-loading analytical balance (Mettler Instruments, 
Greifensee, Zurich, Switzerland) and transferred to a screw-capped test tube that was heated at 
60ºC for one hour and cooled to cooling 25ºC. Spectral data were collected over the IR spectrum 
in the region of 515-4000 cm
-1
 using samples weighing approximately 5 mg. The resultant 
chemical bond shifts were used to analyze the spectra for possible interactions and polymorphic 
changes in the IR spectrum of KTZ. 
 
4.3.2. Selection of solid lipid excipient 
4.3.2.1. Solubility studies 
As there are no standard methods to determine the solubility of a drug in a solid lipid, the 
solubility of KTZ was investigated by dissolving increasing amounts of KTZ in the different 
lipids in the molten state and visually assessing the drug-lipid melt to establish whether drug 
crystals had dissolved in the molten lipid dispersion. The solubility of KTZ in solid lipids was 
determined using a shaking water bath (Laboratory Thermal Equipment, Greenfield, Oldham, 
United Kingdom) set to 50 rpm and with the temperature set to 60°C. Briefly 1.0 g of solid lipid 
and 0.05 g of KTZ were accurately weighed using a top-loading analytical balance (Mettler 
Instruments, Greifensee, Zurich, Switzerland) and transferred to a screw-capped test-tube. The 
solid lipid-KTZ mixture was melted in the water bath at 60°C and then mixed using a vortex 
mixer to facilitate the dissolution of the KTZ in the molten lipid. The drug-lipid mixture was 
allowed to shake and the solubility of KTZ in the molten lipid was assessed visually by observing 
the clarity of the molten lipid after the addition of KTZ. Following dissolution of KTZ the initial 
concentration of 5% w/w was increased to 10% w/w, 15% w/w, 20% w/w and higher until 
saturation solubility of KTZ in the solid lipid was reached. The point at which the saturation 
solubility was reached occurred when KTZ crystals failed to dissolve in the molten lipid after 
allowing the mixture to shake for 12 hours at 60ºC. The solid lipid that was found to exhibit the 
best solubilising potential for KTZ was selected for further thermal and spectroscopic analyses.   
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4.3.2.2. Polymorphism of bulk lipid 
Polymorphic modifications that might occur when bulk lipid material is subjected to temperatures 
used in the production of SLM were established by assessing the crystallinity of the solid lipids 
prior to and following heating using DSC. The first step in the production of SLM involves 
heating the bulk lipid prior to dispersing the molten lipid in a hot aqueous surfactant solution. The 
initial melting of the lipid materials before homogenization may result in changes in the 
polymorphic form of the lipid, which may in turn affect the crystallinity of the lipid in the SLM, 
thereby impacting on the stability of the SLM.  
 
4.3.2.2.1. DSC characterization of Labrafil
®
 M2130 CS 
The DSC system used in these studies has been described in § 4.3.1.1. The DSC thermograms for 
the bulk solid lipid excipient were generated from a scan of a sample of the solid lipid prior to 
exposure to heat and scanning the solid lipid that had been heated from 25ºC to 60ºC for one (1) 
hour and left to cool to 25ºC. The weight of the samples analyzed was between 2 to 5 mg and the 
reference used was an empty pin-holed 40 µl aluminium pan.  
 
4.3.2.2.2. FTIR characterization of Labrafil
®
 M2130 CS 
The FTIR spectrum of the solid lipid was generated as described in § 1.2.6 for a sample weighing 
approximately 2 mg at room temperature, prior to exposure to heat. Thereafter, analysis of a 
sample of the solid lipid following heating to 60ºC for one (1) hour and then cooled to 25ºC was 
conducted. Spectral data were collected over the IR spectrum in the region of 515-4000 cm
-1
 and 
resultant chemical bond shifts were used to analyze the spectra for possible polymorphic 
modifications of KTZ.  
 
4.3.2.3. Interaction of bulk lipid with KTZ 
DSC and FTIR analyses were also used to investigate for potential interactions between Labrafil
®
 
M2130 CS and KTZ using methods similar to those described in § 4.3.1.1 and 4.3.1.2, 
respectively. The concentration of KTZ in the solid lipid-drug mixture was 50% w/w to ensure 
saturation solubility had been reached. DSC and FTIR scans were performed on an unheated 
sample of KTZ and the lipid and a homogenous sample of the drug-lipid mixture that had been 
exposed to heat. The unheated binary mixture of KTZ and solid lipid was prepared by crushing 
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the lipid with KTZ in a 1:1 ratio using a mortar and pestle. The binary mixture that was exposed 
to heat was prepared by heating KTZ and the solid lipid (1:1) to 60ºC for one (1) hour and 
allowing the mixture to stand at room temperature (25ºC) for 24 hours. The weights of the 
samples used for the DSC analysis were between 2 and 5 mg.  
 
4.4. Results and discussion 
4.4.1. Characterization of KTZ 
4.4.1.1. DSC characterization of KTZ 
DSC was used to elucidate the melting, crystalline and polymorphic nature of KTZ prior to and 
following exposure to a temperature of 60ºC for one (1) hour. The DSC profile of KTZ generated 
before and after exposure to heat is depicted in Figure 4.1. The melting events are summarised in 
Table 4.1 including the width of the melting events (WME) which is calculated as the difference 
between melting and onset temperatures. The magnitude of the WME may be used as a measure 
of lattice defects within the crystal structure [241].   
 
Figure 4.1 DSC profile of KTZ prior to and following exposure to 60°C for one (1) hour 
 101 
 
Table 4.1 DSC parameters for KTZ obtained prior to and after exposure to 60°C for one (1) hour 
KTZ Thermal event  Onset (°C) MP (°C) Enthalpy (J/g) WME (°C) 
Prior to heating  Endothermic 146.42 149.27 156.84 2.85 
After heating Endothermic 145.85 149.13 138.37 3.28 
 
The DSC curve for KTZ prior to exposure to heat shows the presence of an endothermic thermal 
event with an extrapolated onset temperature and peak maximum occurring at 146.42°C and 
149.27°C, respectively with a corresponding enthalpy of 156.84 J/g. This event is indicative of 
the melting of a stable polymorphic modification of KTZ and the relatively narrow width of the 
melting event of 2.85°C and sharp and distinct endothermic peak reveal the highly crystalline 
structure of KTZ. No major changes were observed in the melting behaviour of KTZ after 
exposure to 60ºC for one (1) hour although a slight decrease from 149.27°C to 149.13 °C was 
noted in the peak maximum. This decrease in peak temperature was considered insignificant and 
could not be associated with the presence of new polymorphic modifications as only changes of 
more than two degrees in the peak maximum are known to be related to the formation of new 
crystalline forms [416, 417].  
 
In addition a reduction in enthalpy and extrapolated onset temperature from 156.84 J/g and 
146.42°C to 138.73 J/g and 145.85°C were noted, coupled with a broader WME of 3.28°C 
following exposure to heat. The broadening of the WME accompanied by a decrease in enthalpy, 
onset temperature and intensity of the endotherm obtained for KTZ scanned after exposure to heat 
may possibly be attributed to a slight reduction in the degree of crystallinity of KTZ.  
 
4.4.1.2. FTIR characterization of KTZ 
FTIR was used to determine if any molecular changes occurred in KTZ following exposure to 
heat and differences in peak temperatures observed in DSC may imply the occurrence of 
chemical changes in the structure of KTZ or the presence of polymorphic modifications which 
may result in a change in crystalline forms after exposure to heat. The IR spectrum of KTZ 
exposed to a temperature of 60ºC for one (1) hour was compared to the spectrum obtained for 
KTZ prior to heating (Chapter 1, Figure 1.2 vide infra) to identify any changes in the 
characterisitic band assignments. The relevant band assignments are depicted in Figure 4.2 and 
summarized in Table 4.2. 
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Figure 4.2 Infra-red spectrum of KTZ following exposure to 60°C for one (1) hour 
 
Table 4.2 Major infra-red band assignments for KTZ prior to and following exposure to 60°C for one (1) 
hour 
Band position (cm
-1
) Assignment 
Prior to exposure to 
60°C for 1 hour 
After exposure to 
60°C for 1 hour 
 
3177 3179 sp
2 
C-H stretch 
2976 2976 sp3 C-H stretch 
1645 1643 C=O stretching of the ketone (conjugation with imidazole 
ring) 
1458 1457 C-N stretching of the imidazole 
1256 1255 C-O stretching of the cyclic ether group 
1240 1241 C-C=O bend of the ketone 
    NR  
1031 1030 Ar-C-O stretching of the ether 
737 740 C-Cl stretching of chlorine 
   
   
The wavelengths characteristic of KTZ, 1643, 1457, 1255, 1241, 1030, 740 cm
-1 
remained 
unchanged indicating the absence of new crystal forms. The baseline height was also almost 
constant prior to and following exposure of KTZ to heat. Therefore, major differences in the 
degree of crystallinity of KTZ are unlikely. A decrease in the intensity of some peaks was 
recorded after exposure of the KTZ sample to heat and this may be attributed to changes in the 
crystal habits during crystal growth resulting in changes in the physicochemical properties of 
KTZ as observed from the differences in peak maxima during DSC studies [416]. Conversely, it 
is evident from FTIR studies conducted on KTZ prior to and following exposure to heat that KTZ 
consists of the same polymorphic modification and that new polymorphic forms of KTZ are not 
produced when heated to a temperature of 60°C. Nevertheless, it is worth noting that further 
studies using complementary tools such as X-ray diffraction may be required to expound the 
significance of the possible changes in crystallinity and crystal habit of KTZ observed during 
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DSC and FTIR analysis. The main objective of these studies were to elucidate if polymorphic 
modifications had occurred following exposure of KTZ to a temperature of 60ºC for one (1) hour 
from changes in chemical bond shifts, broadening of peaks or occurrence of unique bands in the 
IR spectrum and FTIR was therefore deemed sufficient when used with DSC for this purpose. 
 
4.4.2. Selection of solid lipid excipient 
4.4.2.1. Solubility studies 
Investigating the solubility of KTZ in lipids prior to formulation development and optimization 
studies is essential as the solubility of the API in lipids will impact on the DLC and EE of 
particles [99, 182, 341]. Preliminary solubility studies were performed to select a solid lipid with 
the highest solubilizing potential for KTZ and further analyses using DSC and FTIR were 
subsequently performed on the solid lipid selected. A summary of the solubility data obtained for 
KTZ in different solid lipids is listed in Table 4.3.  
Table 4.3 Solubility of KTZ in different solid lipid excipients 
No. Solid lipid MP (°C) 5% w/w 
KTZ 
10% w/w  
KTZ 
15% w/w  
KTZ 
20% w/w  
KTZ 
1 Precirol
®
 ATO5 52-55 Soluble Partially soluble Insoluble N/A 
2 Compritol
®
 888 65-77 Soluble Partially soluble Insoluble N/A 
3 Labrafil
®
 M2130 CS 38-40 Soluble Soluble Soluble Insoluble 
4 Gelucire
®
 44/14 42.5-47.5 Soluble Soluble Insoluble N/A 
5 Gelucire
®
 50/13 46-51 Soluble Partially soluble Insoluble N/A 
 
The data generated from the solubility studies reveal that KTZ is not very soluble in the solid 
lipids tested at concentrations exceeding 5% w/w. It appears that Labrafil
®
 M2130 CS has the 
best solubilising potential for KTZ. The higher solubility of KTZ in Labrafil
®
 M2130 CS 
compared to the other solid lipid excipients tested could be attributed to the composition of 
Labrafil
®
 M2130 CS. Solid lipids which consist of mixtures of short-chain length acylglycerols 
and PEG-esters viz., Labrafil
®
 M2130 CS and Gelucire
®
 50/13 seem to exhibit a higher 
solubilising potential for KTZ due to their average lipophilicity and good self-emulsifying 
properties. Labrafil
®
 M2130 CS consists of PEG-esters and a C12 glyceride fraction that is partly 
unsaturated thus improving the potential for hydrogen bond formation between the API and solid 
lipid since Labrafil
®
 M2130 CS has a hydroxyl value of 90-110 [410, 411]. Esterification of the 
PEG components may also lead to an increased potential for formation of hydrogen bonds 
between the ester components and the KTZ molecule facilitating the dissolution of KTZ. 
Furthermore, the PEG moiety in Labrafil
®
 M2130 CS imparts self-emulsifying characteristics to 
the solid lipid which improve its surface-active properties thus enhancing the solubility of poorly 
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soluble compounds such as KTZ. Labrafil
®
 M2130 CS also has an HLB value of 4 which 
suggests that it is a good water-in-oil surfactant and wetting agent that reduces the interfacial 
tension between KTZ and lipid molecules and promotes dissolution of KTZ [410].  
 
Gelucire
®
 44/14 showed good solubilising potential for KTZ at concentrations of 5-10% w/w. 
This could be attributed to the PEG-33 moiety in Gelucire
®
 44/14 that improves its surface active 
properties and its relatively short chain acylglycerol consisting of a lauric acid (C12) backbone 
that imparts an average lipophilic character to the lipid [412]. In addition Gelucire
®
 44/14 has a 
high HLB value of 14 that contributes to its self-emulsifying characteristics and promotes 
dissolution of KTZ. Conversely, it appears that Gelucire
®
 50/13 exhibits a poor solubilising 
potential for KTZ which may be explained by its longer steroyl backbone (C18), resulting in 
lipophilicity outweighing self-emulsifying properties [415]. KTZ exhibits poor solubility in solid 
lipids such as Precirol
®
 ATO5 and Compritol
®
 888 as these consist of long chain acylglycerols 
such as stearic (C18) and behenic acids (C22) that tend to increase the lipophilicity of these 
materials [405]. Furthermore, these lipids have low HLB values of 2.0 which do not seem to 
promote good wetting of the lipid and KTZ. Consequently, Labrafil
®
 M2130 CS was selected as 
the solid lipid of choice for use in the development of KTZ-loaded SLM and was subsequently 
used for thermal and spectroscopic analyses in preformulation studies using DSC and FTIR.  
 
4.4.2.2. Polymorphism of bulk lipid 
4.4.2.2.1. DSC characterization of Labrafil
®
 M2130 CS 
The DSC profile of Labrafil
®
 M2130 CS generated prior to and following  exposure to 60°C for 
one (1) hour is depicted in Figure 4.3 and the relevant DSC data generated in these studies is 
listed in Table 4.4.  
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Figure 4.3 DSC profiles of Labrafil
®
 M2130 CS generated prior to and following exposure of the lipid to 
heat at 60°C for one (1) hour 
 
Table 4.4 DSC parameters for Labrafil
®
 M2130 CS generated prior to and following exposure of the lipid 
to heat at 60°C for one (1) hour 
Labrafil
®
 M2130 CS Thermal event Onset (°C) MP (°C) Enthalpy (J/g) WME (°C) 
Prior to heating Endothermic 37.52 39.81 32.41 2.29 
After heating Endothermic 36.40 40.02 35.89 3.62 
 
The DSC scan of Labrafil
®
 M2130 CS generated prior to exposure of the lipid to heat reveals the 
presence of a single peak with an onset and peak maximum at 37.5°C and 39.8°C thus confirming 
the presence of a single polymorphic form. The WME of the thermogram is relatively narrow 
with a value of 2.3°C which may be explained by the slightly amorphous and disordered 
crystalline structure of the lipid prior to heating. The DSC thermogram of the sample that was 
exposed to 60°C for one (1) hour before scanning reveals a single melting event at 40.0°C with an 
onset temperature at 36.4°C. The WME of the DSC curve of Labrafil
®
 M2130 CS after exposure 
to heat is wider compared to that observed for the unheated lipid. A WME value of 3.6°C could 
be explained by the presence of defects within the lipid structure, thereby impacting the 
crystalline structure of Labrafil
®
 M2130 CS. DSC alone cannot be used to confirm the presence 
of different polymorphic forms of Labrafil
®
 M2130 CS following exposure of the lipid to heat 
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and it was necessary to use FTIR to confirm if changes in the crystallinity within the lipid 
structure had occurred.  
 
4.4.2.2.2. FTIR characterization of Labrafil
®
 M2130 CS 
The IR spectra of Labrafil
®
 M2130 CS are depicted in Figure 4.4 and the band assignments are 
summarized in Tables 4.5 and 4.6 for samples investigated prior to and following exposure to 
heat. The IR spectrum of Labrafil
®
 M2130 CS exposed to a temperature of 60ºC for one (1) hour 
(Figure 4.4. B) was compared to the spectrum obtained for Labrafil
®
 M2130 CS prior to heating 
(Figure 4.4. A) to identify if any changes in the characterisitic band assignments for the 
compound had occurred.  
 107 
 
 
 
Figure 4.4 Infra-red spectrum of Labrafil
®
 M2130 CS A) prior to exposure to 60°C for one (1) hour and B) 
following exposure to 60°C for one (1) hour 
B – after heating 
A – before heating 
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Table 4.5 Major infra-red band assignments for Labrafil
®
 M2130 CS prior to exposure to 60°C for one (1) 
hour 
Band position (cm
-1
) Assignment 
3405 O-H stretching (water band) 
2923 Symmetric stretching of CH2 (cis double bond stretching) 
2850 Asymmetric stretching of CH2 
1720 C=O stretching of the ester carbonyl group 
1466 Bending vibrations of CH2 and CH3 aliphatic groups 
1105 Stretching vibration of the C-O ester group 
1030 C-O stretching 
720 =CH2 wagging 
 
Table 4.6 Major infra-red band assignments for Labrafil
®
 M2130 CS after exposure to 60°C for one (1) 
hour 
 
The FTIR spectra of Labrafil
®
 M2130 CS depicted in Figure 4.4 A and B revealed that there is no 
significant difference in the spectrum of the solid lipid prior to and following exposure to a 
temperature of 60°C for one (1) hour indicating that the chemical structure of Labrafil
®
 M2130 
CS does not change after heating. In addition FTIR analysis of Labrafil
®
 M2130 CS revealed a 
lack of significant change in broadening of peaks or occurrence of unique bands in the IR 
spectrum, thereby supporting the data observed in DSC studies suggesting that exposure of the 
lipid to relatively high temperatures does not change the polymorphic form. The minor 
differences observed between the two spectra from the band assignments for Labrafil
®
 M2130 CS 
before and after exposure to 60°C for one (1) hour and summarized in Tables 4.5 and 4.6. The 
FTIR spectra of Labrafil
®
 M2130 CS showed typical characteristic absorption bands for common 
triglycerides which may be attributed to the specific functional groups of the principal 
components of the solid lipid  [380, 386, 418, 419]. The differences observed between the two 
spectra occur due to the stretching, wagging, bending, scissoring vibrations of the CH2 groups of 
the acyl chains, a phenomenon known to occur during IR analysis of lipid structures [381]. The 
band assignments observed for Labrafil
®
 M2130 CS prior to exposure to heat at 2923, 2850, 1466 
and 720 cm
-1
 can be explained by the different vibrations of the CH2 and CH3 groups and it can 
be noted that these absorption bands were not significantly different following exposure of the 
solid lipid to heat on comparison of the two spectra as the corresponding band assignments were 
noted at 2924, 2860, 1465 and 721 cm
-1
 after exposure to 60°C for one (1) hour. In addition the 
Band position (cm
-1
) Assignment 
3380 O-H stretching (water band) 
2924 Symmetric stretching of CH2 (cis double bond stretching) 
2860 Asymmetric stretching of CH2 
1725 C=O stretching of the ester carbonyl group 
1465 Bending vibrations of CH2 and CH3 aliphatic groups 
1127 Stretching vibration of the C-O ester group 
1032 C-O stretching 
721 =CH2 wagging 
 109 
 
presence of water in Labrafil
®
 M2130 CS was detected prior to and after heating of the lipid from 
the broad bands observed at 3405 and 3380 cm
-1
 respectively in the IR spectra enhancing the 
possibility of hydrogen bonding occurring within the lipid structure [379]. Furthermore, the 
interfacial region of the lipid causes strong absorption bands from the ester C=O groups in the 
triglyceride esters which may be seen in the 1720 to 1750 cm
-1
 region of the IR spectra [379, 
381]. In IR analysis of Labrafil
®
 M2130 CS, the carbonyl group stretching prior to and after 
exposure to heat was observed at 1720 and 1725 cm
-1
. The lower peak frequency observed for the 
ester group prior to heating of Labrafil
®
 M2130 CS may be due to the formation of hydrogen 
bonds between the carbonyl functional group and water [379].  
 
4.4.2.3. Interaction of bulk lipid with KTZ 
DSC and FTIR were also used to determine if any interaction occurred between KTZ and 
Labrafil
®
 M2130. A binary mixture of KTZ and Labrafil
®
 M2130 CS (1:1) was used for thermal 
and spectroscopic analyses.  
 
4.4.2.3.1. DSC characterization of bulk lipid with KTZ 
The DSC profiles generated following analysis of a mixture of KTZ and Labrafil
®
 M2130 CS 
following heating to 60°C for one (1) hour is depicted in Figure 4.5 and the DSC parameters are 
summarized in Table 4.7.  
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Figure 4.5 DSC profiles of a binary mixture of Labrafil
®
 M2130 CS and KTZ generated prior to and 
following exposure of the lipid to heat at 60°C for one (1) hour 
 
Table 4.7 DSC parameters of a binary mixture of Labrafil
®
 M2130 CS and KTZ obtained prior to and after 
exposure to heat at 60°C for one (1) hour 
Labrafil
®
 M2130 CS and KTZ Thermal event Onset (°C) MP (°C) Enthalpy (J/g) 
Prior to heating Endothermic 
Endothermic 
37.52 
146.49 
40.10 
151.31 
119.45 
2.63 
After heating Endothermic 
Endothermic 
37.12 
145.32 
39.91 
150.86 
128.76 
7.38 
 
The DSC profiles of the binary mixture of KTZ and Labrafil
®
 M2130 CS prior to and following 
heating to 60°C for one (1) hour reveals the presence of peaks that are due to both KTZ and 
Labrafil
®
 M2130 CS which are present at their typical melting points as reported in § 4.4.1.1 and 
4.4.2.2.1 indicating that there is no obvious interaction between KTZ and the solid lipid. The 
presence of a separate peak for KTZ both prior to and after exposure to heating of the binary 
mixture suggests that KTZ was not soluble in Labrafil
®
 M2130 CS at a concentration of 50% w/w 
as indicated by the solubility studies. KTZ is therefore molecularly dispersed in Labrafil
®
 M2130 
CS.  
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4.4.2.3.2. FTIR characterization of bulk lipid with KTZ 
The IR absorption bands of a 1:1 mixture of Labrafil
®
 M2130 CS and KTZ after exposure to 60ºC 
for one (1) hour are shown in Figure 4.6 and summarized in Table 4.8. The IR spectra of the 
binary mixture can be compared to the individual spectrum and relevant band assignments of 
Labrafil
®
 M2130 CS (Figure 4.4 A, Table 4.5) and KTZ (Chapter 1, Figure 1.3, Table 1.1 vide 
infra) prior to heating to identify if any significant changes in the characterisitic absorption bands 
had occurred.  
 
 
Figure 4.6 Infra-red spectrum of a binary mixture of Labrafil
®
 M2130 CS and KTZ generated following 
exposure of the lipid to heat at 60°C for one (1) hour 
 
Table 4.8 Major infra-red band assignments for a binary mixture of Labrafil
®
 M2130 CS and KTZ 
obtained following exposure to heat at 60°C for one (1) hour 
Band position (cm
-1
) Assignment 
3406 O-H stretching (water band) 
3175 Symmetric stretching of CH2 (cis double bond stretching) 
2920 Symmetric stretching of CH2 (cis double bond stretching) 
2853 Asymmetric stretching of CH2 
1745 C=O stretching of the ester carbonyl group 
1642 C=O stretching of the ketone (conjugation with imidazole ring in KTZ) 
1496 Bending vibrations of CH2 and CH3aliphatic groups 
1422 C-N stretching of the imidazole in KTZ 
1260 C-O stretching of the cyclic ether group in KTZ 
1245 C-C=O bend of the ketone in KTZ 
    NR 
1185 Stretching vibration of the C-O ester group 
1027 Ar-C-O stretching of the ether in KTZ 
1020 C-O stretching 
797 =CH2 wagging 
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The FTIR spectrum of the binary mixture of Labrafil
®
 M2130 CS and KTZ depicted in Figure 4.6 
revealed that it was similar to the individual spectra of Labrafil
®
 M2130 CS and KTZ. The 
absence of broadened peaks or additional absorption bands suggests that there is no interaction 
between the solid lipid Labrafil
®
 M2130 CS and KTZ in the solid state. The typical characteristic 
absorption bands for Labrafil
®
 M2130 CS and KTZ can be observed in Figure 4.6 and no new 
absorption band was detected indicating that no physicochemical interaction resulting in the 
formation of new chemical bonds had occurred in a mixture of the solid lipid and KTZ. The slight 
differences in the intensity and frequency of the peaks may be attributed to the formation of 
hydrogen bonds between Labrafil
®
 M2130 CS and KTZ as KTZ is comprised of polar head 
groups that may give rise to dipole-dipole electrostatic interactions that produce different 
absorption bands. In addition these studies also confirm that the KTZ is molecularly dispersed in 
the lipid Labrafil
®
 M2130 CS which demonstrates the fairly good affinity of KTZ for the lipid. 
 
4.5. Conclusions 
These studies have revealed that KTZ is stable to heat and therefore, a micro-emulsion approach 
may be used for the production of KTZ-loaded SLM. The lipid screening studies performed to 
establish lipids with the best solubilising potential for KTZ revealed that KTZ is moderately 
soluble in several lipids and that Labrafil
®
 2130M CS was found to exhibit the best solubilising 
potential for KTZ. Thermal analysis used in conjunction with FTIR proved useful in analyzing 
the polymorphic behaviour of KTZ and Labrafil
®
 M2130 CS. No significant change in 
crystallinity was observed after heating KTZ to 60ºC for one (1) hour from DSC studies and 
similar results were observed using FTIR analysis. In addition no polymorphic change was noted 
in the lipid structure of Labrafil
®
 M2130 CS when it is heated to 60ºC for one (1) hour as there 
was only a slight shift in the melting endotherm from 39.8ºC to 40.0ºC observed from DSC 
studies. FTIR analysis of Labrafil
®
 M2130 CS prior to and after heating to 60ºC for one (1) hour 
also revealed no significant change in chemical bond shift, broadening of peaks or occurrence of 
unique bands in the IR spectrum, thereby supporting the information obtained from DSC studies 
and suggesting that exposure of the lipid to relatively high temperatures does not result in a 
change in polymorphic form. No interaction was detected between KTZ and the bulk solid lipid 
Labrafil
®
 M2130 CS from DSC and FTIR studies after analysis of the 1:1 drug-lipid mixture 
heated at 60ºC for one hour. This lack of interaction could be detected from the typical peaks 
obtained for both Labrafil
®
 M2130 CS and KTZ in the DSC thermogram after heating hence 
indicating that KTZ exists in its molecular form in the lipid. The relatively high solubility of KTZ 
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in Labrafil
®
 M2130 CS compared to Precirol
®
 ATO5, Compritol
®
 888, Gelucire
®
 44/14 and 
Gelucire
®
 50/13 suggests that a solid lipid matrix prepared from Labrafil
®
 M2130 CS is likely to 
have a higher DLC and EE for KTZ than a matrix consisting of any other lipids tested. 
Consequently, an investigation into the feasibility of incorporating KTZ into SLM using this lipid 
was undertaken. 
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CHAPTER FIVE 
FORMULATION AND CHARACTERIZATION OF AQUEOUS DISPERSIONS OF  
KTZ-LOADED SOLID LIPID MICROPARTICLES 
 
5.1. Introduction  
Formulation studies entailed an investigation into the feasibility of incorporating KTZ into SLM 
to improve delivery for paediatric and other patients. In many cases it is difficult to administer 
tablets or solid oral dosage forms to paediatric patients due to their inability to swallow [420, 
421]. Therefore, liquid formulations are preferred for paediatric drug delivery for convenience 
and ease of administration [420, 421]. As it is common practice in South Africa to administer 
KTZ to paediatric patients in the form of extemporaneous preparations made by crushing tablets 
and mixing the resultant powder with a suspension vehicle it was thought that KTZ would be a 
good candidate for inclusion in aqueous dispersions of SLM as it is a highly lipophilic molecule. 
This novel strategy was also aimed at minimizing the risks of adverse effects associated with the 
lack of stability data available for extemporaneous preparations. Consequently, aqueous 
dispersions of KTZ-loaded SLM were developed, optimized and characterized during these 
studies.  
 
The KTZ-loaded SLM consisted of the lipid Labrafil
®
 M2130 CS. An alternative method of 
production of SLM which does not require the use of complex equipment and toxic organic 
solvents was developed for the laboratory-scale production of KTZ containing SLM. A micro-
emulsion technique was selected due to its simplicity and involves the use of high shear devices 
such as the Ultra Turrax
®
 homogenizer that tends to be routinely available in laboratories when 
compared to high-pressure homogenizers. Formulation development studies were initially 
conducted to identify an appropriate surfactant or combination of surfactants for the incorporation 
of KTZ in SLM. Following selection of the surfactant or surfactant mixture further studies were 
performed to investigate the influence of other formulation parameters such as the concentration 
of the solid lipid, the KTZ:solid lipid ratio and the number of homogenization cycles on the 
quality of the SLM produced. In addition these studies entailed an investigation into the quality of 
the aqueous SLM dispersions throughout formulation development and optimization in terms of 
particle size (PS), particle shape and morphology, zeta potential (ZP), drug loading capacity 
(DLC) and encapsulation efficiency (EE). Furthermore, the stability of the optimized SLM 
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formulations was assessed on days 0, 3, 7 and 30 following manufacture to establish the quality 
and stability of aqueous dispersions after storage at 25°C/65% RH and 40°C/75% RH. The 
objectives of these studies were therefore to investigate the feasibility of incorporating KTZ into 
solid lipid microparticles. 
 
5.2. Materials  
5.2.1. Solid lipid 
5.2.1.1. Labrafil
®
 M2130 CS 
The physicochemical parameters of the solid lipid Labrafil
®
 M2130 CS have been summarized in 
Chapter 4, § 4.2.2.3 vide infra. Labrafil
®
 M2130 CS used in these studies was purchased from 
Gattefossé SAS, Saint-Priest Cedex, France and was used as received from the suppliers without 
further testing. Labrafil
®
 M2130 CS has GRAS status and is physiologically compatible and 
biodegradable.  
 
5.2.2. Emulsifying agents 
5.2.2.1. Soluphor
®
 P 
Soluphor
®
 P (BASF Corporation, Florham Park, NJ, USA) is the proprietary name for 2-
pyrrolidone which is used as a solvent with water in combination with low molecular 
polyvinylpyrrolidone in injectable preparations [404, 422, 423]. Soluphor
®
 P occurs as a 
colourless or slightly coloured liquid which has a faint characteristic odour and tends to solidify 
at room temperature as its melting range is 25-26ºC [423]. Soluphor
®
 P is miscible with water and 
an aqueous solution of 100 g/L of Soluphor
®
 P at 20ºC has a pH of between 8.2  and 10.8 and 
solutions up to 50% v/v tend to have a viscosity of about 4 mPa s [423]. Soluphor
®
 P must be 
stored in airtight containers and storage below 25ºC is recommended to avoid discolouration. 
When stored in unopened original containers at room temperature (20-25ºC), Soluphor
®
 P is 
stable for at least 12 months [422, 423]. Soluphor
®
 P is soluble in water and a variety of organic 
solvents including ethanol, isopropyl alcohol and aromatic hydrocarbons [424]. Soluphor
®
 P has a 
bulk density of 1.103 g/cm
3
 and a partition coefficient (log Po/w) of 0.71 at 25ºC and a dynamic 
viscosity of 10.2 mPas at 30 ºC [422]. Soluphor
®
 P is also used in veterinary injectable products 
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as a solvent with water and has been reported to be of use in solutions for oral delivery of poorly 
soluble API [422, 423]. 
 
5.2.2.2. Soluplus
®
  
Soluplus
®
 (BASF Corporation, Florham Park, NJ, USA) is the proprietary name for polyvinyl 
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer [425]. It occurs as a free 
flowing white to slightly yellowish granule that has practically no taste [425]. Soluplus
®
 is a 
novel polymer that has been designed for solid solutions in an attempt to improve the solubility 
and bioavailability of poorly soluble drugs as it has a unique structure that enables ideal 
interactions with API through hydrogen bonding, thereby positively impacting the stability and 
solubility of drugs [425-427]. Soluplus
®
 is a polymeric solubilizer that can be used to prepare 
solid dispersions by spray drying, melt granulation and co-precipitation [427]. Soluplus
®
 is 
known to be ideal for use in manufacturing approaches such as hot melt extrusion as it possess 
exceptional extrudability and may be easily processed [426]. Toxicological studies performed 
with Soluplus
®
 reveal that its safety has been documented in comprehensive toxicological studies 
[426]. Soluplus
®
 may be used at a broader pH range, since it is non-ionic, without compromising 
its solubilization capacity. Soluplus
® 
 is known to improve  the solubility of KTZ [426].  
 
5.2.2.3. Lutrol
®
 E400 
Lutrol
®
 E400 (BASF Corporation, Florham Park, NJ, USA) is the proprietary name for 
polyethylene glycol (PEG-8) and is used as solvent for oral, topical and parenteral formulations 
[428-431]. Lutrol
®
 E400 occurs as a colourless, almost odourless and tasteless liquid at room 
temperature with a density of 1.13 g/cm
3
 and a molecular weight of 380 to 420 [429]. Lutrol
®
 
E400 is miscible with water and a 5% v/v aqueous solution has a pH of between 4.5 and 7.5 
[430]. The viscosity of Lutrol
®
 E400 at 20ºC is 6.8 to 8.0 mPas and it has a hydroxyl value of 267 
to 295 [429, 430].  
 
5.2.2.4. Pluronic
®
 F68 
Pluronic
®
 F-68 (BASF Corporation, Florham Park, NJ, USA) is the proprietary name for  a 
polyoxypropylene-polyoxyethylene block copolymer [432]. Pluronic
®
 F-68 is a non-ionic 
surfactant that is a difunctional block copolymer of ethylene oxide and propylene oxide that 
terminates in primary hydroxyl groups [432]. The polyoxyethylene portion of the Poloxamer 188 
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molecule is hydrophilic whilst the polyoxypropylene portion is hydrophobic [432]. Pluronic
®
 F-
68 occurs as white, waxy, free-flowing prilled granules or cast solids or as white or almost white, 
waxy powders, micro-beads or flakes [432]. Pluronic
®
 F-68 has a melting point range of between 
52 and 57°C and is generally odourless and tasteless [432]. The HLB value of Pluronic
®
 F-68 is 
29 [404, 432, 433]. The aqueous solubility of Pluronic
®
 F-68 at 25°C is > 100 mg/ml and 
Pluronic
®
 F-68 is freely soluble in water at temperatures < 10°C and produces a clear solution of 
pH 5.0 to 7.5 [404, 432]. Pluronic
®
 F-68 is also soluble in alcohol and practically insoluble in 
light petrolatum [404, 432]. Pluronic
®
 F-68 has been reported to be hygroscopic only at relative 
humidities > 80% [432]. Pluronic
®
 F-68 is used as an emulsifying agent or solubilising agent and 
may also be used as an excipient in inhalation, ophthalmic, oral, topical products and IV 
injections [404, 432]. 
 
The first digit in the name Pluronic
®
 F-68 arbitrarily represents the molecular weight of the 
polyoxypropylene and the second digit represents the weight percent of the oxyethylene portion 
[432]. The letter ‘L’, ‘P’ and ‘F’ represent the physical properties of the poloxamer, such as 
liquid, paste or flakes [432]. Poloxamer 188 is the non-proprietary name of Pluronic
®
 F-68 and 
contains the number 188, the first two digits when multiplied by 100, correspond to the average 
molecular weight of the polyoxypropylene segment of the copolymer molecule and the third digit, 
when multiplied by 10, corresponds to the percentage by weight of the polyoxyethylene segment 
of the molecule [432]. Poloxamer 188 has 75-85 ethylene oxide units, 2-30 propylene oxide units 
with a content of oxyethylene of between 79.9-83.7% and an average molecular weight of 
between 7680-9510 [404, 432]. Poloxamers are regarded as non-toxic and non-irritant materials 
and are not metabolised in vivo [404, 432].   
 
5.2.2.5. Sodium cholate 
Sodium cholate (Sigma-Aldrich, Saint Louis, MO, USA) is the monosodium salt of 3, 7, 12 -
trihydroxy-5β-cholan-24-oic acid and is a hydrophilic anionic surfactant that occurs in bile salts 
[434, 435]. Sodium cholate
 
is obtained in the form of a dark yellowish or sometimes white to off-
white powder and has a critical micelle concentration (CMC) of 6.028% w/v or 9-15 mM at 20-
25ºC above which sodium cholate forms micelles with a MW of approximately 900-1300 [434-
436]. Sodium cholate has an HLB value of 18 and
 
is manufactured by high temperature alkaline 
hydrolysis of bovine, ox or sheep bile as a by-product of the meat processing industry [434-437].  
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5.2.2.6. Tween 80 
Tween 80 (Sharon Bolel Chemical Marketing, Houghton, Gauteng, South Africa) is also known 
as polyoxyethylene 20 sorbitan monooleate, polysorbate 80, PEG (80) sorbitan monoleate and is 
a yellow oily liquid with a characteristic odour [438]. Tween 80 is miscible in water (0.1 ml/ml) 
and yields a clear to slightly hazy faint yellow solution when dispersed. A 1% v/v solution has  a 
pH ranging between 5.5 to 7.2 [438]. Tween 80 is miscible with alcohol, cottonseed oil, corn oil, 
ethylacetate, methanol and toluene and is immiscible with mineral and vegetable oils. Tween 80 
has a GRAS status and is a non-toxic non-irritant material that may be used as a non-ionic 
emulsifying agent, a wetting agent, solubilizing agent in parenteral, food, oral, topical and 
cosmetic products [438]. Furthermore, Tween 80 improves the solubility of KTZ [439]. 
 
Tween 80 has a molecular weight of 1310 Da assuming that it has twenty ethylene oxide units, 
one sorbitol and one unit of oleic acid as the primary fatty acid [438]. The typical fatty acid 
constitution of Tween 80 determined by trans-esterification to yield fatty acid methyl esters, is 
approximately 70% oleic acid and other fatty acids that have been indicated include palmitic acid 
[438]. The HLB value and hydroxyl value of Tween 80 have been established as 15 and 65-60 mg 
KOH/g respectively [438]. Tween 80 has a specific gravity of 1.07 and a dynamic viscosity of 
400 to 620 cP at 25°C [438, 440]. Tween 80 has a saponification value ranging between 45 and 
55 mg KOH/g, an acid value of 2.0% and a surface tension of 42.5 mN/m at 20°C [438]. Tween 
80 auto-oxidizes and is hygroscopic and should therefore be stored in a well-sealed container 
away from light in a cool and dry environment [438] and prolonged storage of Tween 80 may 
result in the formation of peroxides [438]. Tween 80 has been reported to be incompatible with 
alkalis, heavy metal salts, phenols and tannic acid [438, 440].   
 
5.2.3. Water  
Water used in these studies was purified water of HPLC grade and was prepared using the 
purification system described in § 3.3.2.1.  
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5.2.4. Formulation composition  
Aqueous dispersions of SLM were prepared using a micro-emulsion approach adapted and 
modified from that described in § 2.5.3.1. A summary of the SLM preparations investigated in 
these studies is listed in Table 5.1 which shows the composition of all the formulations used for 
these studies. To ensure the selection of optimised formulations in terms of particle size, drug 
loading capacity and encapsulation efficiency of the SLM for further studies, a number of 
formulation parameters were investigated during the initial stages of formulation development 
and included the use of different surfactant(s), solid lipid concentration, drug-lipid ratio and 
number of homogenization cycles. 
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Table 5.1 Formulation compositions of drug-free and KTZ-loaded SLM 
 
 Drug-free SLM KTZ-loaded SLM 
SLM no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Excipients 
KTZ - - - - - - - - - 5 5 5 5 5 5 5 5 5 5 5 10 3.3 
Labrafil 
M2130 CS 
10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 5 15 10 10 
Pluronic
®
 
F68 
4 4 4 4 4 4 5 6 7 4 4 4 4 4 4 5 6 7 4 4 4 4 
Sodium 
cholate 
- - - - 2 1 1 1 - - - - - 2 1 1 1 - 1 1 1 1 
Tween 80 - - - 3 1 2 1 - - - - - 3 1 2 1 - - 2 2 2 2 
Lutrol
®
 
E400 
3 - - - - - - - - 3 - - - - - - - - - - - - 
Soluphor
 ® 
P 
- 3 - - - - - - - - 3 - - - - - - - - - - - 
Soluplus 
®
  - - 3 - - - - - - - - 3 - - - - - - - - - - 
Purified 
water ad 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
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5.3. Methods  
A modified micro-emulsion approach (Chapter 2, § 2.5.3 vide infra) was used to manufacture the 
KTZ-loaded SLM dispersions and a summary is illustrated schematically in Figure 5.1. An 
aqueous mixture of surfactant and co-surfactant was prepared by dispersing the surfactant in 
water at 4°C followed by the addition of the co-surfactant. The micro-emulsion was formed by 
addition of an aqueous surfactant mixture heated to 60°C to the molten lipid phase containing 
KTZ that had been maintained at the same temperature. Following mixing with a vortex mixer the 
hot micro-emulsion was dispersed in cold water maintained at 2-3°C. The micro-emulsion 
dispersion was then homogenized using an Ultra-Turrax
®
 homogenizer (Janke & Kunkel KG, Ika 
Werk, Staufen I. Breisgau, Germany) at 24 000 rpm for 5 minutes prior to homogenization with 
an Erweka GmbH homogenizer (Erweka AR400, Heusenstamm, Offenbach, Germany) for five 
(5) cycles. The aqueous dispersions were stored at room temperature prior to imaging analysis, 
ZP, DLC and EE assessment that were conducted on the day of manufacture.    
 
 
 
 
Figure 5.1 Schematic representation of the modified micro-emulsion technique used to manufacture KTZ-
loaded SLM 
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5.4. Characterization of KTZ-loaded SLM dispersions 
5.4.1. SEM analysis   
The shape and surface morphology of SLM from aqueous dispersion samples obtained in these 
studies were investigated using a Model TS 5136LM Vega Tescan SEM (Tescan USA, Cranberry 
Twp, PA, USA). A sample was deposited on a graphite plate and air-dried for one (1) minute 
after which the sample was metallized with gold under vacuum. Samples were visualized under 
an accelerated voltage of 20 kV.  
 
5.4.2. TEM analysis 
The particle size of SLM was determined using Scandium Soft Imaging software (SSIS) 
(Olympus Soft Imaging Solutions, Center Valley, Philadelphia, USA) coupled to TEM. The 
aqueous dispersions of SLM were plated on a copper grid with a carbon film and allowed to dry 
for thirty (30) seconds after which it was stained with uranyl acetate ( 1% w/v) and allowed to dry 
at ambient temperature (25ºC) for thirty (30) seconds prior to examination using a Model JEOL-
1210 transmission electron microscope (JEOL 1210, JEOL Inc., Boston, Massachusetts, USA) to 
obtain two-dimensional (2-D) images of the microspheres and to determine the particle size and 
particle size distribution of the product.  
 
5.4.3. Zeta potential analysis 
The ZP of the microparticles was assessed using a Nano-ZS Zetasizer (Malvern Instruments Ltd, 
Worcestershire, United Kingdom) in the Laser Doppler Anemometry (LDA) mode. 
Measurements were performed after dilution of each sample in distilled HPLC grade water 
prepared as detailed in § 3.3.2.1. A 20 µL aliquot of each sample was diluted with 10 ml of 
deionized HPLC grade water maintained at a resistivity of 18 MΩcm and the resulting dispersion 
was placed into a cell designed for ZP measurements. LDA measurements were performed in 
triplicates on each sample at an applied field of 20 V/cm and the Helmholtz-Smoluchowsky 
equation (Equation 2.1, § 2.6.4, vide infra) was used in situ to calculate the ZP value 
automatically.  
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5.4.4. Drug loading capacity and encapsulation efficiency  
The DLC and EE of KTZ-loaded SLM from aqueous dispersions were determined in triplicate by 
accurately pipetting 0.5 ml of homogenous aqueous SLM dispersion using a micropipette 
(Hamilton Soft Touch™ 100-1200 µL). The mixture was placed in the sample reservoir of a 
Microcon
®
 centrifugal filter device (Merck Millipore, Massachusetts, USA) equipped with an 
Ultracel YM filter membrane with a nominal molecular weight limit (NMWL) 100 000 Da 
(Merck Millipore, Massachusetts, USA). The sample was centrifuged at 10 000 rpm for 20 min  
using a Model 1EC HN-SII Damon centrifuge (International Equipment Company, Needham 
Heights, Massachusetts, USA). After centrifugation the filtrate was collected from the sample 
reservoir and transferred into a vial or recovery chamber which contained the aqueous phase that 
had been filtered through the membrane. The amount of KTZ in the aqueous phase was 
quantitated using the RP-HPLC method that was developed and validated as described in Chapter 
3. The DLC and EE of the SLM were calculated using Equations 2.3 and 2.4 respectively 
(Chapter 2, § 2.6.6, vide infra). 
 
5.4.5. Stability assessment of optimized formulations 
An evaluation of the stability of two (2) optimized formulations selected from the formulation 
development process was conducted by determining the PS, ZP, DLC and EE on days 0, 3, 7 and 
30 following manufacture. Approximately 8 ml of each SLM dispersion were pippetted 
(Hamilton Soft Touch™ 500-5000 µL) (n=3) into three (3) separate 10 ml glass vials. The vials 
were closed with airtight closures, covered using aluminum foil and placed in stability chambers 
maintained at 25°C±1/60% RH and 40°C±1/75% RH (Binder GmbH, KBF 240, E5.2, Tuttlingen, 
Germany). The stability chambers used in these studies were appropriate for stability tests 
conducted according to the ICH guideline Q1A as they were able to operate under extreme 
climate and site conditions and maintain homogenous climate conditions within the interior of the 
chamber thus ensuring the reproducibility of results. The system consisted of an APT.line
TM
 
preheating chamber and cooling system that were equipped with a controlled humidification and 
dehumidification system which were connected to a water supply. Samples were withdrawn for 
analysis when required and immediately placed back into the chambers. The PS, ZP, DLC and EE 
were assessed on days 0, 3, 7 and 30 after manufacture as detailed in § 5.4.1, 5.4.2, 5.4.3 and 
5.4.4, respectively.  
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5.5. Results and discussion 
5.5.1. Selection of surfactants  
Solid lipid carriers may be produced using ionic, non-ionic or a combination of surfactants. The 
choice of an emulsifying system and the concentration of the emulsifiers has a direct influence on 
the resultant quality of the SLM formulations produced [182]. The choice of the surfactant is 
known to influence the surface morphology of the particles and the use of surfactant mixtures has 
been reported to lower the particle size and improve the stability of solid lipid carriers on storage 
[187, 441-443]. Five surfactants, viz., Soluphor
®
 P, Soluplus
®
, Lutrol
®
 E400, Pluronic
®
 F-68, 
sodium cholate and Tween 80 were investigated to determine their potential to stabilize SLM 
formulations. The choice of a suitable emulsifying system for use in the preparation of aqueous 
drug-free and KTZ-loaded SLM formulations was based on the ability to produce formulations 
with stable, spherical and smooth particles on the day of manufacture when stored at 22°C. Non-
ionic surfactants can be used at concentrations between 2 and 10% w/w to produce solid lipid 
carriers. The use of high concentrations of surfactants is known to produce particles of smaller 
size and surface tension thus preventing particle aggregation [102, 187]. Pluronic
®
 F68 is of use 
in the formulation of solid lipid carriers intended for oral administration due to the ability of the 
block copolymer to prevent enzymatic degradation of the lipids in the presence of lipase. 
Furthermore, Pluronic
®
 F68 is known to exhibit surface-like steric effects when used in 
combination with ionic surfactants [442]. Therefore, Pluronic
®
 F68 was used in combination with 
other surfactants up to a concentration of 7% w/v during these studies to determine the most 
appropriate emulsifying system for the production of KTZ-loaded SLM.  
 
Drug-free (SLM 1-9, Table 5.1) and KTZ-loaded SLM (SLM 10-18, Table 5.1) were 
manufactured using different surfactants, combinations of surfactants and concentrations of 
surfactants. A lipid concentration of 10% w/v was used to manufacture these formulations and the 
physical stability of the SLM formulations was evaluated by determining the particle size (PS), 
shape and surface morphology and zeta potential (ZP). Formulations were considered stable only 
if the particles were discreet, spherical and showed no signs of aggregation on the day of 
manufacture (day 0). The quality of the SLM formulations in terms of particle size, shape and 
surface morphology were assessed using SEM and TEM.  
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The ZP is a good indicator of instability and ZP values of ± 30 mV are generally considered the 
limit of stable and unstable dispersions. However, optimal electrostatic repulsion only occurs at > 
± 60 mV [238]. A large positive or negative ZP value is indicative of greater stability as the 
particles have a higher charge and repulsive potential, thereby avoiding aggregation [444]. 
Limited flocculation occurs in systems that exhibit ZP values of 5-15 mV and rapid flocculation 
occurs below 5 mV [237]. In a formulation containing a combination of surfactants both the 
electrostatic effect and the steric stabilization effect are cumulative and provide additional 
stability at ZP values lower than ± 30 mV [238]. A ZP of -20 to -11 mV corresponds to the 
threshold of agglomeration in dispersions [445]. The tendency of the particles to agglomerate 
may be attributed to an inadequate electrostatic repulsion potential energy that is necessary for a 
good quality of the interface between the particles as postulated by the DLVO theory [446]. The 
DLVO theory may be used to explain the interaction forces over large distances in colloidal 
systems although it cannot be used explain interactive forces between particles that are very close 
to each other such as particles that are separated by distances in the nanometer size range. At 
small separation distances the particle size, shape and chemistry affect the interactions between 
the particles and forces such as solvation, hydration, hydrophobic forces and steric interactions 
may predominate over the attractive and repulsive potentials suggested by the DLVO theory [446, 
447]. However, the DLVO theory gives a good indication of the macroscopic stability of the 
system as the formation of agglomerates within a dispersion reveals that the particles are able to 
overcome the energy barrier of electrostatic repulsion and therefore implying dominating 
attractive Van der Waals forces are present [448].  
 
The SEM and TEM micrographs of SLM formulation are depicted in Figures 5.2 and 5.3 and 
reveal potential differences in the quality of the particles produced using different surfactants. 
The mean PS was established using TEM and the ZP of the particles were measured on the day of 
manufacture for all formulations. The DLC and EE of the drug-loaded SLM formulations 10-18 
were also evaluated and the data generated in these studies is summarized in Table 5.2. 
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Figure 5.2 SEM micrographs of drug-free formulations, SLM 1 to SLM 9, manufactured using different 
surfactants or combinations of surfactants on the day of manufacture 
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Figure 5.3 TEM micrographs of drug-free formulations, SLM 1 to SLM 9, manufactured using different 
surfactants or combinations of surfactants on the day of manufacture 
 
Table 5.2 PS and ZP of drug-free batches, SLM 1 to SLM 9 and PS, ZP, DLC and EE of KTZ-loaded 
batches, SLM 10 to SLM 18 on the day of manufacture 
BATCH SLM 1 SLM 2 SLM 3 SLM 4 SLM 5 
Parameter Day 0 Day 0 Day 0 Day 0 Day 0 
PS (µm) 43.7 ± 3.1 17.3 ± 4.4 21.7 ± 8.6 37.4 ± 6.5 40.6 ± 9.2 
ZP (mV) -18.3 ± 0.5 -13.9 ± 0.2 -14.8 ± 0.6 -18.7 ± 0.9 -11.6 ± 0.7 
BATCH SLM 6 SLM 7 SLM 8 SLM 9  
Parameter Day 0 Day 0 Day 0 Day 0  
PS (µm) 25.5 ± 2.6 22.6 ± 4.1 22.2 ± 7.9 33.4 ± 5.8  
ZP (mV) -31.1 ± 0.2 -32.7 ± 0.1 -19.3 ± 0.3 -15.5 ± 0.3  
BATCH SLM 10 SLM 11 SLM 12 SLM 13 SLM 14 
Parameter Day 0 Day 0 Day 0 Day 0 Day 0 
PS (µm) 39.2 ± 8.1 33.6 ± 4.4 15.7 ± 8.6 24.4 ± 5.2 23.6 ± 7.7 
ZP (mV) -18.3 ± 0.5 -13.9 ± 0.2 -14.8 ± 0.6 -18.3 ± 0.4 -30.9 ± 0.8 
DLC (%) 
EE (%) 
0.04 ± 0.007 
0.09 ± 0.006 
0.89 ± 0.02 
1.85 ± 0.09 
0.97 ± 0.07 
1.93 ± 0.18 
6.9 ± 1.2 
11.5 ± 1.8 
7.3 ± 0.18 
13.3 ± 0.74 
BATCH SLM 15 SLM 16 SLM 17 SLM 18  
Parameter Day 0 Day 0 Day 0 Day 0  
PS (µm) 18.6 ± 3.6 15.6 ± 2.1 24.2 ± 6.5 28.4 ± 8.8  
ZP (mV) -30.1 ± 0.2 -31.6 ± 0.1 -20.7 ± 0.3 -15.6 ± 0.2  
DLC (%) 23.6 ± 1.8 18.6 ± 0.3 17.4 ± 0.1 10.1 ± 0.2  
EE (%) 58.2 ± 2.3 43.2 ± 1.4 29.7 ± 0.9 17.9 ± 0.4  
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The SLM products that were produced were all aqueous dispersions with an off-white appearance 
on the day of manufacture. The mean PS data measured from the TEM micrographs demonstrate 
that the particle size for all batches was < 50 µm although the PS was relatively high for batches 1 
and 10 that were manufactured using a combination of Pluronic
®
 F68 and Lutrol
®
 E400. In 
addition the SEM micrographs depicted in Figure 5.2 reveal that the particles for SLM 1, SLM 2 
and SLM 3 possessed non-spherical shapes and had an irregular surface morphology. The 
particles were not discrete and seemed to exhibit signs of aggregation from the day of 
manufacture. A similar pattern was observed for the KTZ-loaded batch SLM 10, 11 and 12 that 
also contained Lutrol
®
 E400, Soluphor
® 
P and Soluplus
®
 respectively (Table 5.1). It can be noted 
that SLM 1, SLM 2 and SLM 3 produced a semi-solid-like dispersion within a few hours of 
storage at room temperature with the effect being more pronounced for SLM formulations 1 and 
3. The change of state of the SLM formulation was used as a direct indication of the physical 
instability of the dispersion. Therefore, formulations SLM 1, SLM 2 and SLM 3 were not 
considered stable and appropriate for future formulation development studies. The concentration 
of 3% w/v Lutrol
®
 E400, Soluphor
 ® 
P, Soluplus 
®
 were not optimum for adequate reduction of 
surface tension and formation of a protective surfactant layer around the lipid particle. Particle 
partition may therefore have been hindered leading to the agglomeration of uncovered lipid 
surfaces. The surfactants Lutrol
®
 E400, Soluphor
® 
P, Soluplus
®
 were not used in further 
optimization studies for the manufacture of KTZ-loaded SLM as the use of  Pluronic
®
 F68, 
Tween 80 and sodium cholate produced particles of better quality in these preliminary studies. 
Furthermore, DLC and EE of KTZ-loaded formulations, SLM 10, SLM 11 and SLM 12 that were 
produced using Lutrol
®
 E400, Soluphor
 ® 
P, Soluplus
®
 (Table 5.1) were very low which revealed 
poor encapsulation of KTZ due to a lack of stabilization of the particles by the emulsifying 
system used and is evident from the data summarized in Table 5.2. 
 
Drug-free batches, SLM 4 to SLM 9 were manufactured using Pluronic
®
 F68 in combination with 
the ionic surfactant, sodium cholate and the non-ionic surfactant, Tween 80 (Table 5.1). SLM 
formulations 4 to 9 were made up of relatively spherical particles irrespective of the surfactant 
used (Figure 5.1). Batch SLM 9 manufactured using Pluronic
®
 F-68 alone contained discrete but 
rough surfaced particles compared to SLM 5, 6 and 7 that contained sodium cholate and Tween 
80 in combination with Pluronic
®
 F-68 (Figure 5.2). Pluronic
®
 F-68 and Tween 80 enhance the 
stability of SLM by steric stabilization whereas sodium cholate increases the electrostatic 
repulsive potential energy of the particles and can circumvent flocculation within an aqueous 
dispersion [185]. The use of Pluronic
®
 F-68 in combination with Tween 80 has been found to 
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reduce the PS of solid lipid carriers and improve the oral absorption of poorly soluble drugs. The 
surfactants Pluronic
®
 F-68 and Tween 80 may also increase the permeability of the intestinal 
membrane and promote the interaction between the intestinal membrane and lipid particles. 
Furthermore, Pluronic
®
 F-68 and Tween 80 possess moderate inhibiting effects on the P-
glycoprotein (P-gp) efflux system increasing the oral absorption of poorly soluble drugs [449, 
450]. It appears that Pluronic
®
 F-68 alone did not produce adequate stabilization through steric 
effects and the use of Pluronic
®
 F-68 without other surfactants was deemed insufficient for 
stabilization of SLM dispersions. Similarly, the use of Tween 80 in combination with Pluronic
®
 
F-68 in SLM 4 produced rough particles which tend to coalesce via the formation of bridges 
possibly due to inadequate steric hindrance (Figure 5.2). Block copolymers such as Pluronic
®
 F-
68 may act as a plasticizer and gelling agent possibly via the presence of bridging effects that 
result in the incorporation of water within the intralamellar areas of SLM causing the hardening 
of the gel with time [448]. The SLM aqueous dispersions were found to exhibit a slight gelation 
tendency particularly on storage.  
 
The ZP measured for SLM 4 was -18.7 ± 0.9 mV (Table 5.2) which appears insufficient to hinder 
coalescence via steric effects as a ZP range of -20 mV to -11 mV is known to correspond to the 
threshold of agglomeration in dispersions [448]. The SEM micrographs of SLM 8 manufactured 
using a combination of Pluronic
®
 F-68 and sodium cholate revealed spherical and smooth 
particles (Figure 5.2) but the particles seemed to agglomerate. The ZP measured for SLM 8 was   
-19.3 ± 0.3 mV (Table 5.2) which also appears insufficient for cumulative electrostatic and steric 
stabilization from a combination of 6% w/w Pluronic
®
 F-68 and 1% w/w sodium cholate. The 
particles of batch SLM 8 appear to be in a state of limited flocculation which could trigger 
subsequent mechanisms of instability such as sedimentation, aggregation and caking (Figure 5.4). 
It was reported that dispersions may undergo solidification once the ZP values fall within the 
threshold of agglomeration of -20 mV to -11 mV [448].  
 
TEM micrographs of batches SLM 4, 8 and 9 reveal the presence of a wide particle size 
distribution (Figure 5.3 and Table 5.2). The KTZ-loaded SLM formulations 13, 17 and 18 were 
also stabilized using Pluronic
®
 F-68 and Tween 80, Pluronic
®
 F-68 and sodium cholate and 
yielded similar results (Table 5.2). The wide particle size distribution in SLM formulations 4, 8, 
9, 13, 17, 18 could contribute to the aggregation tendency due to Ostwald ripening (Figure 5.4). 
The large differences in particle sizes leads to small particles preferentially dissolving in the 
outermost layer of larger particles to form a supersaturated solution resulting in crystal growth 
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and an increase in particle size [238, 447]. The DLC and EE of SLM 13, 17 and 18 were 
relatively low and SLM 17 manufactured using a combination of Pluronic
®
 F-68 and sodium 
cholate, exhibited the highest EE (Table 5.2). Therefore, a combination of surfactants was 
considered necessary to ensure a high entrapment efficiency for KTZ and further investigations 
were undertaken using a combination of Pluronic
®
 F-68, Tween 80 and sodium cholate to 
stabilize the SLM dispersions.  
Figure 5.4 Mechanisms of instability in solid dispersions and emulsions adapted from [447] 
 
It has been suggested that increasing the concentration of surfactants in a formulation leads to a 
reduction in particle size up to a point [451]. Drug-free batches SLM 5, 6 and 7 and KTZ-loaded 
SLM 14, 15 and 16 were manufactured using a combination of Pluronic
®
 F-68, Tween 80 and 
sodium cholate in different concentrations (Table 5.1). The SEM micrographs of drug-free SLM 
5, 6 and 7 depicts spherical and smooth particles on day 0 (Figure 5.2) with particle sizes < 50 µm 
and a wide particle size distribution was observed for SLM 5 (Table 5.2). However, the KTZ-
loaded SLM manufactured with a similar formulation composition (SLM 14) has smaller particles 
of 23.6 ± 7.7 µm in diameter and a ZP of -30.9 ± 0.8 mV with  DLC and EE values of 7.3 ± 
0.18% and 13.3 ± 0.74% respectively (Table 5.2). Conversely, particles from batches SLM 16 
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and SLM 17 demonstrated higher DLC and EE values than those of batch SLM 14 inferring that 
the stability of the emulsifying system also resulted in a higher retention capability for KTZ. The 
particles observed in the SEM micrograph of particles from batch SLM 14 (Figure 5.2) revealed 
signs of agglomeration and a wide particle size distribution which is likely to promote instability 
of the dispersion due to Ostwald ripening. Batches SLM 15 and 16 produced discrete particles 
with a small particle size and high ZP values of -30.1 ± 0.2 mV and -31.6 ± 0.1 mV respectively. 
The large negative ZP value could be attributed to the presence of the anionic sodium cholate and 
additional steric stabilization due to the presence of Tween 80 that exerts a cumulative effect on 
the stability of the colloidal dispersion. The combination of steric and electrostatic surfactants has 
a synergistic effect leading to a decrease in particle size and improved stability. Therefore, 
particles from batches SLM 15 and 16 manufactured using a combination of three surfactants viz., 
Pluronic
®
 F-68 (4-5% w/v), sodium cholate (1% w/v) and Tween 80 (1-2% w/v) were considered 
to be promising colloidal dispersions and further studies were performed to assess their stability 
and are detailed in § 5.4.5, vide infra. 
 
5.5.2. Selection of solid lipid concentration 
The influence of solid lipid concentration on the quality of KTZ-loaded SLM was investigated 
using three different levels  viz., 5% w/v, 10% w/v and 15% w/v Labrafil
®
 M2130 CS (SLM 15, 
19 and 20, Table 5.1). The potential differences in terms of size, shape and surface morphology of 
KTZ-loaded SLM obtained in these studies were assessed using TEM and SEM (Figures 5.5 and 
5.6). Furthermore, the influence of solid lipid concentration on ZP, DLC and EE of KTZ-loaded 
SLM were evaluated in these studies the results of which are summarized in Table 5.3 and Figure 
5.7 which depict the effect(s) of Labrafil
®
 M2130 CS concentration on PS, ZP, DLC and EE of 
KTZ-loaded SLM batches 15, 19 and 20. 
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Figure 5.5 SEM images of KTZ-loaded SLM manufactured using different concentrations of Labrafil
®
 
M2130 CS: 5% w/v (SLM 19), 10% w/v (SLM 15) and 15% w/v (SLM 20) on the day of manufacture 
 
 
Figure 5.6 TEM images of KTZ-loaded SLM using different concentrations of Labrafil
®
 M2130 CS: 5% 
w/v (SLM 19), 10% w/v (SLM 15) and 15% w/v (SLM 20) on the day of manufacture 
 
The SEM micrographs depicted in Figure 5.5 (SLM 19, SLM 15 and SLM 20) reveal that the 
particles were mostly spherical and had a regular and smooth surface. However, TEM images 
(Figure 5.6) reveal that the particles of SLM 19 were relatively large with a mean PS of 40.2 ± 
3.5 µm. In addition signs of agglomeration were observed on the day of manufacture for batches 
SLM 19 and 20 (Figure 5.5) and this could lead to increased instability due to coalescence on 
storage. Particles prepared using high lipid concentrations require modification of certain process 
parameters such as stabilizer concentration(s) and/or temperature and the formation of lipid 
formulations depends on the concentration of lipid used as lipid aggregates generated during 
diffusion tend to coalesce at high lipid concentrations [451]. The difference in density between 
the lipid and aqueous phases may also lead to an increase in the formation of lipid aggregates at 
high lipid concentrations [452]. The increase in PS may also be attributed to an increase in the 
viscosity of the continuous phase which results in a lower diffusion rate of suspended particles 
and subsequently leads to an increase in aggregation [453]. Although the mean PS on the day of 
manufacture did not increase with increasing concentration of Labrafil
®
 M2130 CS a larger 
number of lipid aggregates was noted for batch SLM 20 (Figures 5.5 and 5.6). 
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Table 5.3 ZP, PS, DLC, EE of KTZ-loaded SLM manufactured using different concentrations of Labrafil
®
 
M2130 CS: 5% w/v (SLM 19), 10% w/v (SLM 15) and 15% w/v (SLM 20) on the day of manufacture 
 
Figure 5.7 ZP, PS, DLC, EE of KTZ-loaded SLM manufactured using different concentrations of Labrafil
®
 
M2130 CS: 5% w/v (SLM 19), 10% w/v (SLM 15) and 15% w/v (SLM 20) on the day of manufacture 
 
The ZP of SLM 19, SLM 15 and SLM 20 were not significantly different which indicates that the 
use of different lipid concentrations did not affect the electrostatic stability of the KTZ-loaded 
SLM formulations (p > 0.05, Table 5.3 and Figure 5.7). In addition DLC and EE studies revealed 
that poor encapsulation of KTZ occurred with a lipid concentration of 15% w/v. A decrease in 
lipid concentration yielded particles with a higher DLC and EE and stability (Table 5.3). 
However, the optimum lipid concentration was considered to be 10% w/v Labrafil
®
 M2130 CS as 
the particles produced with 10% w/v solid lipid (SLM 15) were discrete and relatively small with 
a mean PS of 18.6 ± 3.6 µm and these exhibited fewer signs of aggregation on the day of 
manufacture (Figure 5.5). As the concentration of lipid was increased and the concentration of 
stabilizer was kept constant, flocculation occurred resulting in the formation of larger aggregate 
structures [237]. Increasing the concentration of Labrafil
®
 M2130 CS (Figure 5.7) from 10% w/v 
to 15% w/v led to a decrease in DLC and EE. The decrease in KTZ entrapment could be 
attributed to an increase in drug expulsion due to the occurrence of physical instability within the 
dispersion and possible reduction in the crystallinity of KTZ. Therefore, a concentration of 10% 
w/v Labrafil
®
 M2130 CS was used during further formulation development studies to investigate 
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5% w/v solid lipid (SLM 
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10% w/v solid lipid 
(SLM 15) 
15% w/v solid lipid 
(SLM 20) 
PS (µm) 
ZP (-mV) 
DLC (%) 
EE (%) 
Concentration of Labrafil
®
 M2130 CS (% w/v) 5 10 15 
Parameter on day 0 SLM 19 SLM 15 SLM 20 
PS (µm) 40.2 ± 3.5 18.6 ± 3.6 32.2 ± 4.2 
ZP (mV) -30.2 ± 0.3 -30.1 ± 0.2 -29.5 ± 0.1 
DLC (%) 24.5 ± 2.1 23.6 ± 1.8 15.1 ± 0.23 
EE (%) 59.3 ± 3.5 58.2 ± 2.3 32.9 ± 0.34 
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the influence of KTZ loading on the quality of SLM formulations and these studies are detailed in 
§ 5.5.3.  
 
5.5.3. Influence of drug-lipid ratio 
Aqueous SLM dispersions containing different amounts of KTZ (Table 5.1) were manufactured 
in order to investigate the influence of KTZ loading on the quality of the SLM that were 
produced. The PS, ZP, EE for KTZ-loaded SLM formulations were measured on the day of 
manufacture and the data generated from these studies are summarized in Table 5.4. The 
influence of drug:solid lipid concentration on the quality of KTZ-loaded SLM was investigated 
using three different concentrations viz., 3.3% w/v, 5% w/v and 10% w/v of KTZ (SLM 22, 15 
and 21, Table 5.1). SEM and TEM images (Figures 5.8 and 5.9) depict images of SLM prepared 
using three different concentrations of KTZ. In addition the influence of KTZ loading on ZP, 
DLC and EE of KTZ-loaded SLM were also evaluated. The effect of Labrafil
®
 M2130 CS 
concentration on PS, ZP, DLC and EE of KTZ-loaded SLM batches 22, 15 and 21 are 
summarized in Table 5.4 and depicted in Figure 5.10. 
 
Figure 5.8 SEM images of KTZ-loaded SLM manufactured using different concentrations of KTZ: 3.3% 
w/v (SLM 22), 5% w/v (SLM 15) and 10% w/v (SLM 21) on the day of manufacture 
 
Figure 5.9 TEM images of KTZ-loaded SLM manufactured using different concentrations of KTZ: 3.3% 
w/v (SLM 22), 5% w/v (SLM 15) and 10% w/v (SLM 21) on the day of manufacture 
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Table 5.4 PS, ZP, DLC and EE of KTZ-loaded SLM manufactured using different concentrations of KTZ: 
3.3 % w/v (SLM 22), 5% w/v (SLM 15) and 10% w/v (SLM 21) on the day of manufacture 
 
Figure 5.10 PS, ZP, DLC and EE of KTZ-loaded SLM manufactured using different concentrations of 
KTZ: 3.3 % w/v (SLM 22), 5% w/v (SLM 15) and 10% w/v (SLM 21) on the day of manufacture 
 
On the day of manufacture the KTZ-loaded SLM formulations appeared to be more spherical and 
smooth as the concentration of KTZ was increased although differences in shape and surface 
morphology of KTZ-loaded particles were not significant at concentrations of 5% w/v and 10% 
w/v KTZ (Figure 5.8). The measurement of PS revealed that the mean PS of KTZ-loaded SLM 
was between 18.6 and 28.3 µm with a relatively narrow particle size distribution. Loading 
concentrations have been reported to exert no influence on the PS of solid lipid nanoparticle 
formulations of trans retinoic acid [454]. The findings observed in these studies reveal that the PS 
was not significantly altered when increasing loading concentrations of KTZ as the mean PS 
measured for the drug-free SLM formulation manufactured using the same combination of 
surfactants and lipid concentration (p  > 0.05, SLM 6, Table 5.1) depicted a similar PS range. The 
use of techniques that measure the particle diameter through light scattering effects may be 
required to further investigate the effects of KTZ loading on the PS of SLM formulations.  
 
Similarly, the ZP of KTZ-loaded SLM were not significantly different when increasing KTZ 
concentrations were used to manufacture the formulations (p > 0.05, Figure 5.10). The KTZ-free 
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Amount of drug used in SLM formulations 
PS (µm) 
ZP (-mV) 
DLC (%) 
EE (%) 
Concentration of KTZ (% w/w) 3.3 5 10 
Drug:lipid ratio 1:3 1:2 1:1 
Parameter on day 0 SLM 22 SLM 15 SLM 21 
PS (µm) 27.5 ± 4.9 18.6 ± 3.6 28.3 ± 3.8 
ZP (mV) -30.8 ± 0.6 -30.1 ± 0.2 -28.1 ± 0.1 
DLC (%) 22.5 ± 1.2 23.6 ± 1.8 19.4 ± 0.37 
EE (%) 48.5 ± 2.9 58.2 ± 2.3 49.5 ± 0.79 
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SLM formulation prepared using the same formulation composition as SLM 15 was found to 
exhibit a similar ZP on the day of manufacture (SLM 6, Table 5.2). The ZP values were negative 
due to the presence of sodium cholate and were close to -30 mV which defines the limit for 
stability of colloidal dispersions stabilized by electrostatic interactions alone. The stability of the 
SLM formulations was further improved by the addition of steric surfactants such as Pluronic
®
 F-
68 and Tween 80. 
 
DLC and EE are important properties that can influence drug release characteristics and formed 
an integral part of these formulation development studies. KTZ is known to be a lipophilic API 
and is therefore a good candidate for inclusion in SLM formulations. However, KTZ did not 
exhibit an extremely high solubility in the lipids used during lipid screening studies and due to the 
average solubility of KTZ in Labrafil
®
 M2130 CS only small amounts of KTZ were used to 
investigate the feasibility of SLM to encapsulate KTZ. Concentrations of 3.3% w/v, 5% w/v and 
10% w/v were deemed sufficient for the intended purpose of these studies. The data summarized 
in Table 5.4 and depicted in Figure 5.10 demonstrate that a concentration of 5% w/v KTZ yielded 
maximum entrapment of KTZ with DLC and EE values of 23.6 ± 1.8% and 58.2 ± 2.3%, 
respectively. The data also reveal that the amount of KTZ entrapped in the microparticles for each 
formulation investigated did not vary significantly and seemed to decrease as the concentration of 
KTZ was increased to levels >  5% w/v (p > 0.05). The use of 10% w/v KTZ led to a reduction in 
DLC and EE and an increase in PS (Table 5.4 and Figure 5.10). Therefore, a concentration of 5% 
w/v KTZ, 10% w/v Labrafil
®
 M2130 CS and a combination of three surfactants, Pluronic
®
 F-68 
(4% w/v), sodium cholate (1% w/v) and Tween 80 (2% w/v) were used during further 
formulation development studies to establish the effect of process parameters such as the number 
of homogenization cycles on the quality of SLM formulations manufactured and these studies are 
described in § 5.5.4.  
 
5.5.4. Selection of production parameters 
The method used to manufacture SLM formulations using an Ultra-Turrax
®
 homogenizer at 
24000 rpm for 5 minutes prior to homogenization with an Erweka GmbH homogenizer (Erweka 
AR400, Heusenstamm, Offenbach, Germany) required that an appropriate number of 
homogenization cycles be used to produce particles in an acceptable micrometer PS range and 
that exhibited sufficient entrapment of KTZ. The number of homogenization cycles was changed 
between 3 and 5 and the quality of the SLM dispersion was characterized in terms of particle 
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shape and surface morphology, PS, ZP, DLC and EE.  The SEM and TEM micrographs (Figures 
5.11 and 5.12) depict the SLM formulations manufactured using 5% w/v KTZ, 10% w/v 
Labrafil
®
 M2130 CS and a combination of 4% w/v Pluronic
®
 F-68, 1% w/v sodium cholate and 
2% w/v Tween
 
80 using different numbers of homogenization cycles. The effect of the number of 
homogenization cycles on PS, ZP, DLC and EE of KTZ-loaded SLM batches manufactured using 
3 (SLM 23), 4 (SLM 24) and 5 (SLM 15) homogenization cycles are summarized in Tables 5.5 
and depicted in Figure 5.13.  
 
Figure 5.11 SEM images of KTZ-loaded SLM manufactured using 3 (A, SLM 23), 4 (B, SLM 24) and 5 
(C, SLM 15) homogenization cycles on the day of manufacture 
 
 
Figure 5.12 TEM images of KTZ-loaded SLM manufactured using 3 (A, SLM 23), 4 (B, SLM 24) and 5 
(C, SLM 15) homogenization cycles on the day of manufacture 
 
Table 5.5 PS, ZP, DLC and EE of KTZ-loaded SLM manufactured using 3 (A, SLM 23), 4 (B, SLM 24) 
and 5 (C, SLM 15) homogenization cycles on the day of manufacture 
Number of homogenization cycles 3 (SLM 23) 4 (SLM 24) 5 (SLM 15) 
Parameter Day 0 Day 0 Day 0 
PS (µm) 42.7 ± 6.9 17.8 ± 7.1 18.6 ± 3.6 
ZP (mV) -27.5 ± 0.2 -29.7 ± 0.1 -30.1 ± 0.2 
DLC (%) 20.7 ± 1.9 19.1 ± 3.9 23.6 ± 1.8 
EE (%) 43.8 ± 2.8 42.3 ± 2.5 58.2 ± 2.3 
 138 
 
 
Figure 5.13 PS, ZP, DLC and EE of KTZ-loaded SLM manufactured using 3 (A, SLM 23), 4 (B, SLM 24) 
and 5 (C, SLM 15) homogenization cycles on the day of manufacture 
 
Process parameters such as the number of homogenization cycles have a direct impact on particle 
size as the formation of a finer and more homogenous emulsion permits stabilization of smaller 
particles [451]. Similar observations have also been reported for the preparation of nano-
dispersions using a reversible salting-out effect [455]. The mean particle size measured using 
TEM (Figure 5.12) and the data obtained from these studies reveal that increasing the number of 
homogenization cycles during production of SLM results in a reduction in the mean PS for the 
formulations tested on the day of manufacture. The SEM micrographs depicted in Figure 5.11 
reveal a change in surface morphology of the particles when using five homogenization cycles 
and the surface of the particles in KTZ-loaded SLM C appeared smoother and more regular 
compared to the surface of particles produced using fewer homogenization cycles (A and B). 
Further studies using a higher number of homogenization cycles were not undertaken so as to 
maintain the simplicity of the production process and ensure that the duration of production was 
reasonably short. A slight increase in the ZP of the SLM formulations tested during these studies 
as the number of homogenization cycles was increased was noted. The higher ZP values obtained 
using a higher number of homogenization cycles were close to -30 mV indicating improved 
stability of the SLM formulations possibly due to a reduction in PS. The use of five 
homogenization cycles also led to the production of particles with higher KTZ entrapment 
efficiency as shown in Table 5.5 and Figure 5.13.  Therefore, the production of KTZ-loaded SLM 
using a modified micro-emulsion technique was achieved by passing the micro-emulsion through  
an Ultra-Turrax
®
 homogenizer at 24 000 rpm for 5 minutes prior to  homogenization for five 
cycles using an  Erweka GmbH homogenizer. 
0 
10 
20 
30 
40 
50 
60 
70 
3 4 5 
Number of homogenisation cycles 
PS (µm) 
ZP (-mV) 
DLC (%) 
EE (%) 
 139 
 
5.5.5. Stability assessment of optimized SLM formulations 
The optimized formulations identified through formulation development studies were found to be 
comprised of 10% w/v solid lipid Labrafil
®
 M2130 CS, 5% w/v KTZ and a combination of 
Pluronic
®
 F-68, sodium cholate and Tween
®
 80. At a concentration of 10% w/v of the solid lipid 
and 5% w/v KTZ the use of different concentrations of each surfactant produced good quality 
KTZ-loaded SLM on the day of manufacture in terms of particle shape, surface morphology, PS, 
ZP, DLC and EE. Therefore, for the purposes of these studies two formulations were selected  
viz., SLM 15 and SLM 16 were used for further studies and were stabilized with 4% w/v and 5% 
w/v Pluronic
®
 F-68 respectively, 2% w/v and 1% w/v Tween
 
80 respectively and 1% w/v sodium 
cholate in both cases (Table 5.1). 
 
The stability of the optimized products was assessed using stability chambers (Binder GmbH, 
KBF 240, E5.2, Tuttlingen, Germany) set to 25°C/65% RH and 40°C/75% RH as specified by 
ICH Q1A guidelines for stability testing of new drug substances and products [456]. The 
formulations were tested on days 0, 3, 7 and 30 following manufacture as signs of instability were 
observed after one month of storage. The stability of each SLM formulation was evaluated by 
assessing the PS, ZP, DLC and EE on days 0, 3, 7 and 30 after manufacture. SEM and TEM were 
used to evaluate the PS, shape and surface morphology of the formulations and the ZP was 
established using a Nano-ZS Zetasizer set in the Laser Doppler Anemometry (LDA) mode. The 
entrapment efficiency was also assessed on days 0, 3, 7 and 30 as it was considered to be an 
essential indicator of stability of the SLM formulations that may exert an effect on KTZ release 
[246].  
 
A summary of the PS, ZP, DLC, EE data generated on days 0, 3, 7, 30 at 25°C/60% RH and 
40°C/75% RH for SLM 15 and SLM 16 respectively is listed in Tables 5.6 and 5.7.  
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Table 5.6 PS, ZP, DLC and EE of KTZ-loaded SLM 15 manufactured using 10% w/v solid lipid, 5% w/v 
KTZ, 4% w/v Pluronic
®
 F-68, 2% w/v Tween 80 and 1% w/v sodium cholate on days 0, 3, 7 and 30 after 
manufacture and after storage at 25°C/60% RH and 40°C/75% RH  
 
Table 5.7 PS, ZP, DLC and EE of KTZ-loaded SLM 16 manufactured using 10% w/v solid lipid, 5% w/v 
KTZ, 5% w/v Pluronic
®
 F-68, 1% w/v Tween 80 and 1% w/v sodium cholate on days 0, 3, 7 and 30 after 
manufacture and after storage at 25°C/60% RH and 40°C/75% RH 
 
5.5.5.1. Particle size analysis  
The PS data listed in Table 5.6 reveal that the mean PS of microparticles of batch SLM 15 were 
less than 35 µm following storage at 25°C/60% RH for 30 days. An increase in PS was observed 
on storage of SLM 15 at 25°C/60% RH (Table 5.6 and Figure 5.20). Particles of SLM 15 after 
storage at 25°C/60% RH for up to 30 days are depicted in Figure 5.14. The SEM micrographs 
shown in Figure 5.14 depict spherical and smooth particles that exhibited signs of flocculation 
from the day of manufacture and an increase in flocculation was noted after storage at 25°C/60% 
RH for one month. The particles depicted in Figure 5.14 D for SLM formulation 15 reveals the 
presence of clusters following storage at 25°C/60% RH for 30 days which could indicate early 
signs of instability due to coalescence or Ostwald ripening. Coalescence describes the 
aggregation of flocculated particles into a larger droplet and may be caused by a loss of the 
interfacial film between approaching particles in the aqueous phase [457]. Furthermore, the 
SLM 15 25°C/60% RH 
Parameters day 0 day 3 day 7 day 30 
PS (µm) 18.6 ± 3.6 22.5 ± 2.9 26.7 ± 2.8 29.7 ± 2.4 
ZP (mV) -30.1 ± 0.2 -30.2 ± 0.1 -29.3 ± 0.2 -31.2 ± 0.3 
DLC (%) 23.6 ± 1.8 21.8 ± 2.1 22.4 ± 3.8 22.9 ± 4.6 
EE (%) 58.2 ± 2.3 59.2 ± 4.2 56.9 ± 3.6 57.8 ± 7.5 
SLM 15 40°C/75% RH 
Parameters day 0 day 3 day 7 day 30 
PS (µm) 18.6 ± 3.6 30.1 ± 4.2 46.3 ± 7.5 60.6 ± 8.4 
ZP (mV) -30.1 ± 0.2 -28.4 ± 0.3 -27.6 ± 0.3 -28.6 ± 0.2 
DLC (%) 23.6 ± 1.8 15.4 ± 4.3 8.4 ± 3.6 4.7 ± 1.9 
EE (%) 58.2 ± 2.3 30.2 ± 5.1 17.6 ± 2.4 6.2 ± 2.3 
SLM 16 25°C/60% RH 
Parameters day 0 day 3 day 7 day 30 
PS (µm) 15.6 ± 2.1 25.8 ± 3.7 29.8 ± 1.2 30.6 ± 5.8 
ZP (mV) -31.6 ± 0.1 -29.4 ± 0.2 -28.5 ± 0.1 -32.1 ± 0.3 
DLC (%) 18.6 ± 0.3 16.5 ± 4.3 17.1 ± 1.8 17.9 ± 3.5 
EE (%) 43.2 ± 1.4 41.5 ± 3.2 39.9 ± 2.4 42.6 ± 6.2 
SLM 16 40°C/75% RH 
Parameters day 0 day 3 day 7 day 30 
PS (µm) 25.6 ± 2.2 35.7 ± 4.9 48.9 ± 7.6 70.7 ± 5.1 
ZP (mV) -31.6 ± 0.1 -26.3 ± 0.2 -25.8 ± 0.1 -24.1 ± 0.3 
DLC (%) 18.6 ± 0.3 10.4 ± 2.6 6.7 ± 1.9 3.2 ± 0.6 
EE (%)                                                                                                                                                                 43.2 ± 1.4 31.2 ± 4.3 12.6 ± 3.1 5.6 ± 2.5
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particles depicted in Figure 5.14 D also appear less spherical than those obtained on the day of 
manufacture as depicted in Figure 5.14 A. However, an aqueous suspension of SLM 15 could 
easily be redispersed and no signs of caking were observed. In addition there were no changes in 
state of the dispersion and the lipid microparticles remained in the solid state with no signs of gel 
formation after exposure to 25°C/60% RH for up to 30 days.  
 
 
 
 
 
 
 
 
 
 
Figure 5.14 SEM micrographs of SLM formulation 15 after storage at 25°C/60% RH on day 0 (A), 3 (B), 7 
(C), 30 (D) after manufacture 
 
Particles of SLM 15 after storage at 40°C/75% RH for up to 30 days are depicted in Figure 5.15. 
The data obtained from the SEM reveal a progressive increase in the mean PS of SLM 15 when 
stored at 40°C/75% RH (from 18.6 µm to 60.6 µm) (Table 5.6 and  Figure 5.20). The SEM 
micrographs depicted in Figure 5.15 B reveal clusters of particles from day 3 and larger particles 
possibly resulting from a combination of coalescence and Ostwald ripening from day 7 (Figure 
5.15 C). Furthermore, a slight change in state from a solid to semi-solid state was observed from 
day 7 when stored under these conditions. A change in physical appearance from a uniform 
aqueous dispersion to a semi-solid gel was observed on day 30 following storage of SLM 15 at 
40°C/75% RH and the product was not easily redispersed on shaking. Therefore, storage of an 
aqueous dispersion of SLM 15 at 40°C/75% RH for 30 days resulted in caking and revealed 
potential instability. The SEM micrograph of particles of batch SLM 15 generated on day 30 
following storage at 40°C/75% RH (Figure 5.15 D) revealed clusters of very large and small 
particles, a phenomenon that is characteristic of Ostwald ripening which may be the mechanism 
of instability within this dispersion.  
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Figure 5.15 SEM micrographs of SLM formulation 15 after storage at 40°C/75% RH on day 0 (A), 3 (B), 7 
(C), 30 (D) after manufacture 
 
The TEM micrographs obtained on day 30 for aqueous dispersion SLM 15 revealed an increase 
in the mean PS of the SLM after storage at 40°C/75% RH (Figure 5.16 B) compared to storage at 
25°C/60% RH (Figure 5.16 A). The particles in Figure 5.16 B seem to be rough and non-
spherical and indicate the physical instability of the dispersion due to coalescence or Ostwald 
ripening. Therefore, SLM 15 was not deemed stable under high temperature and humidity 
conditions thirty days after its manufacture. Storage of SLM 15 at 25°C/60% RH appeared to be 
suitable as the stability of the aqueous dispersion did not appear to be altered significantly. The 
slight aggregation of particles noted in the aqueous dispersion of SLM 15 at 25°C/60% RH was 
easily redispersed on shaking of the product. 
 
Figure 5.16 TEM micrographs of SLM formulation 15 after storage at 25°C/60% RH (A) and 40°C/75% 
RH (B) on day 30  
 
SEM micrographs of SLM 16 following storage at 25°C/60% RH are depicted in Figure 5.17 and 
reveal that the mean PS was between 15.6 ± 2.1 µm and 30.6 ± 5.8 µm on days 0 and 30 
respectively (Table 5.7). The particles in aqueous dispersion of SLM 16 were relatively spherical 
and discrete on the day of manufacture. Slight particle growth was observed on days 3 and 7 and 
larger particles surrounded by smaller particles were observed on day 7 possibly indicating that 
aggregation due to Ostwald ripening was occurring. However, the aqueous dispersion of SLM 16 
was easily redispersed into a uniform product for up to 7 days without any sign of gel formation 
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or caking. Some non-spherical particles and presence of a few lipid aggregates are observed in 
Figure 5.17 D. 
 
Figure 5.17 SEM micrographs of SLM formulation 16 after storage at 25°C/60% RH on day 0 (A), 3 (B), 7 
(C), 30 (D) after manufacture 
 
Following storage of SLM 16 at 40°C/75% RH large particles were observed from the day of 
manufacture. The mean PS following storage of SLM 16 at 25°C/60% RH was 15.6 ± 2.1 µm 
whilst storage at 40°C/75% RH for the same time period (2 hours) resulted in particles with a 
mean diameter of 25.6 ± 2.2 µm (Table 5.7). Furthermore, the particles of SLM 16 were non-
spherical following storage at 40°C/75% RH. The aqueous dispersion of SLM 16 exhibited signs 
of physical instability from day 3 as the dispersion was not easily redispersible on shaking and a 
compact layer had been formed at the bottom container. SEM micrographs taken on day 3 and 7 
are depicted in Figure 5.18 B and C reveal the presence of non-discrete particles connected by a 
layer of film. The mean PS was 70.7 ± 5.1 µm after 30 days which indicates that an increase in 
PS had occurred since the day of manufacture. The degree of caking was more pronounced after 
one month of storage of SLM 16 at 40°C/75% RH further revealing the instability of the 
dispersion under these conditions at this temperature.  
 
The presence of solidification within the aqueous dispersion at higher storage temperatures could 
be due to crystal growth that results in the formation of a solid, lipid network. Subsequent 
recrystallisation into platelets or rods-like structures may occur and promote the formation of a 
lipid network.  The extent of solidification is thought to be related to the amount of stable lipid 
modification [448]. Higher kinetic energy of particles will lead to collisions between particles 
which in turn may disrupt the stabilizing surfactant layer around the particles. The formation of 
resulting unprotected interfaces within the dispersion at high temperatures increases the 
likelihood of particles approaching each other from unprotected sides leading to aggregation 
[448].  
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Figure 5.18 SEM micrographs of SLM formulation 16 after storage at 40°C/75% RH on day 0 (A), 3 (B), 7 
(C), 30 (D) after manufacture 
 
The instability of the aqueous dispersion of SLM 16 following storage at 40°C/75% RH was also 
observed in the TEM micrographs (Figure 5.19). On day 30 clusters of large particles were seen 
within the aqueous dispersion as observed in Figure 5.19 B.  The high degree of particle growth 
and caking observed after one month of storage revealed an unstable aqueous dispersion for SLM 
16 when stored at 40°C/75% RH.  
 
Figure 5.19 TEM micrographs of SLM formulation 16 after storage at 25°C/60°C RH (A) and 40°C/75°C 
RH (B) on day 30 
 
A comparison of the particle growth in the aqueous dispersions of SLM 15 and SLM 16 after 
storage at 25°C/60% RH and 40°C/75% RH is depicted in Figure 5.20. An increase in mean PS 
was observed for both SLM 15 and SLM 16 on storage and exposure to higher temperatures 
appeared to aggravate the extent of particle growth. The TEM micrograph depicted in Figure 5.19 
B reveals the presence of cluster of lipid. Furthermore, a higher degree of particle growth and 
physical instability were observed for SLM 16 following storage at 40°C/75% RH indicating that 
the dispersion cannot be stored for more than three days under high temperature and humidity 
conditions. Therefore, these stability studies indicate that particle growth and subsequent 
solidification may be induced through an increase in kinetic energy at high temperatures coupled 
with possible changes in lipid crystallinity, particle film rigidity and steric effects [448].  
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Figure 5.20 Particle size (PS) of SLM formulations 15 and 16 after storage at 25°C/60% RH and 
40°C/75% RH on day 0, 3, 7 and 30 after manufacture 
 
5.5.5.2. Zeta potential analysis  
The assessment of ZP over the storage period is a good indicator of changes in stability within 
aqueous disperse systems. The change in ZP observed following storage of SLM 15 and SLM 16 
respectively over the one-month period is depicted in Figure 5.21. The changes in ZP were not 
significantly different between batches SLM 15 and SLM 16 on the day of manufacture and 
following storage at 25°C/60% RH (p > 0.05). However, a drop in ZP was observed as from three 
days when SLM dispersions were stored at 40°C/75% RH and this observation may explain the 
increase in aggregation observed following storage at high temperature.  
 
Figure 5.21 Zeta potential (ZP) of SLM formulations 15 and 16 after storage at 25°C/60% RH and 
40°C/75% RH on day 0, 3, 7 and 30 after manufacture  
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A decrease in the magnitude of the ZP from -30.1 ± 0.2 mV to -28.6 ± 0.2 mV was observed for 
batch SLM 15 when stored for 30 days at 40°C/75% RH. A larger drop in ZP was noted for batch 
SLM 16 after storage at 40°C/75% RH as the ZP decreased from -31.6 ± 0.1 mV to -24.1 ± 0.3 
mV (Table 5.7). The reduction in ZP indicates a decrease in the surface charge of the particles 
and subsequently a reduction in the repulsion potential of the particles. The resulting increase in 
flocculation observed for batches SLM 15 and SLM 16 at 40°C/75% RH may be attributed to the 
decrease in ZP, thereby promoting aggregation. Limited flocculation is known to occur at ZP 
values between 5 and 15 mV and rapid flocculation occurs at potentials < 5 mV. In these stability 
studies rapid flocculation was observed at higher ZP values following storage at 40°C/75% RH 
and this may be attributed to the high kinetic energy and velocity of the particles that exist at 
higher temperatures leading to an increase in number of collisions and contact time between 
dispersed particles. High temperatures and the presence of light are known to increase the kinetic 
energy of systems and such prevailing conditions in combination with a lower ZP is likely to 
promote aggregation and gelation of the SLM dispersions [448]. Under storage conditions of 
40°C/75% RH the cumulative steric and electrostatic effects of Tween 80 and sodium cholate 
appear to be inadequate to prevent agglomeration that was observed for dispersion of batches 
SLM 15 and SLM 16.  
 
The reduction in ZP may also be due to a shift in the shear plane subsequently resulting in 
insufficient potential energy necessary for electrostatic repulsion that is essential for establishing 
a high quality interface between SLM units. Increasing the energy input into a system may also 
lead to changes in the crystallinity of lipids and enhance the development of lipid modifications 
such as an increase in the formation of the β-modification form. Subsequently, an increase in 
energy input results in crystalline re-orientation that in turn may influence the Nernst potential, 
the surface charge of the particle and resultant ZP. Storage of SLM at high temperatures may also 
lead to crystal growth and for one-dimensional crystal growth the charge density on different 
sides of a crystal may vary, thereby changing the surface ratio of charges that has an impact on 
the ZP [448]. An increase in the temperature of exposure for these systems results in a reduction 
in ZP as observed in Figure 5.21. 
 
5.5.5.3. KTZ loading capacity and encapsulation efficiency 
The DLC and EE obtained for KTZ-loaded aqueous SLM dispersions during stability studies are 
important parameters as they reflect the remaining KTZ content that is encapsulated following 
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storage and provide an indication of the ability of the SLM to retain KTZ. An EE value of at least 
50% following storage for 30 days was deemed necessary for KTZ-loaded SLM intended for use 
in an oral drug delivery system. A reduction of the DLC and EE values on storage implies that 
expulsion of KTZ from the lipid matrix that can be attributed to changes within the lipid structure 
would have occurred. Conversion of metastable lipid modifications to their stable forms during 
storage can result in a change in crystallinity of the lipid from a disordered structure that retains 
API molecules to an orderly structure that  leads to the expulsion of the KTZ [156]. The DLC and 
EE values observed for batches SLM 15 and SLM 16 following storage at 25°C/60% RH and 
40°C/75% RH are depicted in Figures 5.22 and 5.23. 
 
Figure 5.22 Drug loading capacity (DLC) and encapsulation efficiency (EE) of SLM 15 after storage at 
25°C/60% RH and 40°C/75% RH on day 0, 3, 7 and 30 after manufacture  
 
 
Figure 5.23 Drug loading capacity (DLC) and encapsulation efficiency (EE) of SLM 16 after storage at 
25°C/60% RH and 40°C/75% RH on day 0, 3, 7 and 30 after manufacture 
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The stability data revealed that batches SLM 15 and SLM 16 maintained their DLC and EE after 
storage at 25°C/60% RH for up to 30 days. However, SEM and TEM micrographs of batch SLM 
16 taken following storage at 25°C/60% RH for 30 days revealed the presence of non-spherical 
particles and lipid aggregates that may be indicative of particle growth through Ostwald ripening 
which would eventually destabilize the SLM. An increase in particle aggregation as noted from 
the presence of lipid aggregrates in SLM 16 following storage at 25°C/60% RH would 
subsequently lead to expulsion of the API. Therefore, batch SLM 15 was deemed to more stable 
than SLM 16 after storage at 25°C/60% RH for up to 30 days. On the other hand batches SLM 15 
and 16 revealed a reduction in DLC and EE following storage at 40°C/75% RH for up to 30 days. 
The reduction in DLC and EE was more pronounced at storage conditions of 40°C/75% RH for 
batch SLM 16 when compared to that observed for batch SLM 15 implying that batch SLM 16 
was less stable than batch SLM 15. Prolonged storage conditions of KTZ-loaded SLM 16 at 
40°C/75% RH may have resulted in a decrease in the crystallinity of KTZ subsequently 
enhancing its expulsion from the particle. An increase in temperature may result in perturbation 
of the surfactant layer, resulting in a temporary lack of homogeneity of this layer that may 
precipitate particle aggregation and KTZ expulsion [458]. 
 
The transformation of the lipid to stable polymorphic modifications may also result in instability 
within SLM dispersions, since physically stable SLM dispersions usually require the coexistence 
of different modifications [459]. The polymorphic form of a lipid affects the loading capacity of a 
drug in that lipid in addition to affecting the release rate of drug from the technology [102, 460]. 
In lipid formulations the lipid tends to re-crystallize partially in the α-form as opposed to 
preferential re-crystallisation in the β’-form and rapid transformation to the β-form in bulk lipid 
materials [237]. The formation of the β/β’ forms promotes drug expulsion as the crystal lattice 
tends to become  more structured  [237, 460]. This polymorphic transformation is slower in long-
chain triglycerides [460] and as the thermodynamic stability and lipid packing density increases , 
drug incorporation rates decrease in the order β-modification > β’-modification > α –modification 
> supercooled melts [341]. Although the DSC thermogram of the bulk lipid material revealed no 
significant changes in polymorphic state following exposure to heat (Chapter 4, § 4.4.2.2, vide 
infra), Labrafil
®
 M2130 CS may be subject to polymorphic changes after subsequent exposure to 
increased temperature. The recrystallization process following production of the micro-emulsion 
at 60ºC occurs via a cooling step which was reproduced by allowing the lipid to cool to 25ºC 
during DSC studies. In order to evaluate possible polymorphic changes on reheating an additional 
heating step to mimic the impact of high temperature storage conditions will be required during 
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DSC studies to establish whether the structure of Labrafil
®
 M2130 CS changes. Additional 
thermal analysis of KTZ-loaded SLM dispersion during stability was beyond the scope of this 
project and therefore not undertaken. 
 
The stability studies undertaken on two optimized SLM formulations viz., SLM 15 and SLM 16 
infer that there is some degree of instability of KTZ-loaded dispersions when stored under high 
temperatures and humidity conditions. The formulation of batch SLM 15 was found to be of  
better quality and more stable than those of batch SLM 16 when stored at 25°C/60% RH for up to 
30 days. Both batches were found to be unstable when stored at 40°C/75% RH. Therefore, batch 
SLM 15 manufactured using 5% w/v KTZ, 10% w/v Labrafil
®
 M2130 CS, 4% w/v Pluronic
®
 F-
68, 2% w/v Tween
®
 80, 1% w/v sodium cholate was deemed to be an appropriate KTZ-loaded 
SLM formulation produced in these studies. The product can be stored for up to one month at 
25°C/60% RH without a significant loss in stability. It is clear that additional development and 
optimization of this dosage form would be necessary to ensure that a viable product was 
produced. 
 
5.6. Conclusions 
For the development of KTZ-loaded SLM it was important to establish an appropriate surfactant 
or combination of surfactants to use in order to stabilize SLM aqueous dispersions during initial 
formulation studies. The use of Pluronic
®
 F68 in combination with other surfactants such as 
Soluphor
®
 P, Soluplus
®
, Lutrol
®
 E400, Tween
 
80 and the co-surfactant sodium cholate was 
investigated in order to select an emulsifying system for KTZ-loaded SLM manufacture using 
Labrafil
®
 M2130 CS. Pluronic
®
 F68 is known to produce stable dispersions particularly when 
used in combination with other non-ionic surfactants. However, aqueous SLM dispersions 
manufactured using Lutrol
®
 E400, Soluphor
® 
P, Soluplus
®
 in combination with Pluronic
®
 F68 
were found to be unstable and of poor quality in terms of PS, ZP, DLC and EE from the day of 
manufacture. It was observed that KTZ-loaded SLM dispersions manufactured using Lutrol
®
 
E400, Soluphor
® 
P, Soluplus
® 
exhibited signs of gelation, particle agglomeration and a low DLC 
and EE. Conversely, the use of Pluronic
®
 F68 in combination with Tween 80 and sodium cholate 
produced particles of better quality and these surfactants were therefore selected for the further 
development of an optimized KTZ-loaded SLM aqueous dispersion.  
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A simple micro-emulsion technique in which an Ultra-Turrax
®
 homogenizer operated at 24 000 
rpm for 5 minutes followed by homogenization with an Erweka GmbH homogenizer was used to 
manufacture KTZ-loaded SLM dispersions. The addition of increasing amounts of Labrafil
®
 
M2130 CS did not seem to affect the ZP of KTZ-loaded SLM dispersions. High concentrations of 
solid lipid however resulted in particles with a lower DLC, EE and a large PS. Therefore, an 
optimum concentration of 10% w/v solid lipid was used to manufacture KTZ-loaded SLM. 
Increasing the ratio of KTZ to Labrafil
®
 M2130 CS did not affect the ZP of the particles and 
concentrations in excess of 5% w/v KTZ led to a reduction in DLC and EE and an increase in PS. 
In order to improve particle characteristics of  KTZ-loaded SLM dispersions the effect of process 
parameters such as the number of homogenization cycles on the quality of particles was 
established and the results revealed that at least five homogenization cycles using the Erweka 
GmbH homogenizer were necessary to produce particles of acceptable ZP, PS, surface 
morphology, DLC and EE.  
 
An assessment of the stability of the KTZ-loaded SLM aqueous dispersions under different 
temperatures and humidity conditions was essential to establish if changes in the quality of 
dispersions was likely to occur on storage. Optimised KTZ-loaded SLM formulations were 
produced using Labrafil
®
 M2130 CS, KTZ and a combination of the non-ionic surfactants. 
Pluronic
®
 F-68, sodium cholate and Tween 80. The PS, surface morphology, ZP, DLC and EE 
were evaluated following storage at 25°C/65% RH and 40°C/75% RH for up to 30 days following 
manufacture as specified in the ICH Q1A guidelines. The formulations were tested on days 0, 3, 7 
and 30 and stability studies revealed that batch SLM 15 manufactured using 10% w/v Labrafil
®
 
M2130 CS, 5% w/v KTZ and a combination of 4% w/v Pluronic
®
 F-68, 2% w/v Tween 80 and 
1% w/v sodium cholate was the most stable when stored at 25°C/65% RH for up to 30 days, yet  
storage at 40°C/75% RH revealed the formulation was unstable. Storage at 40°C/75% RH 
resulted in an increase in PS, agglomeration of the particles into a solid lipid network, lower ZP 
and KTZ expulsion which may be caused by a disruption of the interfacial film surrounding the 
particles leading to a reduction in electrostatic repulsion of the particles. Changes in the 
crystallinity of the solid lipid during storage may have resulted in the formation of stable 
polymorphic forms which do not retain KTZ within the solid lipid matrix. Additional studies 
using thermal analysis and X-ray scattering would be necessary to investigate changes in the 
polymorphic nature of the lipid matrices used to manufacture the SLM during and after storage.  
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The results of these studies reveal the feasibility of incorporating KTZ into SLM and suggest it is 
a suitable candidate for inclusion into physiologically compatible lipid matrices as it is lipophilic 
in nature. It has been shown that aqueous dispersions of KTZ-loaded SLM can be manufactured 
using a simple micro-emulsion technique and that aqueous SLM dispersions of KTZ were stable 
for up to 30 days when stored at 25°C/60% RH. The method of manufacture of SLM 
formulations developed in these studies permits small-scale production of KTZ-loaded SLM with 
a reasonable DLC and EE for the oral administration of KTZ to paediatric patients who may not 
be able to swallow large solid oral dosage forms. Further optimization studies are required to 
improve the DLC and EE of KTZ on storage. The research reveals the potential for use of SLM 
as a means to avoid extemporaneous preparation of KTZ dispersions prepared using crushed 
tablets which is common practice in South Africa.  
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CHAPTER SIX 
CONCLUSIONS 
 
Ketoconazole (KTZ) is a broad-spectrum imidazole antifungal agent used for the treatment of 
oral and topical mycoses in immuno-compromised patients suffering from cancer and paediatric 
patients requiring antifungal therapy. The mechanism of action of KTZ involves inhibition of 
sterol 14α-demethylase which results in the depletion of ergosterol in fungal cells, thereby 
impacting on cell growth and proliferation patterns. KTZ is a BCS Class II compound and has 
physicochemical and pharmacological properties including a high degree of lipophilicity and 
adequate systemic activity which make it an ideal candidate for incorporation into an oral lipid 
formulation. The lack of availability of antifungal medicines in an appropriate form for paediatric 
use, particularly in developing countries, requires that extemporaneous preparations of KTZ in 
suspension form must be prepared to achieve appropriate antifungal therapy in some public 
hospitals. Solid oral dosage forms that are intended for adult use are usually manipulated by 
breaking or crushing and mixing with a suspension vehicle such as methylcellulose by care-
givers. This may lead to under or over-dosing if providers are not well-informed and are not 
trained in product manipulation. This commonly used practice in South Africa can also 
exacerbate the problem of resistance, thereby further impacting the quality of life of patients. 
Cold chain storage requirements in developing countries due to high temperature and humidity 
conditions are often ignored and the dearth of information on the stability of the extemporaneous 
KTZ formulations prepared in these countries can lead to ineffective antifungal therapy and may 
further complicate the problem of resistance. Therefore, it is essential that research and 
development is focused on the development of novel drug delivery systems with well-established 
chemical and physical stability to circumvent extemporaneous preparation and improve 
antifungal therapy, particularly amongst paediatric patients.  
 
Solid lipid carriers are promising colloidal drug delivery systems that may be used as potential 
carriers for the oral administration of KTZ to paediatric patients. Solid lipid nanoparticles (SLN) 
and microparticles (SLM) combine the advantages of traditional colloidal carriers such as 
liposomes, nano-emulsions, nano-suspensions and polymeric nanoparticles as they consist of lipid 
matrices that are manufactured using physiologically well-tolerated lipid excipients including 
glycerides of fatty acid esters or fatty acids that have GRAS status. In addition SLN and SLM 
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demonstrate physicochemical stability, enhanced bioavailability, have the possibility of 
sustaining drug release and drug targeting. The use of solid lipids instead of liquid lipids in the 
manufacture of solid lipid carriers not only leads to a reduction in the variability of plasma 
profiles but also enables better characterization of lipid excipients and offers a greater possibility 
of scale-up of the manufacturing process. Furthermore, better control can be exercised over the 
release kinetics of encapsulated compounds when solid lipid carriers are used. The drug content 
has been found to be higher for carriers manufactured with solid lipid carriers and these systems 
may be used for the encapsulation of hydrophilic and hydrophobic drugs.  
 
Furthermore, as KTZ is known to undergo chemical degradation, the protection of the API by the 
lipid matrix offers an additional advantage for the administration of KTZ. The objective of this 
study was to investigate the feasibility of developing SLM as a carrier system for the oral 
administration of KTZ to patients in an attempt to circumvent the disadvantages of 
extemporaneously prepared formulations of KTZ and to improve the stability of KTZ. The study 
involved the development and characterization of a KTZ solid lipid micro-particle (SLM) 
formulation containing 5% w/v KTZ and an investigation of the stability of the KTZ-loaded 
aqueous SLM dispersion on storage.  
 
Prior to initiating formulation development studies, it is crucial that a suitable analytical method 
that can be used for the quantitation of KTZ and the characterization of the dosage form during 
the development and assessment process is developed and validated. One of the difficulties 
encountered in the analysis of lipid formulations is interference due to formulation excipients that 
are usually present in technologies with a complex composition. RP-HPLC is a widely used 
powerful and reliable analytical tool that may be used for the in vitro analysis of formulations 
manufactured using a complex combination of adjuvants and has been applied to the analysis of 
gels, ointments, creams and suspensions. Separation and quantitative data may be generated using 
RP-HPLC and interference challenges can be successfully eliminated. Most of the RP-HPLC 
methods that have been reported for the analysis of KTZ from pharmaceutical dosage forms 
involve extensive sample pre-treatment, lack specificity and are costly and tedious to perform. 
There was a need to develop a simple, rapid, sensitive and selective analytical method to 
quantitate the DLC and EE of KTZ-loaded SLM. The initial phases of this project entailed the 
development, optimization and validation of a suitable RP-HPLC method for the quantitative 
determination of KTZ in aqueous KTZ-loaded SLM dispersions during formulation optimization 
and stability studies. The chromatographic separation of KTZ and the internal standard, 
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clotrimazole (CLZ) was achieved using a binary mobile phase consisting of acetonitrile and 50 
mM potassium dihydrogen phosphate buffer adjusted to pH 6.0 using 1 M sodium hydroxide in a 
ratio of 60:40. A flow rate of 1 ml/min was used and the analysis was performed at room 
temperature (22°C) using a Beckman Coulter
®
 ODS column (5µm, 150 × 4.6 mm I.D.). The 
method was developed using a modular isocratic reversed-phase HPLC-UV system at a 
wavelength of 206 nm. The optimized liquid chromatographic conditions were achieved by 
manipulation of the mobile phase composition, buffer pH, molarity and flow rate. The analytical 
run time was 12 min and KTZ and CLZ eluted at 3.7 and 8.7 min, respectively. The RP-HPLC 
analytical method was validated according to USP and ICH guidelines and was found to be linear, 
precise, accurate, specific, sensitive and suitable for the intended purpose of quantitation of KTZ. 
KTZ was found to be stable in methanol following storage at 4°C for at least 7 days and thus all 
calibration standards were prepared using methanol, were stored at 4°C and analyzed within 7 
days after which fresh calibration standards were prepared.  
 
Different methods of preparation of solid lipid carriers exist and include high pressure 
homogenization, micro-emulsion, solvent-evaporation and spray congealing techniques. The 
inclusion of KTZ into SLM manufactured using the solid lipid, Labrafil
®
 M2130 CS was 
achieved using a modified form of the micro-emulsion technique that is relatively simple and 
relies on the use of routinely available homogenizers. This micro-emulsion technique was used as 
it requires relatively low mechanical energy input and imparts good theoretical stability to the 
particles that are produced. The incorporation of a drug into solid lipid carriers depends on the 
solubility of the drug in the lipid, the physicochemical properties of the drug, the chemical and 
physical structure of the lipids, the surfactants used and the production method used to produce 
the particles. One of the pre-requisites to obtain adequate drug loading is a sufficiently high 
solubility of the drug in the lipid melt. Formulation development of KTZ-loaded SLM was 
preceded by studies that were conducted to determine the lipid with the best solubilising potential 
for KTZ. The lipids that were screened for use were Precirol
®
 ATO 5, Compritol
®
 888, Labrafil
®
 
M2130 CS, Gelucire
®
 44/14 and Gelucire
®
 50/13. KTZ was found to be poorly to moderately 
soluble in all lipids tested. Labrafil
®
 M2130 CS was found to exhibit the best solubilising 
potential for KTZ and was therefore selected as the lipid for use in the manufacture of KTZ-
loaded SLM as the solubility of the API in the solid lipid is likely to influence the DLC and EE. 
 
The crystalline nature of the lipid can also influence drug loading as lipids that tend to form 
highly crystalline particles with a perfect orderly lattice structure are prone to drug expulsion and 
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thus unexpected dynamics of polymeric transitions may be one of the disadvantages of solid lipid 
carriers. The micro-emulsion method required that KTZ was dissolved in the solid lipid and 
subjected to heating to 60°C. Methods that involve the heating of the solid lipid during 
manufacture of SLM may lead to changes in the polymorphic and crystalline states of the SLM in 
relation to those of the bulk lipid from which the microparticles are manufactured. Differential 
Scanning Calorimetry (DSC) and wide-angle X-ray diffraction (WAXD) are widely used to 
investigate the crystallinity and polymorphic modification of the lipid. The polymorphic behavior 
of the solid lipid and KTZ was therefore investigated using DSC. Infrared and Raman 
spectroscopy are useful to determine the structural properties of lipids and Fourier-transform 
Infra-Red (FTIR) was used in conjunction with DSC to identify polymorphic modifications, if 
any, of the solid lipid and KTZ. It was necessary to elucidate the thermal behavior of KTZ and 
the Labrafil
®
 M2130 CS prior to and after exposure of 1 hour to a temperature of 60°C prior to 
initiating formulation studies. Thermal and spectroscopic analyses of a 1:1 mixture of KTZ and 
Labrafil
®
 M2130 CS were also conducted to investigate if Labrafil
®
 M2130 CS interacts with 
KTZ prior to and after heating to production temperatures for 1 hour. DSC and FTIR studies 
revealed that no changes in crystallinity of KTZ or Labrafil
®
 M2130 CS occurred after heating to 
60°C for 1 hour. A slight shift in the melting endotherm of Labrafil
®
 M2130 CS was noted. 
However, no changes in chemical bond shift, broadening of peaks or occurrence of unique bands 
were observed in the FTIR spectrum of the lipid suggesting that there are no major polymorphic 
changes within the lipid. Similarly, no potential interaction of KTZ and the lipid was detected 
after heating to 60°C for 1 hour as the DSC thermogram revealed the presence of peaks that were 
due to Labrafil
®
 M2130 CS and KTZ and these occurred at their respective melting points. These 
data show that KTZ is molecularly dispersed in the lipid. The FTIR spectrum of the KTZ-lipid 
mixture shows a superimposition of the bands of KTZ and Labrafil
®
 M2130 CS, thereby 
confirming the lack of physicochemical interaction within the drug-lipid mixture as an interaction 
would result in new bond formation and thus result in the occurrence of additional absorption 
bands. 
 
The incorporation of KTZ into SLM was investigated by developing and manufacturing an 
aqueous micro-particulate dispersion consisting of 10% w/v solid lipid Labrafil
®
 M2130 CS using 
a modified micro-emulsion technique that required the use of an Ultra-Turrax
®
 homogenizer set 
at 24 000 rpm for 5 minutes followed by the use of the Erweka GmbH homogenizer. Particle 
growth and an unpredictable gelation tendency may impair the stability of solid lipid particles and 
successful formulation development requires optimization of the production method, conditions 
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and composition of the formulation including the surfactant/surfactant mixture, properties of the 
lipid and the API to ensure that a product of good quality is manufactured. 
 
A number of characterization techniques may be used to investigate the physical and chemical 
properties of solid lipid nanoparticles and microparticles and for the control of the quality of the 
product during formulation development and optimization procedures. Parameters that tend to 
have a direct impact on the stability and release kinetics of solid lipid carriers include particle size 
(PS), zeta potential (ZP), degree of crystallinity and lipid modification. The co-existence of 
additional structures and dynamic phenomena within the system must also be evaluated. Photon 
correlation spectroscopy (PCS) and laser diffractometry (LD) are used for routine measurement 
of particle size. However, PCS may only be used to measure particles from a few nanometers to 
about 3 micrometers in size. Electron microscopy may also be used to obtain direct information 
about particle size and shape and was used in these studies. Scanning Electron Microscopy 
(SEM) was used for the morphological examination of the particles and Transmission Electron 
Microscopy (TEM) was used to measure the particle size and gather information regarding the 
physical characteristics of particles. The ZP of the nano- or microparticles is used to predict the 
stability of aqueous dispersions of SLN and SLM on storage and was measured using Laser 
Doppler anemometry (LDA) coupled to a Zetasizer. The evaluation of DLC and EE is of prime 
importance since it in part influences the release characteristics of incorporated drug. The factors 
that determine the loading capacity of the drug in the lipid are the solubility of the drug in the 
molten lipid, the miscibility of the drug in the lipid melt, the physicochemical properties of the 
solid lipid matrix and the polymorphic state of the lipid material. The amount of API entrapped in 
the particle is determined after separation of the encapsulated API from the SLM formulation 
using techniques such as ultracentrifugation, centrifugation filtration and gel permeation 
chromatography. The extent of KTZ entrapment was assessed indirectly by determining the 
amount of drug remaining in the supernatant following filtration centrifugation using the RP-
HPLC method that was developed and validated for the quantitation of KTZ.  
 
Initial formulation development studies were conducted to select a surfactant or combination of 
surfactants that would ensure the production of stable KTZ-loaded SLM formulations. The 
selection of an emulsifying system was based on an ability to produce SLM of acceptable size, 
shape and surface morphology and to stabilize KTZ-loaded SLM dispersions on the day of 
manufacture. Pluronic
®
 F68 was used in combination with surfactants such as Soluphor
®
 P, 
Soluplus
®
, Lutrol
®
 E400, Tween 80 and sodium cholate to determine an appropriate emulsifying 
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system for KTZ-loaded SLM manufactured using the solid lipid Labrafil
®
 M2130 CS. Aqueous 
drug-free SLM dispersions manufactured using Pluronic
®
 F68 (4% w/v) in combination with 
Lutrol
®
 E400 (3% w/v), Soluphor
® 
P (3% w/v), Soluplus
®
 (3% w/v) (SLM 1, SLM 2 and SLM 3) 
and KTZ-loaded SLM dispersions using the same combination of surfactants (SLM 10, SLM 11 
and SLM 12) were found to be unstable and of poor quality in terms of PS, ZP, DLC and EE from 
the day of manufacture. The KTZ-loaded SLM dispersions manufactured using 3% w/v Lutrol
®
 
E400, Soluphor
® 
P, Soluplus
® 
exhibited signs of instability such as a gelation tendency, particle 
agglomeration and particularly low DLC and EE on the day of manufacture. The results also 
revealed that the use of Pluronic
®
 F68 alone and in combination with Tween 80 and/or sodium 
cholate produced drug-free SLM of better quality (SLM 4, SLM 5, SLM 6, SLM 7, SLM 8 and 
SLM 9) than drug-free SLM produced using Lutrol
®
 E400, Soluphor
® 
P, Soluplus
® 
(SLM 1, SLM 
2 and SLM 3). Therefore, Pluronic
®
 F68 in combination with Tween 80 and/or sodium cholate 
was further investigated in these initial studies and it was found that a combination of 4% w/v 
Pluronic
®
 F68, 2% w/v Tween 80 and 1% w/v sodium cholate produced the most stable drug-free 
SLM dispersion (SLM 6).  
 
The use of increasing amounts of Labrafil
®
 M2130 CS was investigated and it was found that 
high concentrations of solid lipid produced particles with lower DLC and EE and larger PS. In 
contrast, the ZP of KTZ-loaded SLM dispersions produced with varying concentrations of 
Labrafil
®
 M2130 CS was not significantly affected. An optimum concentration of 10% w/v 
Labrafil
®
 M2130 CS was used to manufacture the KTZ-loaded SLM in further formulation 
development studies. The effect of KTZ loading on the quality of SLM was investigated and 
concentrations in excess of 5% w/v KTZ led to a reduction in DLC and EE and an increase in PS. 
Conversely, an increasing ratio of KTZ to Labrafil
®
 M2130 CS did not appear to influence the ZP 
of the aqueous SLM dispersions. The effect of process variables such as the number of 
homogenization cycles on the quality of the particles produced was investigated and the results 
suggest that at least five homogenization cycles using the Erweka GmbH homogenizer after 
initial homogenisation with an Ultra-Turrax
®
 homogenizer at 24 000 rpm for 5 minutes were 
required for the production of particles with acceptable surface morphology and size. The number 
of homogenisation cycles appeared to influence the surface morphology and particle size (PS) 
using a higher number of homogenisation cycles produced particles with a smoother surface and 
lower PS.  
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In order to establish the potential use of an aqueous KTZ-loaded SLM dispersion in developing 
countries, it was essential to assess stability under different storage conditions. The high 
temperature and humidity conditions encountered in many developing countries require that 
aqueous preparations be stored under cold chain conditions. However, cold chain facilities are 
sometimes not readily available in these countries and it was deemed appropriate to investigate 
the stability of the KTZ-loaded aqueous dispersion at 25°C/65% RH and 40°C/75% RH as 
specified by the ICH Q1A guidelines for up to 30 days following manufacture in order to 
establish the stability of the KTZ-loaded dispersion in cases where cold chain facilities are not 
available. Two optimized KTZ-loaded formulations (SLM 15 and SLM 16) were produced and 
their PS, surface morphology, ZP, DLC and EE were evaluated on days 0, 3, 7 and 30 following 
manufacture and storage at 25°C/65% RH and 40°C/75% RH. The results of these studies 
revealed that SLM 15 manufactured using 10% w/v of Labrafil
®
 M2130 CS, 5% w/v KTZ and a 
combination of 4% w/v Pluronic
®
 F-68, 2% w/v Tween
 
80 and 1% w/v sodium cholate was the 
most stable when stored at 25°C/65% RH for up to 30 days. However, storage at 40°C/75% RH 
resulted in the formulation exhibiting instability. Storage at temperatures and humidity conditions 
of 40°C/75% RH is likely to cause an increase in PS and agglomeration of the particles into a 
solid, lipid network with destabilization of the formulation. This phenomenon of aggregation may 
be a consequence of Ostwald ripening due to a relatively large PS distribution observed in these 
formulations.  In addition the ZP is lowered and the decrease in DLC and EE infers the expulsion 
of KTZ from the lipid matrix on storage. The chain of events leading to the destabilization of 
KTZ-loaded SLM formulations could arise from the disruption of the interfacial film around the 
particles leading to a reduction in electrostatic repulsion forces and changes in the crystallinity of 
the solid lipid to stable polymorphic forms which do not retain KTZ within the solid lipid matrix.  
 
This research has shown that it is feasible to incorporate KTZ into SLM using a simple micro-
emulsion manufacturing technique. The long-term stability of the optimized formulation, SLM 
15, must be established and improved to enable storage at 25°C/60% RH for longer than 30 days 
and increase the stability of the formulation at 40°C/75% RH. The narrowing of the PS and PS 
distribution may assist in preventing particle growth through Ostwald ripening. Elucidation of the 
mechanism of instability using DSC in conjunction with WAXD to investigate potential 
polymorphic modifications and crystallographic changes during storage of the SLM dispersions is 
necessary. The use of DSC and WAXD may also improve the detection of dynamic phenomena 
and co-existence of addition structures that may form during prolonged storage of the SLM 
system. Furthermore, it is important to evaluate the in vitro release rate of KTZ from the SLM 
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dispersion using conventional or novel methods prior to the use of this alternative drug delivery 
system as a carrier for KTZ. In vitro release of KTZ from SLM may be achieved using a dialysis 
bag diffusion technique or an agitation technique followed by ultracentrifugation or centrifugal 
ultrafiltration. In addition, further studies may require an investigation into the biocompatibility 
of the SLM formulation. Although the solid lipid Labrafil
®
 M2130 CS has a GRAS status and is 
known to be approved for its use in oral drug delivery, it may be worthwhile to determine the 
biocompatibility of the SLM formulation, for instance by performing cell culture studies using the 
mouse connective tissue fibroblast L929 cell line in order to investigate its in vitro cytotoxicty as 
specified in the ICH S2 guidelines. Since KTZ is a BCS Class II compound exhibiting poor water 
solubility the potential of SLM as a bioavailability enhancer may be investigated using an in vitro 
method requiring side by side diffusion cells with an artificial or biological membrane or an ex 
vivo method to determine the permeability of KTZ across the gut. Should the KTZ-loaded SLM 
formulation exhibit acceptable physicochemical and biopharmaceutical properties the use of this 
innovative solid lipid carrier system for the oral administration of KTZ can be investigated by 
conducting an in vivo study to confirm that appropriate levels of KTZ are reached in vivo during 
antifungal therapy. The addition of a taste enhancer to improve the palatability of the formulation 
is important if it is intended for paediatric use. The incorporation of additional excipients in the 
SLM formulation may affect stability and therefore further stability studies may be necessary.  
 
This research has revealed that the inclusion of KTZ in SLM is possible and there is the potential 
to improve oral delivery of KTZ for paediatric patients. This approach may facilitate the delivery 
of KTZ in a liquid dosage form, which would circumvent the need for extemporaneous 
preparation of KTZ dispersions made from crushed solid dosage forms. This approach may result 
in enhanced bioavailability of KTZ and improved stability of KTZ, thereby bettering the quality 
of life of patients requiring antifungal therapy in developing countries.  
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APPENDIX I 
 
BATCH SUMMARY REPORTS 
 
The batch summary reports for Batches SLM 1 to SLM 24 are included here. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 1 
Manufacturing date: 19.07.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.06 
Pluronic
®
 F-68 4.00 2.12 
Lutrol
®
 E400 3.00 1.54 
Aqua 83.0 41.5 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 43.7 ± 3.1 
Zeta potential, ZP (mV) -18.3 ± 0.5 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was clumpy and non-homogenous on the day of manufacture 
 Particles were non-discrete, non-spherical and had irregular surfaces 
 Signs of gelation and particle aggregation were visible on the day of manufacture 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 2 
Manufacturing date: 19.07.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.16 
Pluronic
®
 F-68 4.00 2.09 
Soluphor
®
 P 3.00 1.57 
Aqua 83.0 41.2 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 17.3 ± 4.4 
Zeta potential, ZP (mV) -13.9 ± 0.2 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was clumpy and non-homogenous on the day of manufacture 
 Particles were non-discrete and had irregular surfaces 
 Signs of sedimentation and particle aggregation were visible on the day of manufacture 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 3 
Manufacturing date: 19.07.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.05 
Pluronic
®
 F-68 4.00 2.12 
Soluplus
®
 3.00 1.58 
Aqua 83.0 41.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 21.7 ± 8.6 
Zeta potential, ZP (mV) -14.8 ± 0.6 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was non-homogenous on the day of manufacture 
 Particles were non-spherical and formed aggregates 
 Fast rate of sedimentation was observed on the day of manufacture  
 Signs of gelation were observed on the day of manufacture 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 4 
Manufacturing date: 02.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.07 
Pluronic
®
 F-68 4.00 2.03 
Tween 80 3.00 1.63 
Aqua 83.0 41.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 37.4 ± 6.5 
Zeta potential, ZP (mV) -18.7 ± 0.9 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were spherical with improved surface characteristics 
 Sedimentation was observed on the day of manufacture 
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 5 
Manufacturing date: 02.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.09 
Pluronic
®
 F-68 4.00 2.04 
Tween 80 1.00 0.59 
Sodium cholate 2.00 1.13 
Aqua 83.0 41.2 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 40.6 ± 9.2 
Zeta potential, ZP (mV) -11.6 ± 0.7 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were large and spherical  
 A wide particle size distribution (PSD) was noted 
 Signs of aggregation were observed 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 6 
Manufacturing date: 02.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.13 
Pluronic
®
 F-68 4.00 2.06 
Tween 80 2.00 1.14 
Sodium cholate 1.00 0.53 
Aqua 83.0 41.1 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 25.5 ± 2.6 
Zeta potential, ZP (mV) -31.1 ± 0.2 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were smooth, small and spherical 
 High ZP and low rate of sedimentation 
 
 167 
 
RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 7 
Manufacturing date: 25.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.03 
Pluronic
®
 F-68 5.00 2.58 
Tween 80 1.00 0.54 
Sodium cholate 1.00 0.59 
Aqua 83.0 41.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 22.6 ± 4.1 
Zeta potential, ZP (mV) -32.7 ± 0.1 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were small, spherical but tended to aggregate 
 High ZP and low rate of sedimentation  
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 8 
Manufacturing date: 25.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.15 
Pluronic
®
 F-68 6.00 3.18 
Sodium cholate 1.00 0.61 
Aqua 83.0 41.1 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 22.2 ± 7.9 
Zeta potential, ZP (mV) -19.3 ± 0.3 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were small, smooth and spherical 
 Low rate of sedimentation and signs of aggregation were noted on the day of manufacture 
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 9 
Manufacturing date: 25.08.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
Labrafil
®
 M2130 CS 10.00 5.25 
Pluronic
®
 F-68 7.00 3.52 
Aqua 83.0 41.2 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 33.4 ± 5.8 
Zeta potential, ZP (mV) -15.5 ± 0.3 
 
   
Comments / Observations 
 White to off-white aqueous dispersion was produced 
 Dispersion was homogenous on the day of manufacture 
 Particles were larger with irregular surfaces 
 Sedimentation was observed 
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 10 
Manufacturing date: 06.09.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.53 
Labrafil
®
 M2130 CS 10.00 5.16 
Pluronic
®
 F-68 4.00 2.16 
Lutrol
®
 E400 3.00 1.59 
Aqua  78.0 38.6 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 39.2 ± 8.1 
Zeta potential, ZP (mV) -18.3 ± 0.5 
Drug loading capacity, DLC (%) 0.04 ± 0.007 
Encapsulation Efficiency, EE (%) 0.09 ± 0.006 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically unstable  
 Signs of gelation and particle aggregation were visible  
 Very low DLC and EE 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 11 
Manufacturing date: 06.09.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.59 
Labrafil
®
 M2130 CS 10.00 5.14 
Pluronic
®
 F-68 4.00 2.08 
Soluphor
®
 P 3.00 1.61 
Aqua  78.0 38.6 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 33.6 ± 4.4 
Zeta potential, ZP (mV) -13.9 ± 0.2 
Drug loading capacity, DLC (%) 0.89 ± 0.02 
Encapsulation Efficiency, EE (%) 1.85 ± 0.09 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically unstable  
 Signs of gelation and particle aggregation were visible  
 Very low DLC and EE 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 12 
Manufacturing date: 06.09.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.55 
Labrafil
®
 M2130 CS 10.00 5.04 
Pluronic
®
 F-68 4.00 2.18 
Soluplus
®
 3.00 1.51 
Aqua  78.0 38.7 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 15.7 ± 8.6 
Zeta potential, ZP (mV) -14.8 ± 0.6 
Drug loading capacity, DLC (%) 0.97 ± 0.07 
Encapsulation Efficiency, EE (%) 1.93 ± 0.18 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically unstable  
 Sedimentation was observed  
 Very low DLC and EE 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 13 
Manufacturing date: 13.09.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.51 
Labrafil
®
 M2130 CS 10.00 5.05 
Pluronic
®
 F-68 4.00 2.03 
Tween 80 3.00 1.56 
Aqua  78.0 38.9 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 24.4 ± 5.2 
Zeta potential, ZP (mV) -18.3 ± 0.4 
Drug loading capacity, DLC (%) 6.9 ± 1.2 
Encapsulation Efficiency, EE (%) 11.5 ± 1.8 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Low rate of sedimentation was observed  
 Particles were spherical with irregular surfaces 
 Low DLC and EE  
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 14 
Manufacturing date: 25.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.53 
Labrafil
®
 M2130 CS 10.00 5.02 
Pluronic
®
 F-68 4.00 2.03 
Sodium cholate 2.00 1.04 
Tween 80 1.00 0.54 
Aqua  78.0 38.8 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on day of manufacture: 
Particle size, PS (µm) 23.6 ± 7.7 
Zeta potential, ZP (mV) -30.9 ± 0.8 
Drug loading capacity, DLC (%) 7.3 ± 0.18 
Encapsulation Efficiency, EE (%) 13.3 ± 0.74 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Low rate of sedimentation was observed and dispersion was stable on the day of 
manufacture 
 Higher ZP indicating higher stability 
 Particles were smooth, small, spherical and discrete 
 Low DLC and EE 
 A wide particle size distribution (PSD)  and signs of agglomeration was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 15 
Manufacturing date: 25.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.51 
Labrafil
®
 M2130 CS 10.00 5.04 
Pluronic
®
 F-68 4.00 2.08 
Tween 80 2.00 1.10 
Sodium cholate 1.00 0.506 
Aqua  78.0 36.5 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture, after storage at 25°C/60% RH and 
40°C/75% RH for 30 days: 
 Day of manufacture 25°C/60% RH 40°C/75% RH 
Particle size, PS (µm) 18.6 ± 3.6 29.7 ± 2.4 60.6 ± 8.4 
Zeta potential, ZP (mV) -30.1 ± 0.2 -31.2 ± 0.3 -28.6 ± 0.2 
Drug loading capacity, DLC (%) 23.6 ± 1.8 22.9 ± 4.6 4.7 ± 1.9 
Encapsulation Efficiency, EE (%) 58.2 ± 2.3 57.8 ± 7.5 6.2 ± 2.3 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically stable on the day of manufacture 
 Particles were discrete, small, smooth and spherical  
 No signs of gelation or particle aggregation were visible on the day of manufacture 
 High DLC and EE and no significant reduction in DLC and EE on storage at 25°C/60% 
RH for up to 30 days 
 Storage at 40°C/75% RH for 30 days led to instability of the SLM dispersion and loss of 
KTZ retention 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 16 
Manufacturing date: 25.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.57 
Labrafil
®
 M2130 CS 10.00 5.04 
Pluronic
®
 F-68 5.00 2.58 
Tween 80 1.00 1.03 
Sodium cholate 1.00 0.501 
Aqua  78.0 38.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture, after storage at 25°C/60% RH and 
40°C/75% RH for 30 days: 
 Day of manufacture 25°C/60% RH 40°C/75% RH 
Particle size, PS (µm) 15.6 ± 2.1 30.6 ± 5.8 70.7 ± 5.1 
Zeta potential, ZP (mV) -31.6 ± 0.1 -32.1 ± 0.3 -24.1 ± 0.3 
Drug loading capacity, DLC (%) 18.6 ± 0.3 17.9 ± 3.5 3.2 ± 0.6 
Encapsulation Efficiency, EE (%) 43.2 ± 1.4 42.6 ± 6.2 5.6 ± 2.5 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically stable on the day of manufacture 
 Particles were discrete, small, smooth and spherical   
 No signs of gelation or particle aggregation were visible on the day of manufacture 
 High DLC and EE and no significant reduction in DLC and EE on storage at 25°C/60% 
RH for up to 30 days 
 Storage at 40°C/75% RH for 30 days led to instability of the SLM dispersion and loss of 
KTZ retention 
 Particle growth was observed on storage at 40°C/75% RH for 30 days and the dispersion 
was unstable and exhibited particle aggregation and gelation
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 17 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.52 
Labrafil
®
 M2130 CS 10.00 5.05 
Pluronic
®
 F-68 6.00 3.08 
Sodium cholate 1.00 0.511 
Aqua  78.0 38.8 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 24.2 ± 6.5 
Zeta potential, ZP (mV) -20.7 ± 0.3 
Drug loading capacity, DLC (%) 17.4 ± 0.1 
Encapsulation Efficiency, EE (%) 29.7 ± 0.9 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Dispersion was physically stable on the day of manufacture 
 Particles were discrete and spherical 
 Average DLC and EE  
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 18 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.52 
Labrafil
®
 M2130 CS 10.00 5.04 
Pluronic
®
 F-68 7.00 3.59 
Aqua  78.0 38.9 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 28.4 ± 8.8 
Zeta potential, ZP (mV) -15.6 ± 0.2 
Drug loading capacity, DLC (%) 10.1 ± 0.2 
Encapsulation Efficiency, EE (%) 17.9 ± 0.4 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete and spherical but had irregular surfaces 
 Sedimentation was observed on the day of manufacture 
 Low DLC and EE  
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 19 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.56 
Labrafil
®
 M2130 CS 5.00 2.54 
Pluronic
®
 F-68 4.00 2.01 
Sodium cholate 1.00 0.52 
Tween
®
 80 2.00 1.01 
Aqua  83.0 41.4 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 40.2 ± 3.5 
Zeta potential, ZP (mV) -30.2 ± 0.3 
Drug loading capacity, DLC (%) 24.5 ± 2.1 
Encapsulation Efficiency, EE (%) 59.3 ± 3.5 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, smooth and spherical  
 Reasonable DLC and EE  
 Aggregation was observed 
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 20 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.58 
Labrafil
®
 M2130 CS 15.00 7.53 
Pluronic
®
 F-68 4.00 2.03 
Sodium cholate 1.00 0.51 
Tween
®
 80 2.00 1.04 
Aqua  73.0 36.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 32.2 ± 4.2 
Zeta potential, ZP (mV) -29.5 ± 0.1 
Drug loading capacity, DLC (%) 15.1 ± 0.23 
Encapsulation Efficiency, EE (%) 32.9 ± 0.34 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, smooth and spherical  
 Lower DLC and EE with higher concentration of Labrafil® M2130 CS 
 Aggregation was observed 
 A wide particle size distribution (PSD) was noted 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 21 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 10.00 5.08 
Labrafil
®
 M2130 CS 10.00 5.02 
Pluronic
®
 F-68 4.00 2.01 
Sodium cholate 1.00 0.54 
Tween
®
 80 2.00 1.01 
Aqua  73.0 36.3 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 28.3 ± 3.8 
Zeta potential, ZP (mV) -28.1 ± 0.1 
Drug loading capacity, DLC (%) 19.4 ± 0.37 
Encapsulation Efficiency, EE (%) 49.5 ± 0.79 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, smooth and spherical  
 Slightly lower DLC and EE  
 DLC and EE decreased slightly 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 22 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 3.30 1.65 
Labrafil
®
 M2130 CS 10.00 5.01 
Pluronic
®
 F-68 4.00 2.03 
Sodium cholate 1.00 0.52 
Tween
®
 80 2.00 1.01 
Aqua  79.7 39.8 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 27.5 ± 4.9 
Zeta potential, ZP (mV) -30.8 ± 0.6 
Drug loading capacity, DLC (%) 22.5 ± 1.2 
Encapsulation Efficiency, EE (%) 48.5 ± 2.9 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, smooth and spherical  
 DLC and EE decreased slightly with lower concentration of KTZ 
 
 183 
 
RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 23 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.51 
Labrafil
®
 M2130 CS 10.00 5.02 
Pluronic
®
 F-68 4.00 2.01 
Sodium cholate 1.00 0.53 
Tween
®
 80 2.00 1.02 
Aqua  78.0 38.9 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH (3 cycles) 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 42.7 ± 6.9 
Zeta potential, ZP (mV) -27.5 ± 0.2 
Drug loading capacity, DLC (%) 20.7 ± 1.9 
Encapsulation Efficiency, EE (%) 43.8 ± 2.8 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, spherical and had irregular surfaces 
 Larger PS with lower number of homogenization cycles 
 Low DLC and EE with three (3) homogenization cycles 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH SUMMARY REPORT 
 
Formulator:  Henusha Jhundoo 
Product name: KTZ-loaded Solid Lipid Microparticle (SLM) aqueous dispersion   
Batch ID:  SLM 24 
Manufacturing date: 28.10.2010    Batch size: 50 ml 
Homogenizing time: 25-30 min 
Formula 
Material % (w/v) Amount added (g) 
KTZ 5.00 2.50 
Labrafil
®
 M2130 CS 10.00 5.01 
Pluronic
®
 F-68 4.00 2.03 
Sodium cholate 1.00 0.54 
Tween
®
 80 2.00 1.03 
Aqua  78.0 38.9 
 
Production equipment used: 
Water bath:   Model NB-34980 Colora Ultra-Thermostat 
Homogenizer 1: Model 6-105 AF Virtis Ultra-Turrax
® 
Homogenizer 2:  Model HO/HHO Erweka AR400, Erweka GmbH (4 cycles) 
 
Parameters evaluated on the day of manufacture: 
Particle size, PS (µm) 17.8 ± 7.1 
Zeta potential, ZP (mV) -29.7± 0.1 
Drug loading capacity, DLC (%) 19.1 ± 3.9 
Encapsulation Efficiency, EE (%) 42.3 ± 2.5 
 
   
Comments / Observations 
 White to off-white homogeneous aqueous dispersion was produced 
 Particles were discrete, spherical and had irregular surfaces  
 PS is reduced with higher number of homogenization cycles 
 Low DLC and EE with four (4) homogenization cycles 
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APPENDIX II 
BATCH PRODUCTION RECORDS 
 
Note that only the production record for Batch SLM 15 is included here. The batch production 
records for all other formulations manufactured and tested during formulation development and 
optimization studies are available on request.  
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH PRODUCTION RECORD 
 
Product name: KTZ-loaded SLM      Page 1 of 5 
Batch ID: SLM 15       Batch size: 50 ml 
 
MANUFACTURING APPROVALS 
 
Batch record issued by__________________________  Date______________________ 
 
 
Master record issued by__________________________  Date______________________ 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH PRODUCTION RECORD 
 
Product name: KTZ-loaded SLM      Page 2 of 5 
Batch ID: SLM 15       Batch size: 50 ml 
 
Item Material Quantity  
(% w/v) 
Amount/ 
Batch (g) 
Amount 
dispensed 
Dispensed 
by 
Checked 
by 
1 KTZ 5.00 2.50 2.51   
2 Labrafil
®
 M2130 CS 10.00 5.00 5.04   
3 Pluronic
®
 F-68 4.00 2.00 2.08   
4 Tween
®
 80 2.00 1.00 1.10   
5 Sodium cholate 1.00 0.500 0.506   
6 Aqua  73.0 36.5 36.5   
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH PRODUCTION RECORD 
 
Product name: KTZ-loaded SLM      Page 3 of 5 
Batch ID: SLM 15       Batch size: 50 ml 
 
EQUIPMENT VERIFICATION 
Description Type Verified by Confirmed by 
Water bath  Model NB-34980 Colora Ultra-Thermostat   
Homogenizer  Model 6-105 AF Virtis Ultra-Turrax
®
   
Homogenizer Model HO/HHO Erweka AR400, Erweka GmbH   
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH PRODUCTION RECORD 
Product name: KTZ-loaded SLM      Page 4 of 5 
Batch ID: SLM 15       Batch size: 50 ml 
 
MANUFACTURING PROCEDURE 
Step Procedure Time Done by Checked by 
1 Weigh all materials.    
2 Heat water bath to 60°C for at least 30 min.    
3 Pipette 5 ml of distilled water in a test tube and 
store at 4°C for at least 20 min. 
   
4 Measure 36.5 ml of distilled water using a 
measuring cylinder and transfer to a 250 ml beaker. 
Store in a freezer for at least 15 min or until 
temperature is between 2-3°C. 
   
5 Heat lipid Labrafil
®
 M2130 CS until melted to 
60°C in water bath. 
   
6 Dissolve Pluronic
®
 F-68 in 5 ml of water stored at 
4°C for at least 30 min (from step 3) and mix using 
a Vortex mixer until complete dissolution. 
   
7 Add co-surfactant sodium cholate, followed by 
Tween
 
80 to solution of Pluronic
®
 F-68 (from step 
5) and mix using a Vortex mixer until complete 
dissolution to obtain aqueous surfactant solution. 
   
8 Heat aqueous surfactant solution in water bath to 
60°C for at least 15 min. 
   
9 Add heated surfactant solution to molten lipid at 
60°C and mix briefly using a Vortex mixer to form 
microemulsion. Store microemulsion in water bath 
at 60°C. 
   
9 Disperse hot microemulsion in beaker containing 
cold water maintained at 2-3°C from step 4. 
   
10 Homogenize aqueous dispersion using an Ultra-
Turrax
®
 homogenizer at 24 000 rpm for 5 minutes. 
   
11 Homogenize resulting aqueous dispersion with an 
Erweka GmbH homogenizer for five cycles. 
   
12 Store samples at room temperature (22°C) prior to 
characterization. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
 
BATCH PRODUCTION RECORD 
 
Product name: KTZ-loaded SLM      Page 5 of 5 
Batch ID: SLM 15       Batch size: 50 ml 
 
 
SIGNATURE AND INITIAL REFERENCE 
Full name (Print) Signature Initials Date 
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